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This thesis establishes LC/MS as a viable, robust, and attractive alternative 
analytical platform to ligand binding assays for the quantification of therapeutic and 
endogenous peptides/proteins in biological fluids.  A rigorous investigation of the 
parameters that affect assay sensitivity, specificity and robustness revealed that a careful 
combination of mixed-mode solid phase extraction, reversed-phase liquid chromatography 
utilizing sub 2µm charged surface solid core stationary phases, coupled to tandem 
quadrupole mass spectrometry can deliver a generic platform for assay development.  By 
extending the innovations developed in the initial work to a micro-fluidic scale it was 
possible to both reduce sample consumption and increase assay sensitivity by up to 20-30 
fold.  The value of this approach was demonstrated with subsequent validation (to FDA 
guidelines) of 5 separate ultra-high sensitivity assays for large hydrophobic peptides using 
this approach. 
The initial studies focused on understanding the factors that influence LC/MS assay 
performance for the quantification of biotherapeutics and biomarkers in biofluids.  This was 
divided into three discrete sections: sample preparation, liquid chromatography and mass 
spectrometry. This investigation produced a comprehensive set of rules and guidelines to be 
applied during LC/MS method development for biologics quantification.  From an MS 
perspective, these included (but were not limited to) the recommendation to choose the 
highest precursor/product pairs possible, avoid immonium ions, monitor multiple MRM 
transitions during method development, and the importance of tuning at the 
chromatographic flow rate was also noted. The liquid chromatography studies revealed that 
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sub-2 µm superficially porous particles with larger pore size, and/or positively charged 
surface stationary phases, produced the highest efficiency and most sensitive separations, at 
flow rates that yield throughputs compatible with routine bioanalytical work.  In addition, it 
was discovered that decreasing the flow rate, lowering the gradient slope, and increasing 
temperature could all reduce carryover and increase sensitivity further for many peptide 
analyses. 
The rules derived from the basic research were then applied to the development of 
assays for teriparatide (an osteoporosis drug), amyloid beta peptides (putative Alzheimer’s 
disease biomarkers) and human insulin and five analogs. Implementing a protein 
precipitation  plasma pre-treatment step to reduce endogenous background was combined 
with SPE and chromatography based on a charged surface column to yield a quantification 
limit of 15 pg/mL teriparatide from 200 µL human plasma. A key aspect of amyloid beta 
measurement in human cerebrospinal fluid included a guanidine HCl pre-treatment step 
which eliminated aggregation and protein binding, enabling accurate and precise 
quantification of total amyloid beta, with a quantification limit of <40 pg/mL from 100 µL 
human cerebrospinal fluid. Protein precipitation and mixed-mode anion exchange SPE 
coupled to a multidimensional chromatographic system enabled differentiation of human 
insulin from Humalog even though they share many of the preferred product ions, have the 
same precursor masses, and co-elute. The achieved detection limit of 50 pg/mL (8.6 
fmol/mL) enabled measurement of fasting insulin levels. The developed method was 




It has long been known that low-flow LC has significant advantages for high 
sensitivity analysis when coupled to MS. However, the lack of robustness and long analysis 
times associated with early hardware, limited its widespread use.  The initial work on 
teriparatide and insulin analysis as well as additional work on endogenous and injected 
glucagon were adapted to a new prototype integrated micro-fluidic device, resulting in a 20-
30 fold overall sensitivity improvement. In addition, analysis of small cyclic peptides was 
performed at both 2.1 mm ID and 150 µm ID scale, the latter enabling quantification of 
desmopressin from 20 fold less sample with a quantification limit of approximately 6.5 
amol on column, or 2.5 pg/mL from 25 µL human plasma.    
As a result of this work, LC/MS is now a viable alternative to traditional LBA for 
PK studies and biomarker validation, showing the necessary throughput, sensitivity and 
robustness.  Added to this, the assays also have greater precision, wider dynamic range and 
less cross reactivity, facilitating greater confidence in the derived results, faster assay 
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1.1 Peptides and Proteins as Drugs 
 
According to the World Health Organization, the global pharmaceuticals market was 
worth approximately $300 billion in 2013 and expected to rise another $100 billion within 3 
years. Historically, this market was comprised primarily of small molecule drug entities that 
were either derived from plant extracts, synthesized based on endogenous compounds, or 
developed from structural activity relationships (SARs.)[1] These compounds have been 
responsible for almost eliminating many diseases such as measles, mumps, rubella, and 
chicken pox,  controlling such debilitating problems such as high blood pressure and finally 
reducing mortalities due to HIV/AIDS, and certain cancers[2].  Today, a rapidly increasing 
number of new pharmaceuticals, called biopharmaceuticals, are being developed which are 
based on biological molecules such as peptides, proteins, and oligonucleotides. This shift in 
interest towards large molecule therapeutics is primarily due to a number of their inherent 
characteristics including lower toxicity, greater specificity, and higher potency. For 
example, as of 2011, there were 60 peptide based medicines available, and at least another 
400 in late stage clinical trials. Overall, there are over 600 biologically-based candidate 
pharmaceuticals in development, many of which are antibody or peptide-based. [3, 4] In 
fact, according to a recent study through the Peptide Therapeutics Foundation, there are 
approximately 17 new peptide drug entities going into clinical trials each year, and these are 
about twice as successful in  phase III clinical trials than their small molecule 
counterparts.[5] Advances in the various technologies applied for drug discovery and 
biomolecule characterization (i.e., recombinant DNA, fermentation, proteomics, genomics, 
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and informatics) [6] have made it possible for drug manufacturers to successfully develop 
and characterize biopharmaceuticals. These types of compounds have been used to treat a 
variety of serious diseases such as diabetes, cancer, arthritis, and hemophilia. Perhaps the 
oldest, best known, and top-selling peptide therapeutic is insulin, with several analogs 
reaching multi-billion dollar sales, such as insulin glargine (Lantus), insulin lispro 
(Humalog) and insulin aspart (NovoRapid).  While originally dosed by injection, current 
research focuses on developing nasal or transdermal dose formulations, [7] both of which 
will require more sensitive and selective methods than those previously employed.  
Additional peptide-based drug products, including goserelin, leuprolide, and octreotide, 
have also reached over a billion dollars in sales treating critical health issues such as 
osteoporosis and prostate and other cancers.   
Therapeutic peptides are typically modified or synthetic versions of substances that 
already exist in the body, and therefore tend to be better tolerated than many small 
molecule-based medicines, as they do not form toxic metabolites. In addition, by their very 
nature, these biological compounds are often more specific than small molecules used to 
treat the same disease, as they have been designed to mimic behaviour of endogenous 
substances and are mapped to specific receptor proteins. Relative to small molecules, other 
benefits of peptide drugs include greater activity and potency, lower toxicity, improved 
molecular recognition, no accumulation in tissues and organs, and minimal drug-drug-
interactions.  One example is the synthetic peptide desmopressin, a modified form of the 
human hormone arginine vasopressin. It is prescribed as a replacement for antidiuretic 
hormone (vasopressin) and is used to treat bedwetting and diabetes insipidus.  Desmopressin 
provides several treatment benefits over recombinant vasopressin. It degrades more slowly, 
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enabling less frequent dosing, and it does not raise blood pressure unlike the unmodified 
peptide. There are also drawbacks to peptide drugs and their development. Peptide 
pharmaceuticals tend to have low oral bioavailability, often necessitating intravenous dosing 
rather than the patient preferred delivery methods such as tablets or capsules taken orally. In 
addition, their solubility is poor, and peptides are rapidly eliminated from the body and/or 
broken down by enzymatic activity, and finally, due to their hydrophilicity, it is difficult for 
these candidate medicines to cross biological membranes. Poor membrane transfer accounts 
for the fact that the majority of peptide candidate medicines are aimed at extracellular 
targets such as G-protein-coupled receptors[8]. A few companies however, have focused 
their development programs on peptide drugs for intra-cellular, or “undruggable” targets. 
Some of these issues have been resolved through recent research efforts [8]. For example, 
PEGylation, liposomal encapsulation, and conjugation to small molecules, antibodies or 
proteins have been shown to be effective means of improving the stability and in vivo half-




A biosimilar may be thought of as analogous to a generic version of a small 
molecule pharmaceutical. In the small molecule medicine market place  44% of all of the 
medicine prescribed in USA are generics and estimated to be worth $106 billion by 2016 
(http://www.newpharmathinkers.com/wp-content/uploads/downloads/2012/07/Generic-
Industry-Summary.pdf). While small molecule generics must contain the identical active 
ingredient to the original reference drug, biosimilars are close, but not identical to the 
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original biologic. Biologics are created through biological systems such as cell lines, and not 
from stock chemical starting materials, through very complex processes that are difficult to 
duplicate[10]. Many of the most popular biologically based-therapies will come off patent in 
the 2010-2020 time frames. Figure 1.1 summarizes the US patent expiration for key 
biopharmaceuticals. This opens up a tremendous sales opportunity ($200-400 billion for 
insulins alone)[11] for biosimlars or bio-betters research, which necessarily includes a 
significant quantitative analytical chemistry component.  
 
 
Figure 1.1 Important biotherapeutics coming off patent and open to biosimilars competition 
 
The primary focus of bioequivalence studies for small molecule generics is the 
systemic exposure profile, specifically the Cmax and Tmax which must be the same as the 
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Guidance for Industry recommendations for bioequivalence studies[12]. In addition to 
efficacy and PK data, biosimilars registration and regulatory acceptance will also include an 




In addition to development of novel therapeutics, the study and identification of 
peptide and/or protein biomarkers is a critical area of research. Biomarkers are used both to 
predict various disease states prior to onset, and also to identify targets for drug 
development. Peptide and protein biomarkers are endogenous compounds whose 
relationship to a disease state has been identified. The presence or absence of these 
compounds can be linked to the onset or progression of a disease. For example, amyloid 
beta peptides are being studied extensively in Alzheimer’s Disease research[13]. Other 
examples include cardiac troponin for the diagnosis of myocardial infarction and brain 
natriuretic peptide (BNP) for congestive heart failure. Changes in biomarker concentration, 
sometimes subtle, can also be used to measure drug efficacy or to characterize cohort 
populations. Assays used to measure these minor relative changes must, therefore, be 
exceedingly accurate, reproducible and precise. Guidelines for these assays are prescribed 
by the FDA in the Guidance for Industry for Bioanalytical Method Validation[12, 14]. 
Research in this area encompasses several stages, including biomarker discovery- the 
identification and verification of a putative biomarker, and biomarker validation- where 
assay sensitivity, specificity and optimization are carried out. Both of these require ultra-
high sensitivity quantitative or semi-quantitative assays. During the discovery phase, 
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metabolomics or proteomic approaches may be taken to map the biology of systems, using 
relative quantification to identify proteins or peptides which are differentially expressed 
between diseased and normal populations[15]. Throughout the process thousands of 
candidates (discovery) to thousands of samples (validation) are assayed, using both LC/MS 
and immunoassay techniques. Figure 1.2 captures the process of biomarker research and is 
re-printed with permission from Nature Biotechnology[15].  
 
 
Figure 1.2 Process flow for the development of novel protein biomarker candidates 
 
1.2 Bioanalysis of Biopharmaceuticals and Biomarkers 
 
Bioanalysis is one of the most critical activities in the drug discovery and development 
process today. Bioanalytical data is used not only to make critical decisions on progression 
of drug candidates via the measurement of pharmacokinetic parameters, but also to 
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understand efficacy in human patients. The time to fully develop and launch a new drug can 
be as many as 15 years and can cost in the range of 100-900 million dollars[16, 17]. In 
typical small molecule drug development, one may start with ~1500 candidates in 
discovery, with an average of <1% of those progressing to phase I studies in animals[17]. 
The number of candidates decreases further through phase II and III human trials, yielding 
on average less than 2 of the original 1500 coming out of phase III and into registration[17]. 
Bioanalysis plays a role throughout all of these stages. The primary causes for the dramatic 
attrition rate are the selection of candidates that may appear promising in vitro or in phase I 
but lack efficacy in man, poor pharmacokinetics, and poor safety profile. Both the high cost, 
and the high attrition rate have driven pharmaceutical companies to try to improve the drug 
development process through improving both the quality of bioanalytical data and the speed 
with which it is obtained. Those pressures then also translate to CRO’s or generic 
companies. It is these key factors that necessitate innovation in bioanalysis.  
The most common matrices for analysis are plasma, blood, serum, urine, cerebrospinal fluid 
(CSF), faeces, and tissues such as brain or liver. As mentioned, bioanalytical activities are 
performed during both the discovery phase of drug development and during the 
development or regulated phase of the process and are performed to help determine the 
pharmacokinetics (PK) and pharmacodynamics of the drug. PK include the study of the 
Absorption, Distribution, Metabolism and Excretion (ADME) properties of the drug as well 
as a calculation of bioavailability, which is obtained by mapping changes in drug plasma 
concentration over time and comparing the area under the plasma time curve (AUC) for oral 





Figure 1.3 Representative PK profile obtained by plotting changes in plasma drug concentrations over time. 
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Table 1.1 Useful pharmacokinetic terms and their definitions 
 
Due to the increasing number of peptide therapeutics and biomarkers, there exists an 
immediate need for an efficient method development workflow for the bioanalysis of 
peptide therapeutics as well as a comprehensive understanding of their differences with 
respect to small molecules. As described in previous sections, quantification of peptides is 
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important not only for synthetic peptide drugs, but also for peptide biomarkers and for 
quantification of proteins based upon measurement of unique or signature peptides. 
Naturally, the determination of PK parameters and metabolic fate are as critical during the 
drug discovery and development process for peptide therapeutics as for small molecules.  
For small molecule drug candidates, this data is typically generated by liquid 
chromatography/tandem mass spectrometry (LC/MS/MS) analysis of in-vitro (liver 
microsomes, CaCo2 cells, etc.) or in-vivo (animal or human fluids or tissues) samples. In 
small molecule analysis, LC/MS/MS, specifically triple quadrupole MS, has become the 
technique of choice for these activities due to its un-paralleled selectivity and sensitivity.  
In contrast to small molecules, the gold standard for biomolecule quantification has 
historically been ligand binding assays (LBAs) such as enzyme-linked immunosorbent 
assays (ELISAs) and radioimmunoassays (RIAs). While these types of assays remain the 
primary and most widely accepted method of quantifying protein and antibody-based 
therapies, LC/MS/MS has begun to emerge as the technique of choice for quantification of 
synthetic peptides and is increasingly being used to analyze endogenous peptide 
biomarkers[18].  While ligand binding assays have high sensitivity, specificity, and rapid 
“plate reader” detection, they also have several shortcomings that are influencing the 
transition to LC/MS/MS methods.   
 
1.3 Pros and Cons of Traditional Quantitative Assays for Biotherapeutics  
 
LBAs do not quite meet the demands of a high throughput discovery setting where 
the specific biological reagents are not yet available. Not only are specific reagents 
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necessary, but the time required to develop these reagents may be in the order of several 
months to a year. Furthermore, the reproducibility and reliability of quantitative results is 
highly dependent on reagent quality and batch-to-batch consistency.  In addition, LBAs 
have limited linear dynamic range (often requiring extensive dilution of samples to 
accommodate the concentration range of a PK study), cross reactivity (yielding erroneous or 
inaccurate results) and matrix interferences. LBAs also have difficulty distinguishing 
between the drugs and metabolites or other closely related substances. Finally, an individual 
assay is required for each peptide of interest, limiting multiplexing ability.  
 
1.4 Overview of Modern Liquid Chromatography (LC) 
 
Liquid chromatography is a technique used to separate one or more desired analytes or 
compounds from a sample for the purposes of identification (based on its elution time from 
the chromatography column), purification (through fraction collection) or quantification 
(through the use of calibrator and quality control sample injection, followed by detection 
and software processing). The components of a modern chromatographic system include 
one or more pumps, which deliver one or more aqueous and organic mobile phases to the 
column as well as carry the sample from an injector to the head of the column, an injector 
(which delivers the sample from a vial or plate to the column), a chromatographic column 
and a detector (such as ultraviolet/visible, mass spectrometric, refractive index, evaporative 
light scattering, electrochemical, NMR and fluorescence). Separation is primarily achieved 
by varying mobile phase composition, column stationary phase chemistry, temperature and 
gradient profile, which impact both the chemical and physical behaviour of the analyte in 
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the column. Generally speaking, elution of an analyte from the column is related to its 
preference for and partitioning between the stationary phase (particles inside the column) 
and solubility in the mobile phase (liquid moving through the column) at a given time. 
This technique has been applied over a variety of application areas including clinical 
research, forensic toxicology, environmental and food safety analyses, and pharmaceutical 
development. Samples from matrices as diverse as blood, plasma, urine, soil, corn, milk, 
and waste water are all amenable to this technique once these matrices have been simplified 
through initial sample preparation or extraction. 
 
1.4.1 Brief History of Chromatography 
 
Chromatography, derived from chroma (colour) and graph (writing), had its origins 
in the late 1800s when scientists such as Runge, Goppelsroeder and Schonbein performed 
dye and other separations on filter paper[19]. In the 1900s Tswett performed experiments 
with an open glass cylinder and plant extracts, using different solvents to affect 
separation[20]. Over the next century, liquid and gas chromatography were developed and 
LC evolved into essentially what is now high performance liquid chromatography (HPLC). 
As many researchers with divergent aims were involved in the evolution of 
chromatography, it may be more instructive to highlight a few key individuals and their 
respective contributions, rather than to follow a distinct timeline. Their observations form 
the foundation for some of the key performance-assessing equations that shape current LC 
column development and separations.   
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Martin and Synge performed pioneering work in amino acid separations[21-23], 
developing an understanding of the influence of dynamic partitioning and drawing the 
conclusion that smaller sorbent particles and higher pressure were critical to improving 
resolution.  They were the first to describe the concept of a theoretical plate related to 
partitioning of an analyte between the liquid and stationary phase, and eventually won a 
Nobel prize for their work. Essentially, the faster the partitioning, the more theoretical plates 
a column has, or the higher the efficiency of the column. This led to the description of 
HETP, or height equivalent to a theoretical plate (H), whose relationship is the converse- the 
lower the H, greater the efficiency. A simple way to describe H is column length (L) divided 
by plate count or efficiency (N)[24]. Further to this, they proposed three parameters which 
affect the magnitude of H: a partitioning coefficient, the diffusion rate, and the velocity of 
the mobile phase. These concepts should begin to sound familiar to any chromatographer as 
they form the basis for what is  known as the van Deemter equation. 
Incidentally, Moore and Stein came to similar conclusions during the development of a form 
of GPC[25] which precipitated a fruitful collabouration with James Waters and resulted in 
the introduction of the first commercial GPC system[26]. This research further supported 
two concepts affecting increased column resolution: the potential for the use of smaller 
particles (enabling faster flow rates) and the importance of a uniform packing bed. 
van Deemter expanded the concepts proposed by Martin and Synge and delved deeper into 
mass transfer and diffusion, while introducing the incorporation of the physical 
characteristics of the packed bed[27-29].  
Snyder further highlighted the importance of the interplay between the analyte and 
stationary phase and analyte and mobile phase, emphasizing that earlier work did not fully 
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exploit those parameters which could influence selectivity[30]. It was at this point that the 
role of column length, particle size, flow rate, and mobile phase polarity and their combined 
influence on chromatographic performance was reported. 
The conclusions arising from these studies naturally led to a focus on the 
development of smaller, more uniform packing materials and smaller ID columns. This 
resulted in the necessary innovations in hardware capable of withstanding higher pressures 
and novel packing processes capable of achieving high efficiency, uniformly packed beds. 
Traditional HPLC uses columns packed with stationary phase particles ranging in 
size from 3.5 to 10 µm with the most common particle chemistry being a silica-based C18. 
More recently, hybrid particles were introduced which enable LC using a mobile phase pH 
>10. HPLC is performed in several common modes, including reversed-phase (accounting 
for approximately 70-80% of LC separations)[27], hydrophilic interaction chromatography 
(HILIC), normal phase, ion exchange, and size exclusion. As the overwhelming majority of 
separations for quantitative analysis of large and small molecules is performed using 
reversed-phase, the remainder of this section will focus on theory and practice in this mode. 
 
1.4.2 LC Theory 
  
1.4.2.1 Definition of Chromatographic Terms and Relevant Equations and Relationships 
 
A few fundamental equations form the basis of current chromatographic theory and 
provide the tools with which HPLC performance is measured. Comprehensive 
understanding of the equations presented in this section provides a critical foundation for 
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any chromatography-based research. The concepts were utilized in this author’s work to 
facilitate concise development and design of appropriate experiments aimed at optimizing 
and improving the LC component of peptide bioanalytical methods. 
 
Selectivity is a measure of the degree of separation between two analytes under a specific 
chromatographic condition and is shown in equation 1.1 where kB is the retention factor of 
analyte B and kA, that of analyte A. A value of 1 essentially indicates that analytes will not 
be separated under the indicated conditions. This is distinct from resolution which relates to 
the separation of analytes at baseline. 
Equation 1.1                                ߙ ൌ ୩୆୩୅ 
 
Retention time is the time it takes a peak or analyte band to travel from the injector to the 
detector. This is the most often reported attribute for differentiating and describing distinct 
peaks in a chromatogram. In general, greater retention time indicates stronger interaction 
between the analyte and the stationary phase. For example, in reversed-phase 
chromatography, hydrophobic compounds retain longer than hydrophilic compounds. 
 
Peak asymmetry is a measure of the Gaussian nature of a peak. King[27] describes an 
asymmetry-squared method whereby the tail and front of the peak are measured at 4.4% of 
the height and this ratio is squared. 
 
Capacity or retention factor, can be used to normalize retention in order to compare 








In this equation, tr  is the time taken for the analyte to reach the detector and t0 is the time 
for unretained analytes to reach the detector. Vr and V0 represent the volumes required for 
retained and unretained analytes, respectively, to reach the detector. 
 
Efficiency (plate count) is related to, and defines, the efficiency of the column. Practically 
speaking, the higher the N, the narrower and more concentrated the analyte bands are, and 
the more efficient the column. In the equation below, Vn is the elution volume of a peak, w 
is peak width, and a is a constant derived from the peak height at which the width is 
measured[24]. 
Equation 1.3                                 N ൌ ቀ௏௡ఙ ቁ 2	 ൌ ܽ	 ቀ
௏௡
௪ ቁ 2 
 
Linear velocity, u,  refers to  the speed of the mobile phase moving through the column. It is 
normally expressed in centimeters per second. As these are not units used in everyday LC 
analyses, one may see van Deemter-like plots where LC flow rate is used instead. Linear 
velocity is related to flow rate, the internal ID of the column and the particle size. Linear 
velocity is determined by dividing the column length (L) by the retention time of an 
unretained compound t0[27, 32]. This term is particularly useful when transferring a method 




Resolution describes, in its most basic sense, the relationship between the width of two 
peaks relative to the distance between them. The ability to either decrease peak width or 
improve separation between them, increases resolution. The relationship between resolution 
and intra-column band spread can be summarized as follows: 
 








Where N is plate count (efficiency), α is the selectivity, and k is retention factor. 
 
There are a few additional relationships central to understanding modern LC, and 
ultra performance liquid chromatography (UPLC), in particular. The following equations 
describe the relationship between particle size, flow rate, and efficiency[24] and are key to 
understanding the attractiveness of sub 2µm particle LC (UHPLC) and its widespread 
implementation in a broad range of application areas: 
 
 
Equation 1.5                                       ܴݏ ∝ √ܰ 
Resolution is proportional to the square root of efficiency. 
 
Equation 1.6                                         ܰ ∝	 ଵௗ௣ 
Efficiency (N)  is inversely proportional to particle size (dp), meaning that as the particle 




Equation 1.7                                     ܨ݋݌ݐ	 ∝ ଵௗ௣ 
Optimal flow rate for a separation is inversely proportional to particle size, meaning that 
smaller particles yield higher optimal flow rates and thus reduced analysis times. 
 
Equation 1.8                                       ܰ ∝ ଵ௪ଶ 




1.4.2.2 Band Broadening and the Van Deemter Equation 
 
Arguably one of the most often referred to mathematical representations of 
chromatographic performance is the van Deemter equation and derivatives thereof. 
The aforementioned description of HETP from Martin and Synge, though an accepted 
measure of column performance, is albeit a simplistic one. To truly characterize analyte 
behaviour, one must consider the degree of bandspreading. Analytes are initially introduced 
through the LC system as a discrete band, with Gaussian distribution with the highest 
concentration of analyte being in the center of the band. As analytes travel from the injector 
to the column, and then through the column, during this process there are ample 
opportunities for the analyte band to widen or broaden, this is called bandspread or 
dispersion. The result is a dilution effect which produces a chromatographic peak which is 
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broader and less intense. Ultimately, this corresponds to decreased peak height, decreased 
signal to noise, and ultimately reduced sensitivity. Bandspread can be minimized by 
controlling both intra- and extra- column sources. Injection volume, transfer tubing ID, 
connections, packing material particle size, packing efficiency, and diffusion characteristics 
all contribute. 
van Deemter expanded on the original HETP concept to include a more 
comprehensive analysis of three simultaneous diffusion related processes that an analyte  
molecule undergoes as it travels through a column as well as expressing the dependence of 
HETP on linear velocity[28, 33]. Specifically, van Deemter’s equation (Equation 1.9 , 
below) includes a parameter to describe what is called eddy diffusion (the “A term”), 
longitudinal diffusion (the “B term”), and mass transfer (the “C term”). Eddy diffusion is 
generally the movement of analyte molecules to the surface of a particle and around it and is 
related largely to particle size, while longitudinal diffusion corresponds to analyte 
movement within the mobile phase on the stationary phase and tends to decrease with 
increasing linear velocity. Mass transfer relates to the facility of analyte movement in and 
out of chromatographic pores and is affected by linear velocity and the square of particle 
size[24]. A generic van Deemter plot, including a plot of the individual terms of the van 
Deemter equation, appears in Figure 1.4. Another additional equation worthy of mention is 
the Knox Equation, which is a useful way to assess the quality of a column.  
 






Figure 1.4 van Deemter curve with individual components 
 
1.4.3 UPLC Systems 
 
The complexity of sample composition and the need for greater sensitivity and 
analysis speed (throughput) stretched the limits of traditional HPLC systems. As theory and 
practice so amply demonstrated, the use of even smaller particles and higher flow rates 
should provide the needed improvements. Work published by MacNair and Jorgenson[34] 
highlighted the difficulties associated with sub- 2µm particles and the associated pressures 
and paved the way for the introduction of Ultra Performance Liquid Chromatography 
(UPLC) in 2004 and the associated columns packed with 1.7µm particles.  UPLC systems 
were designed to minimize system and column bandspread while enabling operation at 
pressures up to 15,000 psi. These two key hardware attributes finally allowed the full 
realization of the benefits of sub-2µm separations. Subsequent introductions of other sub-
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2µm particle columns and systems capable of operating at pressures up to 9000 psi 
broadened this chromatographic area into what we now call UHPLC, or Ultra High Pressure 
Liquid Chromatography. Practically speaking, since particle size is directly related to 
efficiency and flow rate, use of sub-2µm particles in a minimally dispersive system results 
in higher efficiency separations, faster. Since their introduction, these types of systems have 
become quite common in bioanalytical labouratories [35-67]. 
 
1.4.4 A Review of LC for Peptide Quantification 
 
The challenges associated with chromatography of peptides stem in part from the 
diversity of this class of compounds. As a class, they span a broad range of sizes, molecular 
weights, isoelectric points (pI), three-dimensional structures, and polarity. Although a high 
degree of diversity is present, peptide composition is actually heavily conserved- there are 
only a finite number of amino acids which comprise their sequences, ensuring the presence 
of multiple closely related species. Peptides are present in samples across an extensive 
linear dynamic range, 4-5 orders of magnitude or more. Whether derived from a protein 
digest or present as a naturally existing or synthetic peptide, peptides in biological matrices 
will need to be separated from numerous closely related interferences. For example, missed 
cleavages and secondary cleavages in protein digests result in peptides that are nearly 
identical to the target peptides. Chromatography of peptides is further complicated by other 
additional factors. These large molecules have multiple points of interaction with 
chromatographic surfaces, meaning that different parts of the molecule can interact in 
different ways, possibly yielding poor peak shape or peaks which elute in two places. In 
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addition, larger molecules such as peptides and proteins exhibit slower diffusion properties, 
and undergo secondary interactions with stationary phases, both which can result in poor 
peak shape and/or carryover under conditions traditionally used in bioanalysis.  
  Although LC separation of peptides has been well documented in the context of 
proteomic analyses or peptide mapping for qualitative work, LC conditions for that type of 
research differ significantly from what is required for a bioanalytical workflow. Peptide 
mapping studies commonly utilize long, shallow gradients (60-120 minutes), low flow rates 
(relative to small molecule analyses) or nanoflow systems, and ion pairing agents such as 
TFA. These conditions are not particularly attractive for a bioanalytical labouratory where 
throughput and MS sensitivity are key aspects of method development. LC systems for 
peptide quantification in these types of labouratories must use MS compatible buffers and 
additives, run times should be between 2 to 10 min maximum, if possible, while selectivity 
from endogenous interferences must be obtained. In addition, peak shapes for small and 
large peptides alike should be as Gaussian and narrow as possible (to improve signal-to-
noise) and the LC system should use sub 2 µm particles, which have been shown to 
minimize the potential for matrix effects caused by co-elutions [68]. 
Several reviews have been published over the past 3 years on the topic of LC 
conditions for peptide bioanalysis. Surveying well over 250 journal articles, the most 
common set of conditions found consisted of C18 chromatographic columns with aqueous 
acetonitrile mobile phases, most frequently modified with formic acid.  
Acidic conditions are typically used as the carboxyl groups on peptides are neutral at 
low pH, improving chromatographic retention and minimizing secondary interactions. 
Those peptides having a strong basic quality (containing several arginine or lysine residues) 
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may not exhibit ideal chromatographic behaviour under these conditions, therefore, ion-
pairing reagents such as TFA may be employed to improve chromatographic peak shape. 
TFA however, is known to cause significant ion suppression under electrospray conditions 
and so it is desirable to avoid its use where possible. The suppression observed is due to 
both the formation of strong ion pairs (which cannot be ionized) and the reduction in signal 
as a result of high droplet surface tension and conductivity [69]. 
 In 2005, Garcia [70] published a thorough review of the impact of various modifiers 
on the sensitivity and resolution of peptides and proteins. Though many buffers and 
alternate volatile ion-pairing reagents were assessed, none were suitable replacements for 
TFA when peptide chemistry necessitated its use. The MS suppression experienced in the 
presence of TFA was outweighed by the resolution improvement it afforded. A recent 
review by Ewles and Goodwin [71] describes their findings with respect to balancing the 
drawbacks and benefits of TFA and optimal conditions. In their work it appears that low 
concentrations of TFA (0.01 – 0.05%) in both organic and aqueous mobile phases might 
provide the desired ion-pairing without the degree of suppression associated with higher 
levels. In addition, mixtures of low concentrations of TFA with more standard MS modifiers 
and buffers (i.e., formic acid or ammonium formate) might provide both the peak shape and 
resolution benefits without the concomitant decrease in sensitivity that usually accompanies 
the use of TFA. The exact nature and composition of the mobile phase will be highly 
dependent on the peptide and its sequence as well as the desired retention, resolution, or 
sensitivity. 
On rare occasion, the use of high pH mobile phases has been reported either to 
neutralize basic groups or to provide improved solubility of the peptide. 
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For the majority of peptide separations, acetonitrile is the organic solvent of choice, 
although Giorgianni et al [72] reported improved detection limits for several peptides using 
methanol. On most modern LC systems, it is straightforward to screen ACN and MeOH, 
and should perhaps be considered as part of routine method development for peptides. 
Acetone was also examined as an alternative to ACN [73]. Retention order for a set of test 
peptides remained the same. However acetone resulted in wider peaks, increased tailing, and 
decreased retention relative to ACN. Peptide response by MS however, was similar.  
With respect to peptide chromatography, the final topic worthy of mention is the use of 
Hydrophilic Interaction Chromatography (HILIC). In HILIC separations, acetonitrile is 
typically the weak solvent and water the strong solvent. It is important to note that HILIC 
may only be used successfully for those peptides soluble in higher percentages of 
acetonitrile. Although its use for peptides has been reviewed in the past [74, 75], very few 
quantitative applications have been reported. One very recent example combines both 
HILIC SPE and HILIC chromatography to successfully quantify several arginine-containing 
hexapeptides[76].  HILIC was also employed by Zhan [77] to quantify a tetrapeptide in 
plasma.  In general, peptide separation by HILIC is employed successfully only for smaller, 
more polar peptides. 
The use of end-capped silica-based or hybrid C18 stationary phases is most common 
for quantitative peptide applications[78]. Naturally, materials which minimize interactions 
with surface silanols are normally used, primarily to improve peak shape. The relatively 
recent (1999) introduction of hybrid particles has enabled separations to be carried out over 
a broader pH range and with significantly reduced surface silanol interactions observed than 





1.5 Overview of Modern Mass Spectrometry 
 
1.5.1 Principles of Mass Spectrometry and Common Components 
 
Mass spectrometry is one of the most important and widely used analytical 
techniques today in many application areas. It is fair to say that in bioanalysis specifically, 
LC/MS is the dominant and preferred option for both quantitative and qualitative 
measurements.  
Separation of various compounds occurs on the basis of the mass (m) to charge (z) 
ratio (m/z) of the analyte. Simplistically, mass spectrometry relies on transfer of analyte 
molecules from a liquid to the gas phase and ionization. Analytes are then separated by m/z, 
in a vacuum, using electric fields. Finally, analyte ions are measured at a detector.  
The primary components of any mass spectrometer consist of a sample inlet, an ion 
source, a mass analyzer, a detector, a pumping system (to create and maintain vacuum) and 
a data collection system[79]. There are variations on several of these components, and only 
those that are most relevant to this work are described in any detail herein. Furthermore, 
some of the most powerful and flexible MS systems have arisen out of combining multiples 
of a given component. Examples include triple quadrupole (QQQ) and hybrid quadrupole 
time-of-flight (QTof) instruments, Electrostatic FTIR MS (Orbitrap) and linear ion traps.  
In bioanalysis, the most common way to introduce a sample into an MS system is 
through atmospheric pressure ionization (API) due to its compatibility with LC sample 
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introduction and the fact that it can be used to ionize a broad range of analytes efficiently 
without overly extensive fragmentation in the source, often known as soft ionization. The 
two ionization modes associated with API are electrospray ionization (ESI) and atmospheric 
pressure chemical ionization (APCI.) Common mass analyzers used in bioanalysis include 
quadrupole mass filters, time-of-flight (Tof), and ion traps. In Tof analysis, analyte m/z is 
determined by flight time in a vacuum, with smaller analytes reaching the detector first. 
Common detectors include photomultipliers, electron multipliers and multichannel plate 
detectors. Ion traps operate by accumulating ions in “traps” of varying geometries, and then 
ejecting specific ions to be measured. The first traps were quadrupole ion traps, with poor 
linear dynamic range, which limited their use in quantitative applications. These were 
followed by linear ion traps that had greater ion storage capacity and reduced charging 
effects compared to their predecessors. Perhaps the most interesting and relevant ion traps 
are orbitraps, which are essentially an accurate mass version of an ion trap. The orbitrap 
geometry consists of an outer and inner electrode between which ions spin and are confined 
by RF and voltage. The combination of angular momentum and RF yields high resolution. 
Since the resolution is proportional to the time spent in the trap, the highest resolution is not 
achievable within the sampling rates required for fast separations. Introduction of the C-trap 
timed the injection of ions into the orbitrap, allowing for more efficient use of the duty cycle 






1.5.2 MS Analyzers Most Frequently Used in Bioanalysis (BA) 
 
Most quantitative bioanalytical applications are performed on triple quadrupole 
instruments, although recent increases in sensitivity of accurate mass instrumentation have 
resulted in a rise in their presence in routine BA labs. High sensitivity quantification is 
frequently carried out on QQQs using multiple-reaction-monitoring (MRM) mode whereby 
one or more precursor ions are selected in the first quadrupole, fragmented in a collision 
cell, and one or more products are selected in the second quadrupole for detection. 
Qualitative analysis is often performed on accurate mass instruments such as a QTof or 
orbitrap due to the wealth of additional information that can be gleaned about a sample, 
such as structural elucidation, unambiguous identification based on mass accuracy, or by 
monitoring a broad mass range to obtain an overall profile of sample components. 
Currently, triple quadrupoles operating in MRM mode are the most sensitive 
platform for quantification and are typically capable of achieving 3-5 orders of magnitude 
linear dynamic range. In MRM mode, these instruments enjoy an approximate 5-10X 
sensitivity advantage over comparable vintage accurate mass platforms[80]. Mass accuracy 
on a QQQ is approximately ±0.1- 0.5 m/z and is considered sufficient for most quantitative 
applications. Accuracy at this level is described as “nominal mass measurement.” In 
contrast, “accurate mass” instruments utilizing time-of-flight (Tof) or orbitrap analyzers are 
capable of accuracy to within ±1-5 ppm. In what might be described as “full scan mode” 
(even though Tof instruments are not scanning instruments), Tof platforms provide 
significantly greater sensitivity than QQQs when a comprehensive snapshot of the sample 
components is desired, in the region of 100 to 1000-fold. 
76 
 
Tandem quadrupole and accurate mass platforms differ perhaps most markedly in 
the mass resolution they are capable of delivering. For QQQ, TOF, and orbitraps, resolution 
is defined as the molecular weight (MW) of a compound divided by the peak width at half 
height (FWHM). QQQs normally operate under unit-mass resolution conditions, which 
means that they can distinguish singly charged ions with a valley between the peaks of 
approximately 10-30% depending on instrument tuning. For a compound of MW 600, this 
would mean a resolution of 850-1000, the exact value being dependent on tuning. In 
contrast, accurate mass platforms routinely operate at resolutions of 5000-50,000 or more, 
thus readily enabling visualization of complex multiply charged species such as peptides or 
proteins. Figure 1.5 demonstrates the comparison of spectra for bradykinin acquired under 
various resolution conditions. 
 
 




1.5.3 Electrospray Ionization  
 
Although MS systems are capable of operating in a number of different ionization 
modes, such as ESI, APCI, and CI, this discussion will focus on ESI as it is the predominant 
technique for large molecules. ESI is compatible with analytes of a wide polarity range and 
is desirable as the precursor ion is often left intact. Though Malcolm Dole is credited with 
the initial idea of electrospray[81], its development into a commercially viable technique is 
generally attributed to John Fenn[82]. 
In electrospray ionization, ions are generated in the solution phase, inside the MS 
source. The solvent is then evaporated off (desolvation) and gas-phase ions enter the MS.  In 
one common source/probe geometry, LC effluent passes through a metal capillary in the MS 
probe to which DC voltage is applied, inducing ionization. There are several theories on ion 
desorption. In one accepted ionization mechanism, during desolvation, opposite charges 
repel each other within the droplet causing “coulombic repulsion”[81, 83, 84]. Aided by 
evaporation of the liquid through heating, smaller and smaller droplets are formed, whose 
charge density increases until ions are ejected from the droplet. Figure 1.6 illustrates this 





Figure 1.6 Graphical representation of the electrospray ionization process. 
 
1.6 LC/MS for Biopharmaceutical Quantification 
 
Due to the increasing number of biopharmaceuticals and biosimilars in development, 
LC/MS is increasingly being considered as a replacement for traditional LBAs. LC/MS/MS 
is an attractive alternative to LBAs because it is characterized by short method development 
times, broad linear dynamic range, a higher degree of accuracy and precision (reflected in 
more stringent regulatory guidelines)[14], high specificity, and the ability to simultaneously 
quantify multiple peptide therapeutics within a single injection and/or method 
(multiplexing). In addition, LC/MS/MS is already widely used in most bioanalytical 
labouratories, thus making it accessible to those skilled with the technology. 
Development of LC/MS/MS assays (including sample extraction prior to analysis) 
for peptides is not without its challenges, however. There are those challenges related 
specifically to the nature and handling of peptides, and there are others related to evolving 
regulatory guidelines and our growing understanding of the possible limitations of 
LC/MS/MS. For example, bioanalytical methods have historically relied on the selectivity 
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of triple quadrupole mass spectrometry to generate acceptable data. Reliance on MS 
selectivity was so strong in fact, that ballistic LC gradients and simple quick and dirty 
sample preparation techniques such as protein precipitation became commonplace. The 
evolution of regulatory guidelines since 2007 now requires that scientists develop more 
selective and reliable bioanalytical methods[85, 86]. Discussions relating to acceptable 
results from incurred sample reanalysis (ISR) impact not only assay reproducibility but 
bring a new focus to analyte stability in various matrices (i.e., plasma, blood, urine). New 
guidelines for the acceptable variability of matrix effects will require the most selective 
bioanalytical method possible, placing renewed focus on the bioanalytical method as a 
whole. These guidelines force bioanalytical scientists to consider the chromatography, mass 
spectrometry, and extraction protocol with equal importance to provide accurate and 
reproducible results.  
LC/MS faces a few important and persistent hurdles when being considered as a 
replacement for a previously existing LBA or for new methods. Guidelines for validation of 
LBA methods are less stringent than for chromatographic assays[14]. LC/MS still struggles 
to obtain the sensitivity of LBAs, and more specifically achieve similar detection limits with 
the same volume of sample. LBAs can provide sensitivity in the pg/mL range, consuming 
only 20-50 µL of sample or less. 
Furthermore, from a handling and analysis standpoint, physiochemical properties of 
peptides differ from small molecules in many ways. In many instances, conventional well-
established “small molecule” LC/MS techniques and strategies may not be directly 
applicable to the analysis of peptides, necessitating potentially extensive staff training 
and/or time to acquire the necessary experience. One of the aforementioned differences is 
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the existence of multiple charge states for peptides, which decreases MS sensitivity and 
limits the specific MS instrumentation that can be used. Figure 1.7 demonstrates the 
difference between the MS spectrum for the singly charged small molecule imipramine and 
that of the multiply charged peptide bivalirudin.  
 
 
Figure 1.7 MS spectra for the singly charged small molecule imipramine (top left) and a multiply charged 
peptide bivalirundin (bottom right.) 
 
For instance, only triple quadrupole instruments with at least a 1500 Dalton mass 
range on the first resolving quadrupole can detect the triply charged state of certain larger 
therapeutic peptides (>3000- 4000 MW). Careful attention must also be paid to the choice 
of precursor and fragment ions to avoid isobaric interferences and to improve specificity for 
the peptide of interest. Furthermore, the zwitterionic nature of peptides, their tendency to 
bind in a concentration-dependent manner to storage containers, and the presence of many 
m/z








Observed mass ESI+ = (MW + 2)/2 = 1091




Observed mass ESI+ = MW + 1 = 281
Multiple charging: detection of large peptides 
possible in lower m/z ranges
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other peptides and high abundance proteins in biological samples, increases the complexity 
of the method development process.  
A review of almost 200 articles in the literature[87] shows that many different 
combinations of LC, MS, and sample preparation conditions have been used for bioanalysis 
of peptide therapeutics, making it challenging to identify a common starting point for 
method development. In addition, many of the published references utilize non-selective 
sample preparation methods such as protein precipitation (PPT) and reversed-phase solid 
phase extraction (RP SPE). These techniques are often used either because they are 
inexpensive or require little to no method development. Though common in small molecule 
analysis, the use of less selective sample clean-up for peptides may not only necessitate the 
use of longer chromatographic runs to eliminate the co-elution of endogenous materials with 
the analyte but may also result in methods which fail matrix effects or ISR criteria. Of these 
challenges, perhaps the greatest difficulties in developing LC/MS-based methods which use 
non-affinity extraction, arise during peptide handling. Adsorption, stability, and solubility 
are critical parameters to understand and control during the method development process. 
 
 
1.7  Identifying and Understanding Handling Considerations 
  
Prior to discussing the utility of specific sample preparation techniques, one must 
first understand how the behaviour of peptides, and the challenges associated with it,  
impact the successful development of an extraction method. From the moment the peptide 
standard is dissolved (if it is in lyophilized powder form), one must address the issues of 
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solubility and adsorption. In general, peptide solubility is not resolved in the same manner 
as for small molecules, and many adsorb to the walls of vials, collection plates, LC surfaces, 
etc. This is particularly true for larger, more hydrophobic peptides.  During method 
development, heavy emphasis must be placed on identifying the condition under which the 
peptide exhibits optimal solubility as this impacts every aspect of method development and 
forms the foundation for successful development of a reproducible, sensitive bioanalytical 
assay. In addition, failure to address adsorption/NSB can be likewise detrimental to the 





Peptide solubility is heavily dependent on its specific amino acid sequence, in 
particular the hydrophobicity and acidity or basicity. There exist many sets of guidelines for 
solubilizing peptides, and all seem to agree on a few key points and rely on the use of well 
understood characteristics of amino acids to help predict peptide solubility. Several good 
sets of guidelines, summarized below, can be found on web pages from Sigma-Aldrich, 






Table 1.2 Useful amino acid properties 
 
1. If a peptide is very small, < 5 residues, it will likely dissolve in aqueous solutions unless 
the sequence is entirely comprised of hydrophobic residues.  
2. Peptides containing >25% charged residues and < 25% hydrophobic residues generally 
dissolve in aqueous solutions. 
3. If the peptide is basic, acidic solutions (formic acid or TFA) with a low % organic (5%) 
often work well. The converse is true for acidic peptides, try solubilizing in basic  solutions 
(1-5% NH4OH for example) with a low % organic. 
4. Peptides containing >50% hydrophobic residues may be only slightly soluble or insoluble 
in aqueous solutions. Hydrophobic peptides are best solubilized in DMSO, DMF, strong 
acid solutions (TFA, formic, acetic), or isopropanol. For cysteine-containing peptides, use 
DMF instead of DMSO. 
5. Guanidine HCl or urea may be necessary for those peptides that tend to aggregate and can 
later be removed during sample preparation. 
6. Peptides which contain >75% of S, T, E, D, K, R, H, N, Q or Y may form intramolecular 
hydrogen bonds and form gels in aqueous solutions. These peptides should be treated in the 
same manner as hydrophobic peptides (#4). 
Property Amino Acid
Hydrophobic A, F, I, L, M, P, V, W, Y
Moderate C, G
Hydrophilic D, E, H, K, N, Q, R, S, T, pyro-glutamic acid
Positive Charge K, R, H, N-terminus
Negative Charge D, E, Y, C-terminus
Degradation likely M, W
Prone to de-amidation, 
dehydration, cyclization to pGlu N,Q, C-terminal amides, N-terminal Q







In addition to solubility, every effort must be made to minimize or eliminate 
adsorption. Peptides bind to vials, collection plates, pipette tips and other surfaces. Many 
researchers have reported significant peptide losses, particularly to pipette tips, during 
solution   preparation or sample handling [88-90].  This may be mitigated by “pre-treating” 
the tips through aspiration of the peptide solution up and down in the pipette tip prior to 
dispensing into the final vessel. Other factors that may influence adsorption include solvent 
composition, container material, temperature, and pH. Adsorption occurs primarily in 
solvent standards rather than extracts of biological matrices, although matrices with low 
protein/lipid content such as CSF or urine may still exhibit adsorption. Most biological 
matrices contain residual proteins or other peptides at higher levels which can act as 
carriers, binding preferentially to surfaces rendering them “inert” to the low level peptides 
of interest. Relative to vial/tube/plate composition, side chains of basic peptides can readily 
interact with surface silanols on glass and hydrophobic peptides may bind through 
hydrophobic interactions with polypropylene or other plastic surfaces. This effect is more 
pronounced at low peptide concentrations. Complete loss of peptide during serial dilution 
often results in loss at the low end of the calibration curve, or even absence of the peptide 
peak during analysis of low level solvent standards. For this reason, it is generally 
recommended that when preparing standard curves, one should spike directly into plasma 
from the peptide stock solution (in which adsorption losses are negligible) and then prepare 
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subsequent dilutions for the lower concentration points by diluting the plasma spiked with 
the peptide stock solution with additional plasma.  
   Issues related to adsorption are further exacerbated by inappropriate solvent choice. 
Peptide losses occur readily in aqueous solutions. Adsorption can, in part, be  ameliorated 
using the proper solvent composition. Any information gathered during solubility testing 
should be applied to all subsequent solution preparation. For example, if the addition of 
acid, base, or organic solvent  improves solubility, the appropriate action should be taken to 
include these modifiers in dilutions of the concentrated standard. Peptides are naturally 
more soluble in aqueous solutions if they are charged, and conversely, more soluble in 
organic solutions when uncharged. For particularly hydrophobic peptides, or low 
concentration aqueous solutions of peptides, one might also consider the addition of a 
commercially available protein such as serum albumin to help eliminate non specific 
binding (NSB) to surfaces by blocking adsorption sites. This is not typically necessary for 
plasma or serum extracts. However, urine or cerebrospinal fluid (CSF) extracts may require 
the same treatment as solvent-based solutions. Finally, concentration by evaporation and 
reconstitution should be avoided if at all possible as this frequently results in significant 
losses. Several options exist for addressing this problem. Addition of a small volume of a 
viscous solvent such as dimethyl sulfoxide (DMSO) or glycerol prior to evaporation 
prevents complete dry down. Alternatively, certain SPE formats exist which enable up to 15 
fold concentration of the sample without evaporation. This option has the additional benefits 
of not only increasing throughput by eliminating time consuming evaporation, but also of 
reducing the number of handling steps whilst ensuring that the sample is in a solution which 
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not only provides good solubility for the peptide (if SPE method development has been 




Another common concern is possible peptide instability or degradation occurring in-
vivo or ex-vivo. Reubsaet et al [91, 92] describe instability as falling into two categories: 
physical and chemical instability. Physical instability is primarily associated with unfolding 
(caused by temperature, pH extremes, or guanidine HCl or urea denaturation) and 
aggregation (primarily due to hydrophobic interactions between partially unfolded species). 
Chemical instability is related to modifications in amino acids which can occur through 
oxidation, reduction, deamidation, hydrolysis, arginine conversion, β-elimination, and 
racemisation [91].  It is important to control conditions which may result in modification 
during all phases of method development.  For example, the use of protease inhibitors to 
improve matrix stability has been widely accepted. Ewles and Goodwin [71] report testing 
numerous protease inhibitors. They concluded that 20 mM diisopropylfluoro phosphate 
(DFP) or Pefabloc® (Roche Diagnostics, West Sussex, UK) were among the best options. 
In addition, it was noted that simple addition of acid (formic or hydrochloric) was often 
adequate to inhibit protease activity.  
Chemical instability is primarily caused by hydrolysis, oxidation, pyroglutamic acid 
formation and de-amidation. Peptides containing D (Asp) are most likely to undergo acid 
catalyzed hydrolysis. De-amidation occurs under base catalyzed conditions in the presence 
of N-G (Asn-Gly) or Q-G (Gln-Gly.) Cysteine and methionine easily undergo oxidation, 
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which is accelerated at high pH. The presence of an N-terminal Gln will most certainly 
result in pyroglutamic acid formation. It is important to note the sequence of the peptide you 
are working with and assess the potential for any chemical modifications that may occur 
either as a result of the storage or extraction conditions. It may be necessary to eliminate 
extreme high pH or low pH conditions during an experiment depending on the specific 
amino acid composition. A recent development is the increased use of dried blood spots 
(DBS) in bioanalytical assays[93-107]. In addition to the obvious benefits with respect to 
low sample volumes and less expensive storage and shipping, DBS has shown promise in 
stabilizing unstable compounds. This technique was successfully employed by Kehler et al  
[108] for the analysis of the large peptide Exendin-4.    
 
1.8 Alternative Techniques and Topics 
 
The use of more advanced techniques such as 2D-LC and nano-flow LC have been 
documented in cases where the required detection limits could not be reached with 
conventional approaches[109-112]. This is typically due to ultra-low levels in study samples 
or the presence of closely related endogenous and/or isobaric interferences that could not be 
resolved using more traditional instrumentation.  
Common configurations of 2D LC systems include trap and back elute, trap and 
forward elute, 2 column approaches (RP-RP, RP-HILIC, etc.), parallel column regeneration, 
at column dilution and heart cutting [113]. Trap and elute configurations enable one to load 
more sample at higher flow rates, focus the sample using a trapping column, and flush salts 
and other interferences to waste. Heart cutting configurations maximize resolution by 
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allowing one to take a narrow chromatographic band containing the peak of interest and 
“cut” it from the first column followed by loading of this greatly simplified sample onto the 
second column for further separation. An example of the benefit of 2D LC for the separation 
of desmopressin and octreotide is shown in Figure 1. 8. In the 2D separation, phospholipids 
were removed when the chromatographic band containing octreotide and desmopressin was 
heart-cut and transferred to a second column. The Figure was reproduced with permission 
from PPD Pharma. 
 
 
Figure 1.8 Comparison of a 1D separation (A) of desmopressin and octreotide and a 2D separation (B)  
 
A recent publication by Zhang et al [112] details the development of a sensitive 
method for endogenous oxytocin, which reaches an LLOQ of 1 pg/mL in human plasma 












gradient on the first column, the peak was then heart cut to the second column and eluted 
under isocratic conditions.  
The low flow rates used in nano-LC can provide significant improvements in MS 
ionization efficiency, resulting in dramatic sensitivity gains due in part to improved 
ionization efficiency. However, nano-flow systems are often perceived as having poor 
robustness, requiring a very skilled operator and as being somewhat of an “art.” The narrow 
diameter columns (typically 75-300 µm), sensitivity to integrity of connections and tubing 
cuts, and “finicky” nature of the spray from various tip types contribute to this perception 
and to the limited use of nano-flow in routine bioanalytical labouratories. In addition, the 
low flow rates required result in long chromatographic run times, severely restricting 
throughput. 
Methods which include highly selective isolation and enrichment techniques based 
on affinity purification of peptides, such as immunoprecipitation (IP), prior to analysis can 
achieve even greater specificity. Li et al [114]described such an approach for the 
quantification of amyloid peptides during the 2009 AAPS meeting. Columns packed with 
anti-peptide antibodies have also been used to selectively enrich target peptides. This was 
successfully applied by Neubert et al [111] to enrich signature tryptic peptides of 
pepsin/pepsinogen  for protein quantification. Though in more widespread use currently, 
these approaches are limited by the availability of commercial reagent kits or the internal 







1.9 Research Aims 
 
This research projects aims to overcome the identified short comings of LC/MS as it 
pertains to its adoption for quantification of large molecules, endogenous and therapeutic 
peptides in particular. Specifically, this work will endeavour to increase the sensitivity and 
specificity of LC/MS assays for peptides and ultimately to couple this with a reduction in 
required sample volume. 
 
The research will be carried out in several steps: 
 
Phase 1: Develop an understanding of factors influencing LC and MS sensitivity and 
specificity for peptides and propose rules and guidelines for MS method development as 
well as a starting LC screening protocol. Similarly, various sample preparation techniques 
will be evaluated on the basis of recovery, selectivity, and compatibility with the required 
LC mobile phase. A starting sample preparation protocol will also be proposed. 
 
Phase 2: Apply the fundamental handling issues and proposed resolutions learned in phase 1 
to develop an LC/MS method to quantify amyloid beta peptides, putative Alzheimer’s 
Disease biomarkers, in human CSF. This method is intended to replace IP/LC/MS methods 
and ELISAs. We will also explore and contrast various surrogate matrices to the standard 
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addition approach for quantification in CSF. Finally, 1D and 2D LC strategies will be 
evaluated. 
 
Phase 3: Investigate a multi-stage sample preparation scheme to develop an assay for the 
osteoporosis drug teriparatide with specificity and sensitivity equivalent to the traditional 
RIA.  
 
Phase 4: Investigate multi-dimensional LC coupled to two-stage high-throughput sample 
preparation to simultaneously quantify human insulin and five commonly dosed analogs. 
Demonstrate performance improvements relative to more generic approaches. 
 
Phase 5: Investigate the use of microscale LC and an integrated microfluidic column to 
further improve sensitivity and reduce sample volume required in assays for  teriparatide, 
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Investigating Sample Preparation, LC and MS for Large 
Molecule Quantification: Development of Basic Screening Tools 









Chapter 1 established that the ideal platform for quantification of both small 
molecules and peptides is LC/MS. Within that realm, the most common LC conditions for 
small molecules employ reversed-phase stationary phases. Sample prep for small molecules 
is typically protein precipitation, liquid-liquid extraction (for lipophilic molecules), or SPE 
which has the advantages of being easy to automate, offering a wide variety of stationary 
phases, and the ability to finely tune the wash and elution solutions to obtain specificity. It 
would seem logical to quantify peptides using the same techniques. However, with respect 
to LC, peptides elute in a very narrower window of organic composition relative to small 
molecules. As this thesis focuses on analysis in biological matrices, thousands of other 
peptides can coincidently elute within that same organic composition window, making LC 
separation particularly challenging. In addition, peptides are zwitterionic, further 
complicating LC method development. From a sample preparation perspective, protein 
precipitation extracts are often too dirty to enable low level peptide quantification while 
liquid-liquid extraction uses solvents which are not compatible with peptide solubility. From 
a mass spectrometry perspective there are several key factors that make peptide analysis 
more complicated than that of small molecules. Peptides are multiply charged and therefore 
the precursor ion current is distributed across several different species, each potentially 
containing its own isotope envelope. This means that not only is the parent signal decreased 
relative to small molecules (in general), but one must also optimize the conditions for 
multiple precursors, and subsequently find a way to identify the most specific of these. In 
addition, attempted collision induced dissociation (CID) of the various precursors may 
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result in either minimal or overly extensive fragmentation (into many low abundance 
species), and in fewer cases, the desired production of several well defined fragment 
candidates. As a result, sensitivity is further reduced relative to small molecules either due 
to the production of many singly or multiply charged fragments or when little to no 
fragmentation occurs. Again, one must now identify a way to choose the most specific of 
the many possible fragments available from each of the possible precursors.  
Whilst the obvious starting point for peptide bioanalytical research would be that 
used for small molecules, one must recognize that because the morphology and chemical 
nature of peptides is so different from their small molecule counterparts, this approach is not 
likely adequate for high sensitivity peptide quantification. Therefore, the work described in 
this chapter is aimed at identifying the best possible starting conditions for peptide 
bioanalytical method development. From this, a series of rules and guidelines for high 
sensitivity peptide quantification will be derived. This chapter and the learnings therein will 
form the foundation upon which all subsequent chapters will be based. 
This chapter will be presented in three segments: liquid chromatography, mass 
spectrometry, and sample preparation. Each segment will identify key parameters for 
consideration when using these techniques for peptides, potential pitfalls, and differences 
relative to small molecule analysis. The studies described within each section will result in 
the generation of fundamental rules and guidelines to be applied in Chapters 3-6.  Following 
the successful identification of recommendations from each of the three sections: LC, MS, 
and sample preparation,  a logical, stepwise, and routine strategy to bioanalytical method 
development for peptides will be proposed. Finally, a critical aspect of this work will be the 
development of rules and guidelines which produce more selective, sensitive and 
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reproducible methodologies and ensure their validity with respect to current and evolving 
(future) regulatory requirements.  
 
2.2 Section I. Investigation into Parameters Affecting LC of Large Molecules 
 
A review of over 200 published methods for peptide quantification[1] validates the 
use of reversed-phase  C18 LC for peptide analysis as this condition is employed in the 
overwhelming majority of instances. Furthermore, acetonitrile is the organic solvent of 
choice, representing the optimal condition for the bulk of peptide separations. Finally, this 
same review establishes formic acid as the ideal modifier. Therefore, the focus of this 
section will be limited primarily to ascertaining and distinguishing the important subtleties 
and attributes within this set of conditions which render optimal separation of peptides 
possible. Only a minimal discussion of other modifiers, stationary phases, and organic 
options will be presented. 
 
2.2.1 Influence of Particle Size 
 
It is clear that resolution from closely related endogenous constituents, speed, and 
sensitivity are all absolutely critical for effective, reliable and efficient analysis/separation 
of peptides in bioanalysis. Sub-2 µm porous particle LC, or UHPLC, has been used 
extensively in both small molecule and peptide bioanalytical applications specifically for the 
benefits it provides in terms of these exact parameters [2-12].   As valuable as these 
characteristics are to small molecule analysis, they can be even more critical to successful 
111 
 
peptide analysis. Peptide drugs are often modified versions of substances already in the 
body, meaning that there will almost always be a closely related interference present in the 
sample. The drug desmopressin and the endogenous hormone vasopressin upon which it is 
based, are a good example of this. Desmopressin differs from human vasopressin by the loss 
of an amino group. Thus, the resolving power of the chromatography system used for this 
separation is critical, and sub-2 µm LC has demonstrated improvements in resolution and 
detection limits that are significantly better than conventional HPLC [2-4, 6-12]. 
It is important to understand the differences between small and large molecules as it 
pertains to the use of UHPLC. A van Deemter plot was constructed using flow rate instead 
of linear velocity to demonstrate how the theoretical plate height for large molecules 
degrades much more rapidly than for small molecules at the higher flow rates that typically 
dominate most bioanalytical labouratory operations today (Figure 2.1). The figure was 
developed using the van Deemter equation below, where u = flow rate rather than the more 
traditional linear velocity. In the below equation HETP is equal to the Height Equivalent to 
a Theoretical Plate. 
.  





Figure 2.1 van Deemter plot, for theoretical compounds representing a small molecule and different sized 
peptides, constructed using flow rate expected for a 2.1 mm column 
 
The plot clearly highlights how for small molecules the chromatographic 
performance is conserved at a much higher flow rate (linear velocity) than that for larger 
molecules.  The data displayed in the plot shows that as the flow rate is increased from 0.1 
to 0.5mL/min the HETP is only increased from 10 to 15 for small molecules and changes 
from 12 to 35 for a large peptide, As such small molecules can be analyzed with much 
higher flow rates without a significant loss in separation quality and efficiency versus larger 
molecules like peptides, which must be analyzed using lower flow rates in order to achieve 
the required performance.  This is primarily due to the lower diffusion rates of peptides in 
and out of the pores of the stationary phase.  However, for high throughput applications 
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such as bioanalysis, it is not practical to use the very low flow rates needed for peptide 
separations, nor is it typically practical to use isocratic separations.due to the complexity of 
the matrix, speed required to effect a challenging separation and the throughput required in a 
routine bioanalytical environment. 
In order to compensate for the slower diffusion of peptides, smaller particle sizes can 
be used. Figure 2.2 shows the calculated van Deemter plots for a 2500 MW peptide 
analysed on 2.1 mm diameter columns packed with both 1.7 and 3.5 µm particles.  
 
Figure 2.2 Calculated van Deemter plot, using flow rate, for a model peptide analyzed on a 2.1 mm column 
packed with 1.7 and 3.5 µm particles 
 
While the optimum flow rate for this peptide is similar on both particles (~ 25 – 50 
µL/min), the separation performance of the 3.5 µm particle column degrades much more 





















rapidly than the 1.7 µm particle column as the flow rate increases. From an implementation 
standpoint, this means that better resolution and peak shape can be obtained on sub-2µm 
particles at higher flow rates. At a typical bioanalytical flow rate of 0.4 mL/min the column 
packed with 3.5 µm particles has a 5X increase in plate height compared to its optimum, 
whereas the column packed with 1.7 µm particles exhibits only a 2X increase in plate 
height.  This clearly indicates that the use of smaller particles is preferred for high 
throughput bioanalysis of peptides.  
  From a practical standpoint, however, peptides are typically analyzed using a 
gradient rather than isocratic methods in order to reduce analysis times and to facilitate the 
separation of complex, diverse mixtures with a wide range of hydrophobicities.  To illustrate 
the benefit of using small particles for peptide separations, 3.5µm and 1.7 µm columns 







Figure 2.3 Representative chromatogram of 50 ng/mL desmopressin separated on columns packed with the 
same stationary phase in 1.7 or 3.5 µm particles. The Table on the right summarizes results from other peptide 
analytes showing even greater benefits from using sub 2 µm materials.  
 
Both columns were of a 2.1 X 50 mm geometry, using the same BEH C18 stationary 
phase operated at 0.4 mL/min using a formic acid and acetonitrile mobile phase gradient. 
These columns have the same base particle and differ only in particle size. Both were run on 
a low dispersion chromatography system capable of operating up to 15,000 psi. (ACQUITY 
UPLC system) using the same flow rate and gradient. The peptides  analysed on the 1.7 µm 
particle column consistently elute as sharper, more efficient peaks, which translated into a 
higher signal-to-noise value (peak-to-peak or RMS) and the ability to achieve lower limits 
of detection.  These data correlate well with the previous findings by Gilar et. al, who 
demonstrated a marked increase in peak capacity for peptides using 1.8 µm particles 
compared to either 3.5 or 5 µm particles [5]. 
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2.2.2 Influence of Ligand 
 
Though C18 seems to be the preferred ligand for the majority of reversed-phase 
separations, in our experiments, the use of shorter ligands may occasionally prove 
advantageous for particularly large or hydrophobic peptides. Figure 2.4 illustrates the 
improvement in peak shape and signal intensity that was obtained on a C4 column for the 
HIV fusion inhibitor enfuvirtide when analyzed on columns having identical base 
chemistry, with two different pore sizes (130 and 300Å) and either C4 or C18 ligands. 
Enfuvirtide is a very hydrophobic peptide, having an HPLC index of 155,  therefore it is not 
surprising that a better peak shape is obtained on a less retentive column. From Figure 2.4, it 
is clear that the peak width is greatly improved when larger pore sizes are used (300 versus 
130 Å). Peak width narrows even further as the ligand is changed from C18 to C4 (0.4 min 
versus 0.6 min wide at base) and peak area and intensity are greater (25560 area counts 
versus 15900) on the C4 column. Although other large, hydrophobic peptides were also 






Figure 2.4 Separation of enfuvirtide on ACQUITY BEH C18 130Å, 300Å and BEH C4. 
 
More recently, C18 columns with a positively charged surface were introduced and 
also tested. Initially, such columns were developed to improve performance for basic small 
molecules in low-ionic strength mobile phases, such as formic acid. This is achieved by 
minimizing undesired secondary interactions with the stationary phase, resulting in reduced 
tailing and increased loading capacity. Though originally designed with small molecule 
performance in mind, studies by McCalley[13, 14] suggest that this type of column might 
provide an advantage for peptides. His studies demonstrated that ionic species such as 
peptides exhibit poor peak shape at orders of magnitude lower concentrations than neutral 
species. This behaviour is exacerbated when low ionic strength mobile phases are used (i.e. 
formic acid). The effect could be mitigated through the use of ion pair reagents such as 
TFA, however, this is not compatible with MS detection. Since the charged surface column 
ACQUITY BEH 1.7 µm C18 300Å
ACQUITY BEH 1.7 µm C18 130Å
ACQUITY BEH 1.7 µm C4 300Å
Enfuvirtide: MW  4492
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tested was designed to mitigate these exact short comings, it was a good candidate for 
peptide chromatography. Figure 2.5 demonstrates the peak shape improvement for 
teriparatide provided by a Waters Charged Surface Hybrid (CSH) column when compared 
to analysis on a traditional, uncharged BEH C18 hybrid particle. This is interesting since the 
BEH particle actually has 300 Å pores, while the CSH is characterized by 130 Å pores. The 
improved performance shown in Figure 2.5 may be attributed to the ability of the positively 
charged surface to  minimize secondary interactions with the stationary phase and reduce 
NSB, resulting in narrower chromatographic peaks. 
 
 
Figure 2.5 Separation of teriparatide (MW 4117) on an ACQUITY UPLC CSH C18 and ACQUITY BEH 300 
C18; the same mobile phases, sample, and gradients were used. 
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2.2.3 Influence of Chromatographic Pore Size 
 
The influence of pore size was discussed in the previous section.  No concrete rule 
currently exists as to which pore size to use for peptides of a particular size, which means 
columns packed with particles of different pore sizes need to be evaluated to determine the 
effect on peak shape.  From the data collected in this study using a screening approach 
based on a single column, a larger pore size column gives superior peak shape, and results 
in better signal-to-noise and lower detection limits, particularly for larger peptides. Smaller 
peptides generally perform equally well on columns with either a 130 or 300Å pore size.  
The data shown above suggests that larger pores may mitigate some of the loss in efficiency 
observed for peptides at higher flow rates. 
 
2.2.4 Charged Surface and Fully Porous versus Solid Core Particles 
 
Reports by Wagner, Stefano and Kirkland[15-17] demonstrated a superior mass 
transfer and thus significantly improved peak performance for large molecules using solid-
core particles, making these columns an obvious candidate for evaluation. 
On an individual case basis, the data collected suggests that pore size and presence 
or absence of surface charge could influence the chromatographic peak shape for peptides. 
To evaluate the effect of  particle porosity a more comprehensive comparison of columns 
including a set of test peptides with diverse properties was designed. Test peptides and their 
properties are summarized below in Table 2.1.  Table 2.2 details the specific columns tested 





Table 2.1 Diverse peptides used in chromatographic and sample preparation testing, and their relevant 
physiochemical properties. Not all peptides are used in all tests. 
* HPLC index is used as a measure of relative hydrophobicity. A low value indicates a more polar peptide, a 
high value indicating a more hydrophobic peptide.  
 
 
Table 2.2 Characteristics of the four columns compared for peptide separations. 
 
All columns were analysed on the same low dispersion chromatographic system 
(ACQUITY UPLC) using a generic gradient elution profile from 5 to 75% acetonitrile at a 
flow rate of either 0.25 or 0.4 mL/min. 
Peptide MW pI Residues HPLC Index* 
RASG-1 1000 9.3 10 0.4
Angiotensin II 1046 7.4 8 38.3
Bradykinin 1060 12.0 9 47.8
Vasopressin 1084 9.1 9 7.6
Goserelin 1270 7.3 10 31.7
Angiotensin I 1296 7.5 10 56.2
Somatostatin 1638 10.4 14 52.6
Neurotensin 1673 8.9 13 44.4
Renin Substrate 1758 7.6 14 81
Enolase T35 1872 7.3 16 113.3
Bivalirudin 2180 3.9 20 46.2
Enolase T37 2827 4.0 23 100.2
Melittin 2846 12.1 26 124.4
BNP 3464 12.0 32 15.9
Teriparatide 4118 9.1 34 90.4
Enfuvirtide 4492 4.1 36 155.9
Bovine Insulin 5734 5.3 51
Column Pore Size Å Surface Charge Porous/Solid core Particle Size µm Description
Silica Hybrid C18 130 none added Porous 1.7 BEH C18 130
Silica Hybrid C18 300 none added Porous 1.7 BEH C18 300
Charged Surface silica 130 + Porous 1.7 CSH C18
Solid core charged surface silica 90 + Solid core 1.6 CORTECS C18+
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The primary goals of the study were as follows:  
 to compare efficiency at different flow rates,  
 compare superficially porous to fully porous charged surface columns,  
 to compare different pore sizes on the same chemistry stationary phase,  
 to compare different stationary phase chemistries,  
 and to compare injection solvents.  
The stationary phases were compared for analyte retention, peak shape, and analyte peak 
area. Different flow rate conditions were compared to better understand the relationship 
between linear velocity and mass transfer. The hypothesis under evaluation was that the 
influence of flow rate on chromatographic efficiency would be greater for larger peptides on 
traditional fully porous columns, than on solid-core stationary phases. A similar hypothesis 
was made regarding larger pore size stationary phases, chiefly that peak shape and intensity 
would suffer less at higher linear velocities when larger pore size stationary phases were 
employed.  
In addition, peptide standards were prepared in solutions containing carrier protein 
(0.05% by volume rat plasma) and either 1% formic acid, or 0.5% TFA. This was carried 
out to address both the potential solubility differences as well as to assess whether the 
presence of an ion pairing reagent would influence peak shape and sensitivity. Both peak 
area and peak width were measured under all conditions. Summaries of the results of these 






Figure 2.6A Summary of relative peak areas for test peptides separated on either a silica hybrid C18 (BEH 
300Å) or solid core charged surface silica (CORTECS C18+ 90 Å) column using either 0.5% TFA or 1% FA 
as the injection solvent.  
 
 
Figure 2.6B Summary of relative peak area for test peptides separated on the four columns in Table 2.2, using 
a flow rate of either 0.25 or 0.4 mL/min. 
 
* Peak Area 0.5%TFA/1.0% FA




Figure 2.6C Summary of relative retention for test peptides separated on the four columns described in Table 
2.2, using a flow rate of 0.4  mL/min and 1% FA as the injection solvent. 
 
 
Figure 2.6D Summary of relative peak widths for test peptides separated on the four columns described in 











Figure 2.6E Summary of relative peak areas for test peptides separated on the four columns described in Table 
2.2, using a flow rate of 0.4 mL/min and 1% FA as the injection solvent. 
 
 
Figure 2.6F Comparison of peak widths for melittin on four different columns. 
* Normalized to average area of peptide across the 4 columns
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Figure 2.6G Comparison of peak widths for bovine insulin on four different columns. 
 
 
Figure 2.6H Comparison of peak widths for teriparatide on four different columns. 
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Although it was hypothesized that one could use the properties of a peptide to 
choose the best column, the data prove otherwise. Furthermore, insulin appears to be an 
outlier in many tests and will be the subject of a more thorough assessment and 
comprehensive method development in Chapter 5. From these data, there are, however some 
conclusions and generalizations that can be made. Figure 2.6A indicates that, in general, 
peak areas on the silica hybrid with 300 Å pores (BEH 300) column are roughly equivalent 
whether aqueous trifluouroacetic acid (TFA) or aqueous formic acid (FA) are used as the 
injection solvents. In contrast, using aqueous TFA as the injection solvent on the 
superficially porous charged surface silica column (CORTECS C18+) generally yields 
lower peak areas. Those that suffer most in the presence of TFA, enfuvirtide, the T37 tryptic 
peptide of enolase, and brain natriuretic peptide (BNP), are diverse in that some are acidic, 
some basic, some polar and some quite non-polar. The only common property that might 
link them is their size as all are >2800 MW and could be considered “large”. This is the first 
instance where insulin is a clear outlier, preferring TFA under either column condition. It is 
presumed that this is primarily due to solubility. Figure 2.6B demonstrates clearly that, 
regardless of column selection, peak areas are on average 25-50% greater at 0.25 mL/min 
than observed at 0.4 mL/min. In cases where absolute sensitivity is not critical, the higher 
flow rate may be advantageous as it yields improved throughput. Figure 2.6C summarizes 
relative retentivity of the various columns and establishes that the CORTECS C18+ (the 
only superficially porous column tested here) is the least retentive, conversely, the porous 
charged surface column provided a modest 10% increase in retention. Not surprisingly, both 
traditional C18 columns offer the greatest peptide retention. Figure 2.6D examines peak 
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widths and in fact supports the theory that, using a traditional C18 stationary phase broader 
peaks may be observed for larger hydrophobic peptides such as insulin, teriparatide, and 
melittin. The narrowest peaks are typically observed using charged surface columns. 
(Figures 2.6F-H provide additional detail that may not be clear when looking at the 
averaged bar graph in Figure 2.6D.) Figure 2.6E summarizes peak areas across all columns 
tested and, for insulin, highlights that the greatest area is achieved on the large pore size 
C18, but at the expense of peak width (Figure 2.6D), which is significantly narrower on 
either of the charged surface columns. Other large peptides such as BNP, T37, enfuvirtide, 
and teriparatide do not follow this trend. A more detailed examination of chromatograms 
exposes an obvious trend. Figures 2.6F-H compare the chromatographic performance for 
melittin, insulin, and teripartide, respectively. It is clear that peak widths for all three of 
these large hydrophobic peptides exhibit the same trend. Narrowest peaks are found on the 
solid core charged surface column (CORTECS C18+), and become increasingly broad as 
one progresses to the fully porous charged surface (CSH), fully porous silica hybrid with 
300 Å pores (BEH 300), and finally, the broadest peaks are observed on a fully porous silica 
hybrid with 130 Å pores (BEH 130.) 
Monolithis columns were not examined in this study as they do not provide adequate 
resolution in lengths that are practical for the application. 
 





The investigation of particle diameter, pore size, and stationary phase chemistry 
suggests that choice of optimal column for achieving maximum sensitivity for a specific 
peptide may not be predictable based on the peptide properties. Rather, it must be 
determined through a series of simple screening experiments. However, from the data 
presented above, the following set of guidelines for LC method development have been 
derived. Initial method development for peptide chromatography should consist of screening 
3 columns, all C18, packed with  <2 µm particles, and in 2.1 X 50 mm dimension. 
Specifically, our data indicates that a C18 column with 300Å pores, a fully porous charged 
surface hybrid C18 column, and a superficially porous, or solid core, C18 with a positively 
charged surface should be evaluated. The use of a 2.1 x 50 mm column provides both the 
throughput required and adequate separation, especially if used in conjunction with selective 
sample preparation. If improved separation is needed, longer columns should be used. A 
gradient from 15% to 75% acetonitrile should be employed as an initial screening regime as 
it brackets the typical elution window for peptides with a broad range of hydrophobicities. It 
is important to note that during gradient elution, gradient conditions should be set to ensure 
the elution of the peptide within the above defined window. The use of ballistic gradients, 
common in small molecule analysis, which could cause elution at very high percentages of 
organic, may result in precipitation of the peptide on the column. Once a peptide has 
precipitated on the chromatographic column, it may be very difficult to remove, and may 
result in poor chromatography (broad/split peaks, carry-over) in subsequent runs and ghost 
peaks. 
An optimal flow rate of 0.4 mL/min on a 2.1 mm diameter column correlates with 
our own data and previously published findings [18] and represents a starting point which 
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balances speed with sensitivity arising from resolution and peak shape.  Although the 
parameters defined here represent an appropriate starting point, they may be optimized 
during method development to achieve the desired resolution, run time, and limit of 
detection for a particular assay. 
In order to evaluate the feasibility and utility of the proposed chromatographic 
starting point for peptide bioanalysis, a subset of therapeutic or endogenous peptides (listed 
in Table 2.1) were selected for analysis. The peptides were chosen based on their diversity 
in molecular weights, acidity/basicity, and hydrophobicity.  Throughout these studies, 
HPLC index is used as a measure of relative hydrophobicity. A low value indicates a more 
polar peptide, a high value indicating a more hydrophobic peptide.  
A separation of 5 representative therapeutic/endogenous peptides using the UHPLC 
screening conditions recommended above is shown in Figure 2.7.  All peptides elute within 
the specified organic composition window, despite their divergent hydrophobicities, size 
and pI. Each exhibits a Gaussian peak shape and elutes in a narrow chromatographic band, 
having peak widths ~ 2 seconds wide at base. Furthermore, the separation power is such that 
vasopressin (human antidiuretic hormone), peak 1, and desmopressin, peak 3, are baseline 
resolved using the proposed screening method. These compounds are analogous to each 
other, differing only in the loss of an amino group (in desmopressin), making this separation 
particularly challenging. The presence of highly similar endogenous peaks in an extracted 
sample is expected to be quite common in real world bioanalytical studies, therefore such 





Figure 2.7 Representative separation of 5 peptide therapeutics using the proposed LC screening. 
 
The method above is proposed simply as an LC screening method or starting point. 
It should be recognized that optimization and/or troubleshooting may be necessary upon 
examination of initial results. Therefore the following recommendations for subsequent 
steps in separation optimization are proposed. These are derived from experiences gained 
during this research. 
In addition to the challenges already addressed (selectivity, resolution, throughput, 
and peak shape), other common pitfalls encountered when analyzing peptides include 
analyte carryover, adsorption, and issues related to peptide solubility in the mobile phase 
and the injection solvent. In particular, solubility and adsorption problems can manifest 
themselves as any of the following: carryover, poor peak shape, poor linearity, poor 
reproducibility and loss of sensitivity at low concentrations. In the case of suspected 
carryover, one needs to first determine if the carryover is occurring in the chromatographic 
column or in the LC instrument itself (i.e. tubing, injector port, sample needle.)  
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A simple test to determine the source of carryover involves performing an internal 
gradient. In other words, the gradient is repeated within the same run without performing a 
separate injection. If a peak appears in the second gradient at the expected retention time of 
the peptide of interest, then the carryover is suspected to be due to incomplete elution of the 
peptide from the stationary phase in the first gradient.  This can be resolved in several ways. 
Column carryover (also called memory effect) is due to the inability of the chromatographic 
conditions to fully elute the peptide during the run, either due to slow and incomplete 
diffusion in and out of the chromatographic stationary phase pores and/or poor solubility in 
the mobile phase with the modifier and flow rate being used. To improve solubility in the 
mobile phase, the separation temperature can be increased. In addition, flow rate may be 
decreased to allow more time for diffusion into the mobile phase. These changes often not 
only decrease carryover, but also increase peak area as more of the peptide is effectively 
solubilized in the mobile phase and/or speed of partitioning increased.  Figures 2.8 and 2.9 
demonstrate significant improvements in area counts for an amyloid beta peptide (MW 
4330). Specifically, at higher temperature the data show a ~50% increase in area, and at 





Figure 2.8 The effect of column temperature on area count for amyloid beta 1-40 (MW 4330) 
 
  
Figure 2.9 The effect of flow rate on area count for amyloid beta 1-40 (MW 4330) 
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Lower flow rate increases area 48% and reduces carryover
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Reducing  the gradient steepness can also have a similar effect, as highlighted in the 
separation for teriparatide in Figure 2.10.  In this case, the shallower gradient allows more 
time for the peptide to diffuse into the mobile phase, thus improving its recovery and 
ultimately area counts and sensitivity.  In addition, a higher strength or higher percentage of 
the mobile phase additive can be used (i.e. increasing % of formic acid.)  
 
 
Figure 2.10 The influence of gradient slope on peak area for teriparatide (MW 4117): column temperature is 
60°C and flow rate is 0.4 mL/min. 
 
If the internal gradient test does not show carryover due to incomplete elution from 
the stationary phase, then the carryover is occurring in the injection fluidics, and adjustment 
of the needle washes and/or injection solvents may be required. In a recent paper by 
Mitulovic et al [9] the authors identified an efficient wash solvent using several percent 
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trifluoroethanol (TFE) to clean not only the autosampler, but also a trap column if used. 
Based on this data, it could be hypothesized that  TFE might also be added to mobile phases 
for additional column cleaning for particularly troublesome peptides. Figure 2.11 
demonstrates the increased area counts for the large peptide teriparatide when 5% TFE is 
added to mobile phase B, which consisted of 0.1% formic acid in acetonitrile. This suggests 




Figure 2.11 A comparison of peak area for teriparatide when either 0.1% FA or 0.1% FA + 5% TFE are used 
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An injection solvent that does not contain a sufficient concentration of organic 
solvent and modifier may also cause carryover, as peptides can precipitate out of solution 
during the injection process and deposit on the connecting tubing and other components in 
the system, resulting in adsorption and non-specific binding (NSB).  Adsorption and NSB 
represent perhaps the greatest difficulty encountered when handling peptides and must be 
assessed as early in method development as possible, as they can affect not only the LC 
method but also the sample preparation. Care must be taken when choosing LC vials or 
plates. In general plastic is better than glass, especially for basic peptides as they can 
interact with surface silanols in glass vials and plate inserts via ionic attraction. Recently, 
so-called “low binding” tubes and plates have been introduced by such manufacturers as 
Eppendorf. These tubes and plates are now widely used in peptide and protein analysis due 
to the significantly reduced binding. 
As a result of the findings above some general comments can be made regarding 
peptide analysis: in general peptide solutions should be dissolved in an aqueous solution 
containing a minimum of 5% organic (v/v) and 0.1% formic acid or 0.05% TFA (v/v), both 
of which help to keep target peptides in solution. It is prudent to add a carrier protein to all 
solvent standards and stock solutions, even if NSB is not predicted. Either 0.05% plasma 
(by volume) or 40 µg/mL bovine serum albumin (BSA) have shown to exhibit an equivalent 
effect, and can not only reduce binding to containers, but may also reduce unwanted 
secondary interactions with the column stationary phases. Figure 2.12 shows the 
equivalence of the two carrier protein options (Figure 2.12B), and also demonstrates the 





Figure 2.12 The influence of the addition of rat plasma as carrier protein on the peak shape of teriparatide 
(2.12A) and a comparison of two carrier protein options (2.12B)  
 
It may be advantageous to employ injection solvents with even higher concentrations 
of organic solvent and acid / base modifier in order to maintain solubility throughout the 
duration of an overnight analytical run and autosampler stability tests. The data displayed in 
Chapter 4 on the quantitation of amyloid β peptides[19]  demonstrate this concept quite 
nicely. For the analysis of amyloid peptides, the final injection solvent consisted of ~40% 
organic solvent and ~5% NH4OH, both of which were essential for maintaining solubility 
and minimizing adsorptive losses for these incredibly hydrophobic class of peptides.  
 




Chapter 1 established that triple quadrupole (QQQ) or ion trap MS are the best 
options for high sensitivity quantification. TOF MS was not used as it currently does not yet 
have the sensitivity of QQQ in the MRM mode, and MALDI is only semi-quantitative and 
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lacks the upfront LC separation necessary to resolve the peptides of interest from 
endogenous compounds in the complex matrices associated with bioanalysis.  
The vast majority of quantitative analysis in bioanalytical labouratories is performed 
on triple quadrupole mass spectrometers due to their specificity and selectivity resulting in 
highly sensitive analytical assays. This section will focus on the use of triple quadrupoles 
(QQQs) as they represent the instrument configuration in most widespread use, though ion 
traps and quadrupole time of flight instruments are also employed. Recent advances in MS 
instrument design have resulted in the increased use of hybrid-TOF instruments, but reduced 
sensitivity versus QQQs in multiple reaction monitoring (MRM) mode have limited their 
use as a platform for ultra-low level peptide quantification. At the present moment in time 
triple quadrupole instruments, operated in MRM mode, still offer the highest sensitivity for 
targeted analyses, and are the platform of choice for both small molecule and peptide 
quantitative applications.  
Mass spectrometric analysis of peptides differs significantly from that of small 
molecules in that  the overall signal obtained for peptides is often lower than for small 
molecules for a similar molarity or analyte concentration. There are several reasons for this. 
Firstly, peptides are multiply charged species whereas small molecules are typically singly 
charged, and second, there may be several different multiply charged precursors present, 
both of which dilute the overall ion intensity across several species. Furthermore, peptides 
tend to form many low abundance fragments rather than one or two intense ones, reducing 
overall signal for MRM experiments. An even greater loss of signal can be observed for 
large peptides that are not as efficiently transferred into the gas phase during ionization as 
are small molecules.  It may be advantageous to sum transitions to either improve signal 
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intensity or reduce variability if the relative abundance of a specific precursor changes 
during the analysis. Clearly, one not only needs to consider the sensitivity of the MS 
specifically for large molecules, but also any additional aspects of the method (LC, sample 
concentration during extraction, etc.) that can be used to improve assay sensitivity.  
During analyte signal optimization in the mass spectrometer, it is common to see 
several different precursor ions due to multiple charging. Whereas small molecules gain or 
lose a single proton, large biomolecules have multiple protonation sites and therefore can 
gain or lose several or many protons, generating what are called “multiply charged” species. 
For example, the N terminus and the various amino acid side chains of peptides are common 
sites of protonation. If one considers that mass spectral detection is performed on the basis 
of the mass to charge (m/z) ratio, the following equations can be used to calculate the 
expected m/z for the various possible multiply charged precursors a peptide may produce: 
Singly charged = M + H/1, doubly charged M + 2/2, triply charged = M + 3/3, and so on, 
corresponding to double, triple, quadruple, and even higher charge states. 
The most common mode of MS analysis for peptides is electrospray positive 
ionization mode, and in this mode of analysis peptides fragment in a very predictable 
manner. Primary fragmentation yields a series of ions corresponding to cleavage at the 
amide (or peptide) bonds between the amino acids that comprise the peptide sequence. If the 
charge is retained on the N-terminal fragment, the ions are classified as b ions; if the charge 
is retained on the C terminus, the ions are classified as y. There are other internal cleavage 
ions and immonium ions, but b and y ions are the most frequently observed [20]. 
Coincidently, these are also good choices for quantification as they tend to be inherently 
specific for the peptide of interest.  The final point related to fragmentation is that the most 
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complete and the most useful fragmentation is typically obtained when the highest possible 
charge state is fragmented [20]. This reinforces the importance of tuning on multiple 
precursors. 
 
2.4.2 MS Guidelines for Peptide Quantification 
 
As a result of the experiences gained in this research the following conclusions can 
be drawn on the optimization of the mass spectrometer for peptide quantification. Firstly, 
the source conditions should be tuned for maximum transmission of the precursor without 
in-source fragmentation. As mentioned, it is good practice to tune and optimize several 
different MRM transitions. These may be multiple fragments from a single precursor or the 
same or different fragments from different precursors. These transitions can be used for both 
confirmation as well as to provide options for obtaining the best specificity and sensitivity, 
particularly for biological samples that contain many endogenous interferences. It is 
important to note that a transition that appears to be most intense during tuning of solvent 
standards may not be the transition with the highest signal for an extracted sample. This is 
due to the potential for isobaric and co-eluting matrix interferences which may either 
suppress the analyte signal or increase the background so much as to obscure low levels of 
analyte. 
When performing MS/MS tuning and optimization of the precursor ion signal 
intensity using collision induced dissociation (CID), one must consider that fragments from 
multiply charged precursors may be multiply or singly charged. This requires MS/MS to be 
performed across a broad mass-to-charge range, often up to the maximum range of the 
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quadrupoles. This can vary from 1000 m/z to 3000 m/z depending on the manufacturer and 
model. Careful choice of both precursor and fragment ions can be the critical factor in 
developing a robust and reliable MS method for peptide therapeutics.  The following  
guidelines can be employed in choosing the optimal peptide fragment for analysis. The 
choice of fragment ion is fairly straightforward in the case of small molecule therapeutics, 
where the most intense fragments are most often chosen for quantitation.  Conversely, the 
most intense peptide fragments may not always be the most specific. In addition to non-
specific water losses, it is quite common to see intense peptide fragments at low m/z values 
such as m/z 136, 110, 129, etc. These specific fragments correspond to immonium ions, a 
result of secondary fragmentation, arising from individual amino acids in the sequence. The 
m/z ratios of 136, 120, 129, 110, and 86 indicate the presence of tyrosine, phenylalanine, 
arginine, histidine, and leucine/isoleucine, respectively. Transitions based on this type of 
fragment are often non-specific, resulting in increased baseline noise and multiple peaks 
from other isobaric peptides present in biological extracts, and should be avoided if 
possible. In a similar manner, high intensity ammonia losses are commonly observed. These 
also often prove to be significantly less specific in extracted samples. Figure 2.13 
demonstrates this quite clearly for 500 pg/mL glucagon extracted from human plasma. In 
this example, although the glucagon peak arising from an ammonia loss is 10X higher in 
absolute signal intensity, the signal to noise is equivalent to the peak obtained when 
monitoring the fragment at m/z 940. Furthermore, the background is significantly lower in 





Figure 2.13 MS spectra for 500 pg/mL glucagon extracted from human plasma. Top panel was acquired using 
an MRM transition corresponding to an ammonia loss; bottom panel was acquired using an MRM transition 
corresponding to a specific b/y ion. 
 
Occasionally, when a peptide does not fragment well (either no fragments are 
generated or too many low abundance fragments result, the so called “all or nothing” 
phenomenon), the use of SIR, where both quadrupoles are set to the same precursor m/z 
value, may be required. This approach may require extensive sample preparation and/or 
multidimensional LC to separate isobaric interferences that are not distinguished by unit 
mass resolving mass spectrometers such as quadrupoles. The ideal fragments for reliable, 
reproducible quantitation are b or y sequence ions. 
An additional consideration for both precursor and fragment ion choice is the use of 
higher m/z ions, for example using a 4+ instead of a 5+ precursor and/or the use of a 
fragment present at higher m/z than alternative choices. Transitions based on higher m/z ion 
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pairs often benefit from reduced chemical noise relative to the equivalent pair (i.e. the same 
compound, same fragment, but different charge state) from a higher charge state present at 
lower m/z values. This is illustrated in Figure 2.14 in which two separate transitions for an 
amyloid β peptide with a molecular weight of 4132 are monitored during analysis of a 
human plasma extract. The transitions represent quadruply (4-) or quintuply (5-) charged 
versions of the same precursor to fragment pair. These data clearly show that reduced 
background and improved signal to noise can be obtained if the highest precursor/fragments 
pairs possible are chosen for quantitative analysis. 
 
 
Figure 2.14 Analysis of amyloid beta 1-38 using MRM transitions for the same precursor to fragment pair 
derived from either monitoring the 4th (top) or 5th (bottom) charge states. 
 
In another example, absolute sensitivity of insulin lispro in solvent standards is 
approximately 2X higher when monitoring a transition which includes the 5+ precursor at 
m/z 969 than when the 6+ precursor at m/z 1163 is chosen (Figure 2.15). However, the 
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signal to noise (S:N) is actually about 3X better for the ostensibly “less sensitive” 1163 
transition. This again demonstrates the specificity advantage of using precursor/fragments at 
the highest m/z possible which still provides adequate sensitivity. 
 
 
Figure 2.15 MSMS analysis of insulin lispro using either a 5+ (top) or 6+ (bottom) precursor paired to a 217 
fragment. 
 
An important aspect of MRM analysis of peptides is the mass range of the first and 
second quadrupoles. For example, the MS infusion of enfuvirtide (MW 4492) produced a 
dominant 3+ precursor at approximately m/z 1498, requiring an instrument with a mass 
range of at least 1500 (Figure 2.16). Similarly, the MS/MS analysis of the 2+ precursor of 
bivalirudin (MW 2180) at m/z 1091 produced two major singly charged fragments at m/z 
650 and m/z 1531 (Figure 2.17), again demonstrating the need for adequate mass range. A 
mass range of ≥2000 Dalton on both quadrupoles allows the use of higher mass precursors 
and fragments which have less chemical noise (Figures 2.13, 2.14 and 2.15), resulting in 
MSMS of 5+ Precursor
1163 -> 217.3
MSMS of 6+ Precursor
969 -> 217.3
Lower m/z precursor yields higher intensity but lower signal to noise
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greater signal to noise and improved detection limits for peptides. Although TQ instruments 
with limited mass range quadrupoles (i.e. 1000, 1200 or 1500 amu, for example) provide 
higher transmission for small molecules and hence high  sensitivity for those species, 
transmission and sensitivity for larger molecules may suffer. 
 
 















Figure 2.17 MSMS of the doubly charged bivalirudin precursor at m/z 1091 
 
There are various factors that influence the nature and relative abundance of peptide 
precusors formed in the MS source. Chief among these are mobile phase flow rate, pH and 
concentration of the mobile phase modifier. It is not uncommon, for example, to observe 
different charge state precursors dominating at different flow rates. A recent publication 
[21] on the quantitation of angiotensin II describes the predominance of a triply charged 
precursor at 700 µL/min and that of the doubly charged under nanoflow conditions (250 
nL/min). One possible explanation for this phenomenon is that the turbulence between the 
solvent stream and the injection bolus would cause dilution at the boundaries between the 
two, leading to small changes in concentrations, ultimately resulting in changes in the 
observed protonation envelopes. This theory is one that fits the observed data. 
Another well studied [22-24] phenomenon is the relationship between charge state 
distribution and analyte concentration. Wang and Cole [25] demonstrated that the charge 
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state envelope shifts toward lower values as the peptide concentration increases. For 
example, one might observe more doubly charged species than triply charged at higher 
analyte concentrations. This observation further supports the recommendation that one 
should monitor transitions from several charge states during method development and assess 
any potential impact on quantification. 
 
2.5 Section III. Peptide Extraction and Sample Preparation 
 
2.5.1 Understanding the Differences Between Sample Preparation Techniques and 
Impact on Results 
 
Once the issues of solubility, adsorption, and instability have been addressed, an 
extraction technique must be developed in order to isolate a peptide from a complex 
biological sample containing many closely related interferences. There are three main  
extraction techniques used in bioanalysis: protein precipitation (PPT), solid phase extraction 
(SPE), and liquid-liquid extraction (LLE), with SPE figuring most prominently in the 
peptide literature [1]. The following section will review the pros and cons of each technique 
and then propose a broadly applicable screening method. In addition, due to the recent 
introduction of additional regulatory criteria that must be met during bioanalytical method 
validation (e.g., matrix effects, incurred sample reanalysis), a strong emphasis must be 
placed on selectivity of the various methods and their role in facilitating meeting evolving 
regulatory guidelines.  
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Depending on the specific matrix, components that must be separated include but are 
not limited to phospholipids, salts, proteins, other peptides, formulation agents and dosing 
media, amongst others. This discussion will focus primarily on plasma and serum as these 
are the most common matrices in bioanalytical labouratories. 
Prior to the extraction itself, it is essential that the binding between the therapeutic or 
endogenous peptides and proteins present in the biological matrix is disrupted. This binding 
may be stronger than the binding between small molecules and endogenous proteins, 
necessitating additional pre-treatment alternatives. Common means of disrupting protein 
binding include pretreatment with acid (4% phosphoric, formic, 1-10% TFA, or TCA) or 
base (5% NH4OH), or for particularly hydrophobic peptides, denaturation with guanidine 
HCl  or urea may be necessary. These reagents can later be removed during solid phase 
extraction without concern for peptide losses. Protein binding problems typically manifest 
themselves as apparent “low recovery” during the extraction process.  Peptides that are 
bound to proteins in the matrix either co-precipitate along with endogenous proteins during 
PPT or pass through an SPE device during sample loading. An easy test to confirm the 
presence of protein binding is to prepare a set of spiked samples in both the study matrix 
and in phosphate buffered saline (PBS). Recovery should be calculated according to 
equation 2.1 below. If recovery is higher in the PBS samples, then protein binding is likely.  
 
Equation 2.1 
% SPE recovery= (average peak area in pre-spiked extracted samples/average peak area in 




In plasma, 22 proteins make up 99% of the total protein content. Of these, albumins 
(MW ~65 kDa) make up about 45% of the total protein content, and are present at tens of 
mg/mL. Immunoglobulins (MW ~150 kDa) make up another 15-30% [26]. These proteins 
are present at many orders of magnitude higher concentration than peptide therapeutics and 
biomarkers, and are often even less soluble.  
In addition to high levels of proteins, plasma phospholipids (PLs) are a major source 
of concern for both small and large molecule bioanalytical assays. The presence of high 
levels of residual PLs in sample extracts is particularly concerning considering their role in 
matrix effects. Bennet and Van Horne identified PLs as the major source of matrix effects in 
plasma in 2003 (AAPS posters, 2003) and discussions relating to their removal continue to 
dominate industry-related conferences. A thorough investigation of various sample 
preparation techniques and their influence specifically on phospholipid removal clearly 
demonstrated several important differences between the techniques [27]. 
Overall, PPT is universally regarded as a quick, inexpensive technique. However, 
with respect to removal of the various aforementioned interferences, the resultant extract is 
exceedingly “dirty” due to the entirely non-specific nature of the procedure. As long as the 
protein binding is disrupted, most high abundance plasma proteins (typically proteins >~40 
kDa) can be precipitated or separated using PPT. However, PPT has several serious 
drawbacks. For example, it does not precipitate phospholipids (PLs), salts, other peptides, 
metabolites,  or dosing media and formulation agents, therefore they remain in high 
concentrations in the supernatant that is used for analysis. PLs are less soluble in  ACN, it is 
preferred both as a precipitation solvent and as an SPE elution solvent. Figure 2.18 





Figure 2.18 Level of phospholipids remaining in elution solvents based on ACN (top) and MeOH (bottom) 
 
If ACN is to be used for PPT of a sample containing a peptide analyte, one must 
carefully choose the ratio of organic to plasma as peptides precipitate if the organic 
concentration is too high. Optimization of the final organic composition and the nature of 
the organic used in the precipitation solvent and sample may balance precipitation of 
unwanted proteins with peptide solubility and hence peptide recovery. The addition of TFA 
or trichloroacetic acid (TCA) may help in cases where peptide solubility in the precipitation 
solvent is limited. In order to better understand the utility of PPT as a selective pretreatment 
step several mini-studies were performed. Plasma samples were precipitated 1:1 with either 
100% ACN or 70% ACN, resulting in final sample compositions of 50 or 35% organic, 
respectively. The recovery of proteins of MWs ranging from ~6000 (insulin) to ~77,000 
(apo-transferrin) was calculated in each supernatant, and is summarized in Figures 2.19A 
and 2.19B. Recovery was calculated using the post-extracted spike method. 
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Figure 2.19B Comparison of levels of various proteins remaining in supernatant after protein precipitation 
































The data presented highlighted several important results. First, 1:1 precipitation with 
ACN essentially eliminates human serum albumin (HSA) from the extracts (2.19A). 
Presumably, larger proteins such as IgGs,are also eliminated. This is supported by the 
absence of apo-transferrin (MW ~77,000) in either extract (Figure 2.19B). Second, smaller 
proteins such as insulin are preserved in both cases. Proteins in the 10-20 kD range are 
present with ~40-50% recovery in the 35% (final organic concentration) extract and to a 
much lesser extent or not at all in the 50% (final organic concentration) extract. These data 
suggest that a type of pseudo-fractionation, or depletion of high abundance proteins, may be 
performed using PPT in the proper ratio, without loss of smaller peptides. A higher final 
organic solvent composition and the addition of modifiers were also tested during 
pretreatment of teriparatide in human plasma, prior to SPE. Results are shown in Figure 
2.20. 
 
Figure 2.20 Effect of various pretreatment options on the recovery of teriparatide from human plasma 
 























From this data, one can conclude that teriparatide is partially precipitated when the 
organic content is too high, for example when a 2:1 ratio of organic to plasma is used versus 
1:1. The data in Figure 2.20 also suggest that teripartide may be more soluble under basic 
conditions than acidic as recovery is higher in the presence of aqueous ammonia versus 
formic acid, TFA, or acetic acid. 
It should be noted that the non-specificity which characterizes PPT as a stand-alone 
technique, often leads to severe matrix effects which cause variability, poor robustness and 
poor reproducibility in the final assay. For this reason, our studies utilize PPT primarily as a 
pre-treatment option and not as the primary mode of peptide isolation.  
  As established in Figure 2.20, it is clear that when a 2:1 ratio of organic to 
plasma is used versus a 1:1 ratio, recovery for teriparatide decreases significantly this is due 
to the fact that teriparatide is precipitated with plasma proteins under the higher organic 
conditions. In addition, modifying the solvent pH with a base results in increased recovery 
for teriparatide over acid modification as a result of improved solubility or disruption of 
protein binding, or both. 
The use of LLE to extract peptides from plasma has been reported only a handful of 
times, and with lower than desired recovery. In general, the ionic nature of peptides and 
their poor solubility in very apolar solvents severely restricts the utility of this approach. 
Furthermore, typical LLE solvents such as methyl tertiary butyl ether (MTBE), hexane, 
ethyl acetate, etc. also extract lipids efficiently, yielding final extracts saturated with 
phospholipids. LLE also does little to separate peptides of interest from other peptides 
present in the sample or many of the other common interferences. Separation of a target 
peptide from other peptides in the sample is most readily accomplished by SPE, where 
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manipulation of both organic content and nature and concentration of modifier can result in 
very selective final eluates[27]. Neither protein precipitation nor liquid-liquid extraction 
possess the degree of resolving power necessary to accomplish this as both rely on simple 
separation mechanisms: either physical precipitation only, or distribution between aqueous 
and organic layers. Historically with SPE, silica-based C18 and more recently polymer-
based reversed-phase (RP) or mixed-mode (having both RP and ion exchange retention 
mechanisms) sorbents, seem to be the method of choice for peptide extraction[1]. There are 
many reasons for the popularity of SPE for selective peptide isolation. In general, one can 
load aqueous solutions rather than working with organic solutions which may cause 
precipitation. In contrast to other techniques, any reagents used to disrupt protein binding, 
such as denaturants, acids, bases, etc. will be eliminated during the process through a series 
of wash steps.  In addition, the majority of unwanted proteins are eliminated during the 
sample loading step of an SPE method due primarily to their exclusion from the 
chromatographic pores of the sorbent. Dosing media and formulation agents may not be 
efficiently removed by protein precipitation or liquid-liquid extraction, but may, once again, 
be removed using SPE and judicious choice of wash and elution steps.  
Most SPE methods can be automated or converted to on-line protocols such as that recently 
described by Calderon-Santiago et al [28]. While on-line extraction methods eliminate many 
of the manual components of performing an extraction, extraction times of 7-12 minutes per 
sample (prior to LC) are commonplace. Method development may be more challenging 
when using on-line systems as risk of carryover increases with multi-use cartridges and 
recovery and matrix effects are more difficult to determine. For these reasons, this research 
focuses on optimizing off-line SPE. 
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Extraction by SPE can be used with polar, non-polar, acidic and basic samples, for 
both  large and small peptides, making it an attractive platform for a universal method 
development approach. Solid phase extraction, specifically mixed-mode SPE, is identified 
as the technique that provides the most selective final eluates [27].  A recent review of 
techniques specifically for peptide bioanalysis [29] also concluded that mixed-mode 
sorbents in conjunction with RP chromatography is the ideal platform for this application. 
Mixed-mode SPE sorbents typically contain both a reversed-phase backbone functionalized 
with a strong or weak cationic or anionic moiety. This allows analytes or interference 
molecules to bind to the solid support by either reversed-phase or ion exchange interactions, 
providing dual orthogonal mechanisms with which to perform a separation. Furthermore, 
one can manipulate the organic content within each wash or elution step to further improve 
the selectivity and cleanliness of the final elution(s). Finally, extraction of peptides using the 
ion exchange elution step and subsequent LC separation in the reversed-phase dimension 
imparts orthogonality of the bioanalytical method as a whole. Selective sample preparation 
in conjunction with a high resolution chromatographic separation are critical as tandem 
quadrupole MS systems operated at unit mass resolution and cannot differentiate between 
two isobaric peptides sharing an isobaric fragment ion. Unfortunately, this instance occurs 
more frequently than we would like due to the highly conserved chemical nature of peptide 
composition. There are only 20 naturally occurring amino acids that make up all of the 
peptides and proteins in the body, making separation challenging, and thus requiring a 
multidimensional approach such as the one described herein which uses mixed-mode SPE to 
complement RP LC. 
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Properties such as pI may be useful in choosing an SPE sorbent and/or in optimizing 
wash and elution solvents. Additionally, the pH of wash and elution solutions as well as the 
specific nature of the SPE sorbent can be manipulated or changed to facilitate separation 
from other peptides based on knowledge of pI. For example, basic peptides such as 
desmopressin (pI 8.6) or octreotide (pI 8.3) are expected to bind to a mixed-mode (MM) 
cation exchange sorbent whereas an acidic peptide such as bivalirudin (pI 3.9) should bind 
to a (MM) anion exchange sorbent. Depending on the exact concentration of organic 
required to elute the target peptide, wash solvents should contain as much organic as 
possible without eluting the peptide as this will effect elution of many of the endogenous 
peptides in the sample. The elution solvent should also contain the minimum concentration 
of organic required to elute the peptide in order to minimize the presence of more 
hydrophobic interferences in the extract. Not only can peptides of opposite ionic nature be 
separated from each other, but peptides of similar pI’s can also be separated from each other 
through judicious choice of the organic solvent content in the wash and elution solutions.  
Using different wash and elution solvents allows for refinement of the SPE method to 
sequentially and systematically optimize the organic composition such that the elution 
window of the peptide is tightly controlled. Finally, utilizing a small volume elution SPE 
device can eliminate the need for an evaporation and reconstitution step, which frequently 
results in peptide losses due to adsorption to the plates or tubes used for evaporation or 
insolubility in the reconstitution solvent. This low elution volume format can effectively 
concentrate a sample up to 15 fold through well-researched plate designs which allow the 




To further reinforce the benefits of mixed-mode SPE for peptide extraction, studies 
were performed to compare traditional sample preparation methods (PPT, LLE, and RP 
SPE)  and ultimately highlight their shortcomings relative to mixed-mode SPE. Initially this 
was performed using the two peptides desmopressin and bivalirudin. Analyte recovery was 
calculated to compare and contrast extraction efficiency using generic methods for each 
technique and matrix effects calculations (Equation 2.2)  were used to reflect sample 
cleanliness and as a representative measure of selectivity of the extraction types. Regulatory 
guidelines for bioanalytical method development[30-32] recommend that matrix effects be 
assessed and controlled. Specifically, it is recommended that the CV of matrix factors (a 
subset of equation 2.2) in multiple sources of matrix not exceed 15%.   Once the limitations 
of these techniques were characterized and understood,  the next step was to develop a 
simple screening method for the extracted peptide solution.  
In these studies, equation 2.1 (previously described) was used to calculate the 
recovery of each peptide from human plasma.  
Matrix effects were calculated according to equation 2.2 below. 
 




Results from the initial characterization experiments, which accentuate the low recovery 











Figure 2.21 Absolute recovery (left) and matrix effects (right) for bivalirudin and desmopressin using a variety 
of different common sample preparation techniques 
 
While recovery for the two peptides was highest using reversed-phase SPE or 
protein precipitation, both produced extracts with an unacceptable level of matrix effects. 
Although liquid-liquid extraction was capable of eliminating matrix effects, recovery was 
<2%, rendering it completely unsuitable for this purpose. 
The data shows that none of the techniques provided both the high recovery required 
to meet challenging detection limits and low matrix effects (which would indicate improved 
removal of interferences and greater specificity). In addition to the benefits previously 
described, mixed-mode SPE has been shown to reduce matrix effects to a greater extent than 
other sample preparation techniques while still providing high analyte recovery [27].  Due 
to their zwitterionic nature, the behaviour of peptide therapeutics under various SPE 
conditions can be difficult to predict. Therefore, initial proof-of-concept studies were 
performed on 4 different mixed-mode sorbents, using a generic set of conditions originally 
developed for small molecule screening [27]. As each sorbent consists of a moiety that 
imparts reversed-phase behaviour as well as an ion exchange group (strong or weak cation 
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or anion exchange) for additional selectivity and therefore is capable of producing 2 
elutions: one that contains compounds bound by reversed-phase (elute 1) and a second 
containing compounds bound by ion-exchange (elute 2).  Recovery was calculated for both 
elute 1 and elute 2 fractions on all four of the mixed-mode sorbents and is summarized in 
Figure 2.22.  
 
  
Figure 2.22 Recovery for desmopressin and bivalirudin extracted from human plasma using four mixed-mode 
SPE sorbents. 
 
A careful inspection of the data in Figure 2.22 shows that using protocols designed 
for small molecules, recovery for test peptides was split between the two elutions and was 
on average <60%, whereas these same protocols typically yield recoveries for small 
molecules that are >80% on average. It was clear that knowledge and application of general 
peptide physiochemical properties was needed if the advantages of these mixed-mode SPE 
sorbents were going to be successfully applied to develop a generic approach to peptide 






























extraction. Conventional “small molecule” thinking and protocols incorporate steps and 
solvents used in a manner that yields poor results for peptides. For example, if one considers 
maximizing the recovery for small molecules, the elution window is quite broad ranging 
from 0-5% organic required to elute very polar compounds to 100% organic for the most 
hydrophobic small molecules. Generic SPE protocols for small molecules often use 100% 
organic in the elution to ensure the highest recovery, even for many small molecules of 
potentially diverse properties. In contrast, if one considers peptides as a class, the elution 
window is much tighter, with most peptides eluting between approximately 20 to 55% 
acetonitrile. This basic information should be applied during extraction method 
development as application of solutions containing higher than optimal organic content 
often result in peptide precipitation onto the SPE cartridges. It is also common to include 
modifiers such as formic acid in wash and elution steps for small molecules. However, 
stronger acids may be required if maximum solubility, and thus recovery, of peptides is to 
be obtained. 
Further experimentation with additional peptides and examination of the resultant 
data was performed in order to formulate a hypothesis for a peptide screening protocol. The 
data indicated that strong anion exchange and weak cation exchange sorbents produced 
higher recoveries on average in the ion exchange elutions for the therapeutic peptides tested. 
Subsequently, changes were made to the original small molecule protocols, including 
optimization of wash and elution solutions, to generate a protocol developed specifically for 
peptides which incorporates basic knowledge of peptide hydrohobicity, solubility, and their 
zwitterionic nature. Among these changes were to use a 75% organic elution as opposed to a 
100% organic elution. In addition, TFA was added to improve solubility of hydrophobic 
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peptides. TFA showed a significant improvement in recovery for larger, more hydrophobic 
peptides over formic acid without deleterious effects to sensitivity. The concentration of 
TFA employed was equally as important. Several concentrations in the final elution were 
tested, and 0.1 or 0.5% TFA were found to be inadequate in providing high recovery values 
for some of the larger or more hydrophobic peptides. A final concentration of 1% TFA 
provided the optimal recovery for a diverse set of peptides. It is concluded that a 
combination of improved solubility in the organic solvent and ion-pairing to reduce 
secondary interactions are responsible for the recovery increases. The elution solvent 
composition described has the advantages of providing optimal solubility for a wide range 
of peptides, eliminating the majority of phospholipids (which typically require higher 
organic to elute and are thus retained on the extraction column) and producing an eluate 
ready for injection onto an LC/MS/MS system without further manipulation.  
 
 
2.5.2 Proposed Peptide Extraction Screening Protocol 
 
This section describes the method details for a universal screening protocol 
optimized for the mixed-mode SPE extraction of peptides from biological matrices. It is 
derived from the results of the previous section of this chapter. The methodology screens 
two complementary SPE sorbents (strong anion exchange and weak cation exchange) 
simultaneously to rapidly identify the best starting conditions on either the mixed-mode 
SAX (strong anion exchange) or WCX (weak cation exchange) plates. Although one may be 
able to predict the appropriate sorbent for a peptide based on pI, the data collected in this 
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study suggests that it is not always a definitive indication. The location of charged residues 
in the sequence and their accessibility to the sorbent influence retention and may result in 
unpredictable behaviour vis a vis pI and sorbent type. For example, two peptides with 
similar pI’s may interact differently with the same SPE sorbents, reinforcing the need for a 
screening protocol. Based on experimentation and resultant conclusions discussed above,  
the following  general screening protocol is suggested.  
Sorbents to be screened are weak cation exchange and strong anion exchange, and 
the format recommended is 96-well µElution (2 mg sorbent/well). The µElution format was 
chosen as it facilitates concentration without evaporation thus minimizing the potential for 
peptide losses due to adsorption during dry-down which would lead to an erroneous result. 
A schematic of the well design is shown in Figure 2.23.  The sorbent bed is taller and 
narrower than traditional formats, acting more like a column than a flat disk. It is this 
geometry that enables elution in smaller volumes.  
 
Figure 2.23 Well design for Waters µElution format 96-well extraction plate 
 
vacuum
Narrow and Tall bed
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Proposed Screening Method for Mixed-mode Weak Cation and Strong Anion Exchange 
Sorbents: 
1. Condition with 200 µL MeOH.  
2. Equilibrate with 200 µL H2O.  
3. Load diluted, pretreated sample. 
4. Wash with 200 µL 5% NH4OH in H2O. 
5. Wash with 200 µL 20% ACN in H2O. 
6. Elute with 1 or 2 × 25 µL 1% TFA in 75/25 ACN/H2O. 
7. Dilute with 25 or 50 µL H2O if necessary. 
 
This proposed screening protocol was tested against a panel of twelve diverse 
therapeutic and endogenous peptides having pI values from 3.9 to 12, ranging in size from 
~1000 to 4500 Da, and varying from very polar to very non-polar. SPE extraction recovery 
for these twelve peptides, using this protocol is summarized in Figure 2.24. 
 


























  Recovery for 9 out of the 12 peptides was deemed acceptable (>80% recovery) on a 
first pass using the screening method, this result clearly indicates that a single SPE platform 
can be successfully used for peptide method development.  Minor modifications to the 
method (described below) were made to improve recovery for BNP, somatostatin, and 
enfuvirtide. Brain Natriuretic Peptide (BNP) is very polar, as indicated by HPLC index of 
15.9. It could be theorized that it is due to the polar nature of the molecule that the recovery 
was low, as it was not being retained on  the sorbent during loading when applied at low pH. 
To address this the BNP samples were diluted with ammonium hydroxide at (5% v/v) 
instead of 4% H3PO4 to change the initial binding behaviour. Another compound with low 
recovery, enfuvirtide, suffers the opposite problem in that it is extremely non-polar, as 
indicated by an HPLC index of 155.9. Its chromatographic behaviour and retention (Figure 
2.4) are also representative of its sticky nature. These factors are excellent predictors of 
possible high protein binding. If an analyte exhibits high or strong protein binding, it may 
pass through the sorbent during the loading step. In this case, more aggressive pre-treatment 
with TFA resulted in reduced protein binding and increased recovery. Upon further 
investigation, it was discovered that somatostatin was labile at high pH. The high pH wash 
step in the generic protocol was exchanged for a pH 6 buffer. The buffer ensures that both 
the Oasis® WCX sorbent and analyte are charged, increasing ion-exchange retention 
capacity as well as eliminating conditions under which somatostatin was not stable.  






Table 2.3 Final % SPE recovery and % matrix effects for test peptides extracted from human plasma using the 
proposed screening method 
 
2.5.3 Recommendations for Troubleshooting 
 
The minor modifications to the screening protocol necessary for three of the peptides 
serve here to highlight areas for troubleshooting should peptide recovery be low using the 
described  screening protocol. In general, there are a few primary reasons for actual or 
apparent low peptide recovery from a biological matrix: protein binding, inadequate 
solubility in the final elution solvent, chemical modification/instability (which changes the 
mass, rendering the original MRM incapable of quantifying the modified peptide), 
incomplete ionization of the peptide and sorbent during loading, non-specific binding, and 
insufficient solvent strength. In general, the larger and more hydrophobic a peptide is, the 






Octreotide 9.3 1019 88 <10%
Angiotensin II 7.35 1046 82 8%
Desmopressin 8.6 1069 104 <11%
Vasopressin 9.1 1084 100 -3%
Goserelin 7.3 1270 100 -2%
Angiotensin I 7.51 1296 109 *
Somatostatin 10.4 1638 94 *
Neurotensin 8.93 1673 114 6%
Bivalirudin 3.87 2180 100 10%
BNP 12 3464 84 *
Teriparatide 9.1 4118 97 9%
Enfuvirtide 4.06 4492 102 *
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greater the likelihood of encountering one of these issues. In addition, one should examine 
the amino acid content of the target peptide and refer to Table 2.4 to identify any possible 
chemical modifications that could occur during processing or conditions which could cause 
instability.  
 
Table 2.4 Properties of individual amino acids and mass shifts due to modifications 
 
As a first step toward improving recovery and/or determining the cause of low recovery, 
the following optional experiments may be performed: 
1. Extract the sample in PBS + 10 µg/mL bovine serum albumin (BSA) and compare 
recovery to the target matrix. If recovery in the PBS solution is higher, this may 
indicate poor disruption of protein binding in the target matrix, indicating that a 
change in pre-treatment is required. If the generic acid pre-treatment is inefficient, 
higher concentrations of acid or base, or denaturation with guanidine HCl or urea 
may be necessary. 
 Property Amino Acid
Hydrophobic A, F, I, L, M, P, V, W, Y
Moderate C, G
Hydrophilic D, E, H, K, N, Q, R, S, T, pyro-glutamic acid
Positive Charge K, R, H, N-terminus
Negative Charge D, E, Y, C-terminus
Degradation likely M, W
Prone to de-amidation, 
dehydration, cyclization to pGlu N,Q, C-terminal amides, N-terminal Q








2. Increase the concentration of TFA in the final elution to 5% or 10%. This may 
improve solubility for larger or more hydrophobic peptides. Do not increase the 
organic % in the final elution, this often results in precipitation. 75% acetonitrile is 
sufficient. Alternatively, different modifiers such as acetic acid, may be assessed. 
3. Exchange 10 mM ammonium acetate (pH ~6) for the NH4OH wash in the generic 
protocol if using weak cation exchange. This may improve the ionization of the 
sorbent and peptide, facilitating complete binding upon sample loading. This 
modification also eliminates high pH steps from the protocol, allowing one to 
accommodate base-labile peptides without loss. 
4. For acid-labile basic peptides, a strong cation exchange sorbent may be used with 
the ammonium acetate wash described in option 3 and the standard high pH elution.  
 
2.5.4 Exploring Large Pore Size SPE Sorbents 
 
Improved peak shape and column recovery, especially for larger peptides, was 
observed during this study when using 300Å versus 130Å chromatographic particles in 
UPLC separations. This led to questioning whether this same benefit could be realized 
during SPE, if sorbent pore size was similarly increased. To that end, SPE employing a 
prototype polymeric reversed-phase sorbent with an average pore diameter (APD) of 80-
100Å was compared to the equivalent particle with an APD of approximately 400-600Å. 
Both particle substrates were 18-20 µm polymeric reversed-phase SPE material. Although 
the recommendation for peptides is to use mixed-mode sorbents, it was thought that starting 
with reversed-phase only sorbents for this test would simplify data interpretation. 
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Specifically, if mixed-mode sorbents were used, one would have to consider dual retention 
mechanisms, ionic interactions and other variables. The experiment was considered to be 
better controlled and more focused on pore size influence when the retention mechanism 
was limited to reversed-phase. These were further compared to a commercially available 30 
µm product of the same base reversed-phase polymer. For these experiments, 96-well 
µElution format plates were packed with 2 mg sorbent per well. An initial set of test 
proteins is described in Table 2.5. For the first set of experiments, proteins were diluted in 
aqueous solutions to test and compare recovery based on sorbent pore size.  
 
 
Table 2.5 Test proteins for evaluation of wide pore polymeric reversed-phse SPE materials 
 
A simple generic set of extraction conditions were applied to both plates packed with 
small or large pore sorbent material. The sorbent was conditioned with 200 µL MeOH, 
equilibrated with 200 µL water, and then 100 µL diluted protein standard was applied. 
Samples were washed with 200 µL 5% methanol in water and finally eluted with 2 x 25 µL 
75% methanol in water, with or without 1% TFE. Final eluates were diluted with water prior 
to injection. As these were aqueous standards and not plasma extracts, UV detection at 
wavelength 254 was employed. A summary of protein recovery in the final eluates and in 











the load fractions from the various sorbents are shown in Figures 2.25 and 2.26, 
respectively. 
 
Figure 2.25 SPE recovery of test proteins in final eluate from a 20 µm wide pore sorbent, a 20 µm typical 
pore size sorbent, and a 30 µm typical pore size sorbent. 
 
 
Figure 2.26 SPE recovery of test proteins in load fraction from a 20 µm wide pore sorbent, a 20 µm typical 
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While insulin (the smallest protein) was recovered on all sorbents, some of the larger 
proteins were only recovered to any appreciable degree on the wide pore sorbent (Figure 
2.25).  Furthermore, when one looks at the presence of proteins in the load fraction (Figure 
2.26), it is clear that the overwhelming majority of the protein in passing through on the 
load step when either of the smaller pore size sorbents is used. Although recovery is not 
high for all proteins in the final eluate on the wide-pore prototype, the proteins do appear to 
be at least partially retained. The assumption is that because proteins are not in the load step 
on the wide-pore sorbent, they are retained. Therefore, the extraction method will be 
modified to improve protein recovery. The elution solution was changed to 75% acetonitrile 
in water + 5% TFA. This method was applied to the initial set of test proteins as well as to a 
200 µL sample of 250 µg/mL mouse murine IgG. The resultant improved recovery for all 
proteins in the final eluates is captured in Figures 2.27A and B. 
 
 

















































Figure 2.27B Recovery in SPE final elution for mouse murine IgG on wide pore and standard pore size 20 µm 
sorbents as well as 30 µm standard pore size sorbents 
 
This data would appear to suggest that there is a clear advantage for retaining large 
proteins using a larger pore size SPE sorbent material. Figure 2.27A indicates that even a 
77KDa protein such as transferrin can be recovered with reasonable efficiency on the wide 
pore sorbent. Other proteins in the 10-18KDa range, while not retained at all on typical pore 
size sorbents are well retained and recovered using this wide pore counterpart. It was also 
encouraging to see that a 150KDa IgG can also be retained and recovered, though to a lesser 
extent as ~50% is still found in the load fraction, using this prototype material. 
As a follow up experiment, the influence of different organic solvent concentration in the 
final eluate was investigated, hypothesizing that fractionation might be possible based on 
acetonitrile %. Recovery is detailed in Figure 2.28. 
 
 
















Figure 2.28 Recovery of various test proteins using different concentrations  of acetonitrile in the elution 
solvent 
  
The maximum recovery was achieved for insulin and ribonuclease A with only 25-
35% ACN, indicating that these 2 proteins could be isolated from the others. Optimal 
recovery for the remaining proteins was obtained in 55-65% organic solutions, indicating 
that fractionation amongst those proteins was not possible under the current conditions. 
The next step was to test this approach with proteins in human plasma. Using the wide pore 
prototype (DWB), recovery for test proteins was calculated in both human and in solvent 
standards (Figure 2.29). The data shows that the recovery was significantly lower when 
proteins were extracted from human plasma compared to that in solvent. This was expected 
due to the high levels of endogenous proteins present in the sample which would be 
expected to compete for sorbent capacity on the stationary phase. Plasma recovery across 
the three test sorbents was also compared, Figure 2.30. Whereas in solvent standards, the 
wide pore prototype showed a clear recovery advantage, particularly for proteins in the 10-
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fact that at high concentration (~60-80 mg/mL) human serum albumin (HSA), could be 
preferentially binding, in part due to its gross excess in plasma solutions, and significantly 
reducing the available binding sites for other proteins. To test this theory the recovery for 
HSA was calculated, Figure 2.31. The data clearly supports the theory, as the wide pore 
prototype retains significantly more HSA than either the 20 or 30 µm material with typical 
pore sizes.  
 
Figure 2.29 Extraction recovery of proteins from either human plasma or solvent standards using a wide pore 














































Figure 2.30 Extraction recovery of proteins from human plasma using a wide pore prototype (DWB-178), a 
comparable particle size typical pore size sorbent (HLB HT) and a commercially available 30 µm typical pore 
size sorbent (Std HLB) 
 
 
Figure 2.31 Extraction recovery of human serum albumin (HSA) from human plasma using a wide pore 
prototype (DWB-178), a comparable particle size typical pore size sorbent (HLB HT) and a commercially 















































High endogenous levels of transferrin impede quantitation;













From the data shown above it can be concluded that although wide pore prototypes 
provided a clear benefit in terms of retaining large proteins in plasma, such as HSA, it was 
not going to be viable for our bioanalytical experiments aimed at isolating other key 
proteins or peptides while eliminating albumins, and therefore was not pursued further. 
 
 
2.6 Examples of Semi-validated Methods for Small Peptides 
 
The generic LC and SPE conditions described in this chapter were used to quantify 
several therapeutic peptides in human plasma. Detection limits in extracted human plasma 
were determined for a subset of the test peptides. Blank human plasma and samples 
prepared at 0.001, 0.005, 0.01, 0.02, 0.05, and 0.1 ng/mL (approximately 1 to 100 fmol/mL) 
and were extracted according to the generic screening method. Chromatographic results 
were evaluated to determine limit of detection (LOD) and Lower Limit of Quantification 
(LLOQ).  In bioanalytical assays, the LOD is defined as the level that is three times that of a 
extracted blank matrix sample; similarly, LLOQ is defined as five times the level of the 
blank[30, 31, 33]. 
Resulting representative chromatograms are shown in Figures 2.32 and 2.33, for 
desmopressin and angiotensin I, respectively, demonstrating the successful application of 
this combination of techniques to attain detection limits in the single pg/mL range. 
Naturally, the exact detection limits achievable are dependent on many factors including 
size and hydrophobicity of the peptide, ionization and extraction efficiency, specificity of 
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MS transition, chromatographic behaviour, volume of sample used and sensitivity of MS 
instrumentation employed, amongst others.  
 
Figure 2.32 Representative chromatograms for 1 and 5 pg/mL desmopressin extracted from 500 µL human 




Figure 2.33 Representative chromatograms for 5 and 20 pg/mL angiotensin I extracted from 350 µL human 













































This platform and approach was also successfully applied in the development of a 
flexible, sensitive, and selective method for β-amyloid peptides, putative biomarkers for 
Alzheimer’s disease, and will be the subject of Chapter 4 [19]. β-amyloid peptides are 
considered one of the more difficult peptide classes to analyze due to their hydrophobicity, 
poor solubility, propensity to aggregate, high degree of non-specific binding, low circulating 
levels, poor MS sensitivity, and protein binding. Each aspect of peptide handling and each 
step of the extraction process were evaluated and optimized as per the recommendations in 
this chapter, ultimately yielding a method which overcame the inherent challenges faced. 
Lessons learned from this problematic group of peptides may be applied to other 
challenging peptides as well. 
Although this chapter focuses on therapeutic peptides, the extraction techniques 
described, and to a certain extent, the chromatography, can be applied to the more 
elabourate application area of protein quantification using signature peptides once digestion 
of the protein has been accomplished. Surfactants, denaturation, reduction, and alkylation 
reagents as well as digestion enzymes and other peptides can be removed during SPE of the 





Figure 2.34 Comparison of LC-MS/MS analysis of a signature peptide from trastuzumab before (A) and after 
(B) SPE clean-up using a mixed-mode weak cation sorbent and generic protocol 
 
  Figure 2.34 demonstrates the potential benefit of mixed-mode SPE clean up for a 
signature peptide from trastuzumab. Not only are many background peaks removed and the 
spectra simplified, but signal intensity for the target peptide increased significantly as result 
of clean up using mixed-mode SPE. Recovery for the signature peptide was ~83%. In this 
case, the extraction protocol also provided a 5-fold concentration of the sample, which was 
diluted during addition of the various reagents without evaporation. 
 
2.7 Summary of Key Rules and Guidelines Established in This Chapter 
 
Liquid Chromatography 








 Larger pore size sorbents may improve peak shape for larger peptides 
 Superficially porous and charged surface stationary phases may improve peak shape 
for peptides 
 Reducing flow rate, increasing temperature, and shallowing gradient slope may all 
improve peak shape, reduce carryover, and increase sensitivity for peptides 
 Always use carrier protein when working with solvent standards 
 Ballistic gradients may result in peptide precipitation and loss 
 TFE can be used in wash solvents and mobile phase B to reduce carryover 
 Passivation of the chromatographic column with precipitated plasma prior to use 
may be required 
Mass Spectrometry 
 Choose the highest m/z precursor and fragments possible for greatest specificity 
 Avoid immonium ions, water losses and ammonia losses where possible 
 Choose b/y sequence ion fragments where possible 
 MRM transitions wherein the fragment m/z is higher than the precursor m/z are 
preferred 
 Positive ion mode should be used where possible rather than negative ion 
 LC flow rate can influence the nature and relative abundance of specific precursors 
 Always tune peptides at the chromatographic flow you will be using 
 The highest sensitivity fragments may not be the most specific 
 Monitoring of several MRM transitions in method development  is important to 
ensure that the most specific of these is identified 
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 Choose an MS system with a mass range of ~2000 amu on both quadrupoles to 
allow selection of and enable highest sensitivity of higher m/z precursors and 
fragments 
Sample Preparation and Peptide Handling 
 Mixed-mode SPE provides the greatest specificity for peptide isolation 
 Protein precipitation may be used as a pre-treatment step to further improve 
specificity 
 Peptide solubility must be carefully considered when protein precipitation is used 
 Increasing the % of acid/base in an elution solution can improve peptide recovery 
 Organic composition of the SPE elution solution should not exceed 75% 
 Screening both mixed-mode anion and mixed-mode cation sorbents most readily 
identifies conditions of greatest recovery and highest specificity 
 pI can help predict optimal solubility 
 HPLC index predicts relative hydrophobicity and can help predict non-specific 
binding and protein binding 
 Avoid evaporation of extracts if possible 
 TFE can be used to improve SPE recovery 








The growing market for biotherapeutic peptides and the development of quantitative 
methods for those analytes has brought to light the challenges facing the analysis of this 
broad range of compounds. Regulatory requirements are encouraging development of 
methodologies that are time- and cost-effective, while still producing assays that are 
sensitive enough to cope with biological matrices. This chapter identifies and discusses the 
challenges in detail, provides potential solutions and then proposes a generally applicable 
platform to peptide bioanalysis method development. The generalized strategy incorporates 
an understanding of peptide morphology and chemistry to enable more efficient 
development of methods which readily achieve the robustness, speed and specificity 
required of a generally-applicable quantitative peptide assay. This was subsequently 
demonstrated using a relevant panel of therapeutic and endogenous peptides extracted from 
a biologically-relevant matrix. Highly targeted, specific assays can be developed 
individually for each of these peptides, but an approach aimed at a diverse set of peptides 
serves to examine the multiple factors that need to be considered in detail for assay 
development. Overall, the data in this chapter suggests that bioanalysis studies for peptide 
therapeutics are amenable to a platform-based approach to methods development when 
knowledge of peptide chemistry is carefully applied. Such standardized approaches for 
determining optimal SPE enrichment and MRM-based LC/MS analysis should permit a 
reduction in method development timelines and shorten time–to-market for peptide drugs. 
Where needed, advanced analytical techniques can provide the additional selectivity and/or 
sensitivity needed for exceedingly difficult or unique assays such as quantitation of certain 
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endogenous biomarkers or low level protein analysis through targeted enrichment and 
isolation of signature peptides.  
Subsequent chapters in this thesis will examine, through real world quantitative 
applications, implementation of the principles uncovered in this fundamental research and 
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Developing a High Sensitivity LC-MS/MS Method for Direct Quantification of Human 
Parathyroid 1-34 (Teriparatide) in Human Plasma 
 
This chapter is based on the following publication: 
High Sensitivity LC-MS/MS Method for Direct Quantification of Human Parathyroid 1-34 
(Teriparatide) in Human Plasma 
Erin E. Chambers, Mary E. Lame, Jon Bardsley, Sally Hannam, Cristina Legido-Quigley, 
Norman Smith, Kenneth J. Fountain , Eileen Collins, and Elizabeth Thomas 





3.1  Introduction  
Osteoporosis is a major global health problem, responsible for 1.5 million bone 
fractures a year. In 2005 alone, the estimated cost for osteoporosis-related fractures was 
approximately $19 billion[1]. One of the most common treatments for osteoporosis includes 
bisphosphonate drugs, which reduce bone turnover, increase bone mass and mineralization 
through osteoclast inhibition[2]. Teriparatide, however, is the first treatment for 
osteoporosis that stimulates new bone formation. It is an anabolic drug that acts to build up 
bones and has the potential to improve skeletal micro architecture and increases bone 
density[3-6].  
Teriparatide (FORTEO®) is a recombinant form of a fragment of human parathyroid 
hormone, used in the treatment of osteoporosis. It is the smallest fragment of the full length 
(1-84) parathyroid hormone with the desired biological activity[7]. Specifically, teriparatide 
is comprised of the first 34 amino acids (the biologically active region) of the 84-amino acid 
human parathyroid hormone (PTH), and is also referred to as, rhPTH (1-34).   
These types of biologics have historically been quantified using ligand binding assays 
(LBAs), but there are several reasons for the analysis of large molecules to be carried out by 
LC-MS/MS[8].  As previously mentioned in Chapter 1, LBAs can suffer from significant 
cross-reactivity issues and lack of standardization. For example, manufacturers of LBAs for 
the same analyte often use different capture reagents with different affinities for the target 
analyte as well as different cross reactivities[9]. This leads to significant differences in 
reported results as well as inaccurate results. In fact, in some instances, entire studies have 
been devoted to the standardization of peptide immunoassays[10]. LC-MS/MS has the 
advantage of shorter development times, greater accuracy and precision, the ability to 
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multiplex, and can readily distinguish between closely related analogues, metabolites or 
endogenous interferences. Furthermore, studies have shown that both ELISA and RIA assay 
accuracy can be significantly impacted by the stability of protein standards used or 
undetected peptide degradation[11]. In the latter case, an MS assay produced an analyte 
concentration that was 5% less than the Radio Immuno Assay (RIA). The RIA could  not 
differentiate between the intact and degraded peptide of interest, and therefore was over-
reporting the peptide concentration. Most published assays for teriparatide have been 
performed using RIA for quantification or other affinity-based methods[3, 6, 12, 13], 
therefore there is a requirement for an analogous and more specific LC-MS/MS method to 
be developed. One of the major hurdles one faces in developing an LC-MS assay, however, 
is in achieving detection limits that are similar to immunoassay. For teriparatide, an assay 
LOQ of between 10 and 50 pg/mL was shown to be clinically relevant[3, 14]. Using LC-
MS, this quantification level is particularly difficult to achieve, especially for large peptides 
such as teriparatide. The primary challenge for MS sensitivity when using MRM 
quantification for large peptides comes from dilution of the primary precursor ion signal 
(from several different multiply charged species) and either poor collision induced product 
ion formation or further dilution of product ion signal due to  extensive fragmentation. In 
addition, MS sensitivity is reduced due to poor analyte transfer into the gas phase. 
Teriparatide, like other large hydrophobic peptides [8], displays significant non-specific 
binding and poor solubility, making chromatography and sample preparation method 
development challenging.  
The pharmacokinetics of teriparatide are characterized by rapid absorption within 30 
minutes and rapid elimination with a half-life of 1hr, resulting in a total duration of 
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exposure to the peptide of approximately 4 hours[14]. At the practical clinical dose of 20 
µg, typical teriparatide levels are ~50 pg/mL, further reinforcing the need for a very high 
sensitivity method.   
 The data presented below provides a single, simple LC-MS/MS method for the 




Figure 3.1 Structure and amino acid sequence for teriparatide 
 
The method uses analytical scale sub-2µm LC and fast, selective sample preparation 
in a 96-well format to achieve an LOD of 10 pg/mL and a clinically relevant dynamic range 




3.2 Experimental  
3.2.1 Chemicals and Reagents  
Teriparatide acetate was purchased from ChemPep (Wellington, FL).  Human 
parathyroid 1-38 (rhPTH 1-38) was purchased from American Peptide Company 
(Sunnyvale, CA) and rat parathyroid hormone 1-34 was purchased from Sigma-Aldrich (St. 
Louis, MO). The teriparatide sequence is depicted in Figure 3.1. Normal, non-diseased 
human plasma was purchased from Biological Specialty Corporation (Colmar, PA). Rat 
plasma was purchased from Equitech Bio (Kerrville, TX). Water for mobile phase and 
sample preparation was obtained from a Milli-Q lab water system (Millipore, Billerica, 
MA). Acetonitrile, methanol, and formic acid (concentrated solution, 99%) were purchased 
from Fisher Scientific (Fair Lawn, NJ). All other chemicals and reagents were purchased 
from Sigma (St. Louis, MO) unless otherwise stated.  
3.2.2 Preparation of samples, calibration standards and quality control samples 
Concentrated stock solutions were prepared by dissolving lyophilized teriparatide 
and rhPTH 1-38 powders in DMSO, each to a concentration of 1 mg/mL. A working 
solution of teriparatide at 10 µg/mL was prepared by dilution from the DMSO stock in 
80/19/1 water/acetonitrile/formic acid containing 0.05% rat plasma. RhPTH 1-38 was used 
as the internal standard (IS) and was prepared in the above diluent at a concentration of 2 
ng/mL to be used for spiking. For standard curve and quality control (QC) samples, spiking 
solutions of teriparatide were made through serial dilution of the 10 µg/mL stock in the 
above diluent containing formic acid, ACN, and rat plasma. All stock, working, and spike 
solutions were prepared in Lo-Bind tubes (Eppendorf.) For each intended standard curve 
point and QC level, 1 mL of control human plasma was spiked with an appropriate volume 
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of the appropriate concentration of analyte spiking solution. Standard curve points were 
prepared at 0.01, 0.015, 0.03, 0.04, 0.06, 0.08, 0.1, 0.2, 0.4, 0.5, and 1 ng/mL in human 
plasma. Quality control samples were prepared in human plasma at 0.02, 0.035, 0.075, 
0.125, and 0.25 ng/mL. Blank human plasma samples were also analyzed for determination 
of limit of detection (LOD.) A 200 μL aliquot of each sample was extracted as described in 
section 3.2.3 using a protein precipitation pretreatment followed by SPE. 
3.2.3 Sample Preparation  
Pretreatment: Protein Precipitation (PPT) 
20 µL of internal standard solution (2 ng/mL) was added to 200 µL human plasma 
(standard curve point, QC or sample) and mixed. The final IS concentration was 200 pg/mL. 
Samples were precipitated in a 1 mL 96-well plate with 200 µL acetonitrile containing 5% 
ammonium hydroxide, and centrifuged for 15 minutes at 4000 rpm. 
The supernatant was transferred to a 2 mL 96-well plate containing 1 mL of water and 
mixed.   
Solid phase extraction (SPE): Oasis® HLB µElution 96-well plate 
Wells of the SPE plate were first conditioned with 200 µL methanol, followed by 
equilibration with 200 µL water. The entire diluted PPT supernatant (~1.4 mL) was loaded 
onto the extraction plate in two steps of approximately 700 µL each using an electronic 8-
channel pipettor. The wells were then washed with 200 µL 5% methanol in water. 
Teriparatide and the IS were eluted sequentially with two 25 µL aliquots of 60/34/5/1 
ACN/water/TFE/TFA. Eluates were diluted with 50 µL water and 30 μL was injected onto 
the LC system. 




Equation 3.1 Calculation of matrix factor (MF) 
MF = (peak area of post-extracted spiked samples)/(peak area of solvent standards) 
 
3.2.4 Chromatographic Conditions  
The SPE eluate was injected onto an ACQUITY UPLC CSH C18 column (2.1 x 50 
mm, 1.7 µm, 130Å) using a Waters ACQUITY UPLC system equipped with a 50 µL fixed 
loop autosampler. Samples were kept cooled at 10°C and column temperature was 
maintained at 60°C. Mobile phase A consisted of 0.1% formic acid (by volume) in water 
and mobile phase B consisted of 0.1% formic acid (by volume) in acetonitrile. After an 
initial 0.2 minute hold, teriparatide and the IS were eluted using a linear gradient from 15% 
B to 50% B over 3.6 min at 0.4 mL/min, which was directly introduced into the MS, without 
splitting. Mobile phase B was then ramped from 50 to 98% over 0.1 min and held for 0.5 
min to clean the column. This was followed by an equilibration at initial conditions. Total 
cycle time was 6 minutes. 
3.2.5  Mass spectrometry and Software 
For teriparatide and the IS, collision induced dissociation (CID) products of multiply 
charged precursors were detected in positive ion multiple reaction monitoring (MRM) mode 
using a Waters Xevo™ TQ-S mass spectrometer (Milford, MA). The electrospray voltage, 
source temperature,  desolvation temperature and desolvation gas flow rate were 3.0 kV, 
150 °C, 600 °C and 1000 L/Hr, respectively. MRM transitions and charge states for 
teriparatide and the IS as well as their respective cone voltages and collision energies are 





Table 3.1. MRM transitions, collision energies, and cone voltages for teraparitide and human parathyroid 1-38 
(rhPTH (1-38)), the internal standard (IS) 
 
MassLynx instrument control software version 4.1 was used for data acquisition. All 
peak area integration, regression analysis and sample quantification was performed using 
TargetLynx.  
3.3 Results and Discussion 
3.3.1 Development of sample pre-treatment and solid-phase extraction  
As mixed-mode SPE has been shown to yield the most selective extractions in our 
previous work [15, 16], it provided the optimal starting point for extraction method 
development. An experimental comparison between SPE and protein precipitation (PPT) 
confirmed that the endogenous background from PPT samples was too high to allow 
quantification at the sub-ng/mL level (Figure 3.2). It can be seen from the data in this figure 
that the background at the teriparatide retention time is significantly reduced when samples 
are processed by SPE following acetonitrile precipitation (bottom panel) relative to 
precipitation alone (top panel). Furthermore, precipitation with acetonitrile rather than zinc 
sulphate prior to SPE also results in a cleaner background. As a result, not only do we 






Teriparatide 687.05 > 787.26 45 18
824.25 > 983.79  45 25




precipitation is preferred over zinc sulphate for background reduction.  Sample preparation 
development focused on the use of a low sorbent bed-mass SPE format as a means to allow 
for sample concentration without evaporation, as evaporation of extracts containing peptides 
often results in significant peptide loss due to adsorption to surfaces and inefficient re-




Figure 3.2 Comparison of MS background present in final eluates from various sample preparation techniques, 
relative to the retention time of teriparatide 
 
 Initial recovery experiments, using generic peptide extraction protocols [16] on 
mixed-mode strong anion exchange and weak cation exchange sorbents yielded recoveries 
of approximately 50%. Previous reports have shown that apparent “low extraction recovery” 
arises from several distinct possible sources: non-specific binding (NSB), protein binding, 
chemical instability, incomplete elution due to choice of elution solvent, or insufficient 
capacity in the extraction device[18]. Each of these possibilities was examined and tested. 
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The starting SPE method called for dilution of the plasma with 4% aqueous H3PO4. It can be 
hypothesized that this may not be sufficient to disrupt any protein binding that could occur 
between teriparatide and plasma proteins. To address this issue alternate dilution options 
were assessed prior to SPE extraction, including dilution with TRIS base, 5% NaOH, 10% 
H3PO4, guanidine HCl denaturation, zinc sulphate precipitation and organic precipitation. 




Figure 3.3 % SPE recovery of teriparatide following different plasma pre-treatment options 
 
It can be seen from this data that organic precipitation, TRIS or Guanidine increased 
recovery by approximately 10%, whereas all other options resulted in negligible changes.  
Thus it was concluded that protein binding was not the primary cause of low recovery. 
Although instability in human plasma was not thought to be an issue[19], it was investigated 






















in recovery. Next, the loading capacity of the plate was tested to eliminate the possibility of 
sample loss due to insufficient capacity. There was no increase in recovery when the sample 
size was reduced from 200 µL to 50 µL, indicating that the plate capacity was sufficient for 
the 200 µL sample load. Elution solvents were also optimized through the addition of 
varying percentages of acidic and basic modifiers, as well as varying types and mixtures of 
organic solvent (ACN, MEOH, IPA), and with and without the addition of trifluoroethanol 
(TFE), which has been proven to improve solubility of peptides and proteins[20]. These 
modifications to the elution solvent did not improve recovery significantly, though the 
addition of TFE did increase MS area counts for teriparatide, perhaps indicating improved 
solubility. Finally, a rudimentary test for NSB was conducted. In one instance, the SPE plate 
was pre-conditioned with crashed plasma supernatant (to coat any surfaces available to bind 
teriparatide) and in another instance, TWEEN-20 (0.02%) was added to the samples, again 
to aid in coating surfaces. Neither treatment improved recovery significantly.  
At this point, a more fundamental assessment of teriparatide recovery from plasma 
was performed using PPT alone, simply to confirm that high recovery could be obtained 
using the simplest approach possible. Both 2:1 and 1:1 ratios of modified and unmodified 
acetonitrile to plasma were tested. Recovery using a 1:1 ratio versus 2:1 ratio of organic 
solvent to plasma yielded approximately two-fold higher recovery. (The complete data 
summary from this experiment was previously shown in Chapter 2, in Figure 2.20). Thus for 
a larger peptide such as teriparatide, one must balance peptide recovery with precipitation of 
high abundance, unwanted plasma proteins. When the 2:1 ratio is used, it can be concluded 
that teriparatide is partially precipitated, resulting in low recovery (30-50%).  This 
supposition is based on findings from Ewles et al[21] where they demonstrated that higher 
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percentages of organic are necessary to precipitate peptides of decreasing size, while  larger 
peptides require much less organic.  In addition, base-modified ACN yielded higher 
recovery than acid-modifed ACN, due to a combination of improved solubility and more 
efficient disruption of protein binding. Precipitation with ACN was more efficient than 
MeOH or IPA. Final precipitation conditions adding 1:1 ACN + 5% NH4OH to plasma 
yielded recovery in excess of 95% for teriparatide.  
Once it was determined that teriparatide could be almost completely recovered using 
PPT whilst simultaneously reducing background high abundance proteins such as albumin, 
the focus returned to refining the subsequent SPE step in order to obtain adequate specificity 
for the assay.  In this investigation a reversed-phase SPE sorbent was chosen for evaluation 
together with the mixed mode phase sorbents previously tested. Generic SPE methods 
described in Chapter 2 were modified to reflect what had been learned from the 
precipitation and pre-treatment experiments for teriparatide, as well as to eliminate any steps 
that might encourage NSB (such as 100% aqueous washes).  The protein precipitation 
experiments demonstrated a higher recovery using ACN-based solutions, and higher peak 
areas when TFE was added to the elution solvent, with an average recovery greater than 
90% of that obtained from the PPT step. The PPT conditions were then incorporated into the 
SPE method, specifically acid- and base-modified elution solutions containing ACN and 
TFE were tested first. Reversed-phase recovery was 89%, while maximum recovery on 
mixed-mode sorbents was approximately 50%. 
Modification with acid or base provided little advantage in terms of recovery. 
However, elution with acid was chosen over basic elution to provide a degree of retention 
orthogonality relative to the basic loading conditions. Finally, tests were performed to 
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determine the minimum concentration of organic required to maximize teriparatide 
recovery, thus creating the most selective elution conditions possible when combined with 
the pH switch. In addition, low organic % in the elution solvent ensures that phospholipids 
and other more hydrophobic endogenous interferences are retained on the SPE plate.  
Elimination of 100% aqueous wash steps coupled to an elution solution comprised of 60% 
ACN, 5% TFE, and 1% TFA yielded >90% recovery on Oasis HLB with <2.5% matrix 
effects. The highest recovery was achieved on the reversed-phase only sorbent, therefore 
this sorbent was selected for teriparatide extraction.  Normally it is preferred to use mixed-
mode SPE as specified in Chapter 2. However, extraction recovery for teriparatide was 50% 
less on the mixed-mode versus reversed-phase only sorbent. Attempts to increase recovery 
on the mixed-mode sorbent were unsuccessful. Finally, it was decided that this particular 
application would have to be performed using reversed-phase only SPE. The addition of a 
protein precipitation pre-treatment step helped to improve specificity and facilitate the use 
of reversed-phase SPE for this particular case. 
 
3.3.2 Mass Spectrometry of Teriparatide 
While a single precursor is typically used to generate fragments for small molecule 
analyses, there are advantages to selecting multiple precursors to evaluate fragmentation of 
a peptide. Not only do the various charge states fragment differently, but it can be difficult 
to predict the specificity of a particular MRM transition in a sample derived from a 
biological matrix.  Therefore having several precursors to choose from allows a degree of 
selection during the method development process. Several multiply charged precursors were 
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observed for teriparatide and human parathyroid hormone 1-38 (IS); the full scan MS 
spectra are shown in Figure 3.4.1.  
 
 
 Figure 3.4.1. MS spectra of teriparatide (A) and human parathyroid 1-38 (B) 
 
The 6+ and 7+ charge states of teriparatide at m/z 687 and 589, respectively, were observed 
to be the most intense ions. The 5+ precursor at m/z 824 was about half the intensity of the 
others. Fragmentation of m/z 687 produced a selective product ion at m/z = 787 (Figure 
3.4.2B), corresponding to a 5+ y32 ion. This was chosen as the primary transition used for 
quantitative analysis. The 7+ precursor at m/z 589 did not yield any usable product ions 
(Figure 3.4.2C). Fragmentation of the less intense m/z 824 precursor (Figure 3.4.2A) 
produced fragment ions, including a 4+ y32 ion at m/z 984, of sufficient intensity only to be 
used for confirmatory purposes. MSMS spectra obtained at the optimized collision energies 
are shown in Figure 3.4.2. Fragments chosen for quantification are highlighted with an 
asterisk. A low intensity 4+ precursor was observed at m/z 1030, which yielded a 3+ y29 
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fragment at m/z 1201.This mass pair, though specific, did not yield sufficient intensity for 
quantitative purposes.  
 
 
Figure 3.4.2. MSMS spectra of the 5+ teriparatide precursor at m/z 824 (A), the 6+ precursor at m/z 687 (B), 
and the 7+ precursor at m/z 589 (C). Fragments chosen for quantification are highlighted with an asterisk and 
correspond to y32 ions. 
 
In addition, it is good practice to avoid any fragments below m/z 200. Although 
many peptides produce intense fragments in this range, these ions (often immonium ions) 
result in high background in extracted samples due to their lack of specificity. This was 
demonstrated in a recently published insulin assay[8]. The 5+ precursor at m/z 824 actually 
produces a high intensity fragment at m/z 159, which may be as much as 10X more intense 
in solvent standards. However, in an extracted plasma sample, Figure 3.5 demonstrates that 
although the 159 fragment is more intense than the 984 fragment used for quantification, the 
signal to noise is significantly lower. In this teriparatide assay, the use of y ion fragments 









and extraction methodologies which ultimately achieve detection limits similar to that of 




Figure 3.5 MS/MS analysis of teriparatide extracted from human plasma monitoring either m/z 824-> 984 
(top) or m/z 824-> 159 (bottom)  
 
3.3.3 Liquid Chromatography 
The value of 300Å pore size LC columns for the separation of peptides has been 
documented previously[21, 22] and was established in Chapter 2. These columns were 
shown to significantly improve peak shape, particularly for large peptides, relative to more 
standard pore size (i.e., 90-130Å) columns. Unexpectedly, and specifically for teriparatide, a 
300Å bridged-ethyl hybrid (BEH) column produced peaks characterized by severe tailing 
and widths of approximately 6-8 seconds wide at base (Figure 3.6, bottom panel). Several 
intact insulins demonstrated similar behaviour [8], which was resolved through the use of a 
column containing BEH particles modified with a low level, positively charged moiety (also 
referred to as Charged Surface Hybrid, or CSH). It is believed that these peptides interacted 
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824.4 > 159.21, 
more intense but 
lower signal to 
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824.4 > 983.9, less 




with the uncharged, hydrophobic C18 surface of the conventional BEH 300 Å columns to a 
greater degree than other peptides and as such, diffusion in and out of the chromatographic 
pores was not efficient, resulting in the observed broad peaks and tailing. Due to the low 
level positive charge on the particle surface of the CSH phase, peak shape under formic acid 
conditions was improved. Figure 3.6 (top panel) demonstrates the improved peak shape for 




Figure 3.6. A teriparatide 1 ng/mL neat standard chromatographed on an ACQUITY UPLC CSH C18 column 
at 35°C (top panel) and an ACQUITY UPLC BEH C18 300 column at 35°C (bottom panel.) Both columns are 
2.1 X 50mm, 1.7 µm. The flow rate is 0.4 mL/min and the gradient is 20-65% B in 2 minutes 
 
The isoelectric point (pI) for teriparatide is approximately 9.1, making it positively 
charged under the low pH mobile phase conditions employed. Improved peak shape could 
be due to the positive charge on the stationary phase minimizing secondary interactions. 
During method development, flow rate, temperature, gradient, organic modifier, and the 
addition of TFE to mobile phase B were all evaluated. Experiments determined that 
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teriparatide follows similar trends to other large peptides with respect to temperature and 
gradient slope. Strangely, a lower flow rate, 0.3 versus 0.4 mL/min, produced an unexpected 
decrease in signal as shown in Figure 3.7.  We then hypothesized that an even faster flow 
rate might further increase teriparatide signal. However, an experiment was run using a flow 
rate of 0.6 mL/min and not only did the teriparatide signal decrease, but carryover was 
observed. We believe that teriparatide either begins to precipitate and/or not enough time is 
allowed for efficient diffusion, when the faster flow rate is used. These observations serve to 
highlight the balance that must be achieved between speed, sensitivity, and 







Figure 3.7 LC/MS analysis of teriparatide using a test gradient of 20 to 65% B over 2 minutes run at either 0.4  







Shallower gradient slopes produced the expected effect of increasing area counts. 
For example, a gradient of 15-50% B in 3.6 minutes versus a steeper gradient from 15-50% 





Figure 3.8 LC/MS analysis of teriparatide using a gradient of 15% B to 50% B over either 3.6 (top) or 1.8 
(bottom) minutes 
 
  Increasing temperature from 35 to 60° C  also increased area counts and reduced 
carryover, likely due to increased mass transfer, and this is consistent with previously 
reported work [23]. The use of ACN in mobile phase B versus MeOH or IPA resulted in 2X 
higher area counts. Although adding 5% TFE to mobile phase B also increased area counts 
for teriparatide (see Figure 2.11, Chapter 2), it resulted in an equal increase in background, 
1000pg/ml  0.5%TFA 37.5ACN 0.05%RP
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and therefore was not included. TFE was used in the needle wash, however, to further 
reduce any remaining carryover. 
A representative chromatogram of the separation using the final gradient conditions 




Figure 3.9. UPLC separation of teriparatide and internal standard, from a 125 pg/mL extracted plasma sample, 
using a 2.1 X 50mm ACQUITY UPLC CSH column and the final gradient conditions 
 
3.3.4  Human Plasma Standard Curve and Quality Control Data 
Dynamic range and assay accuracy and precision were determined using standard 
curves and quality control (QC) samples prepared in human plasma spiked with teriparatide 
and a constant concentration of the IS (final concentration 200 pg/mL). Peak area ratios 
(PARs) of teriparatide and the internal standard were determined and calibration curves 
generated. Teriparatide concentrations in QC samples were calculated from their PARs 
against their respective calibration lines. Calibration standards used for quantification of 







values for all curves were found to be in the range > 0.998. The average CV of all points on 
3 independent standard curves was 4% and average accuracy was 101%, indicating a very 
reproducible and accurate method. Statistics from a representative standard curve are 
























15pg/ml 15 16.65 0.64 3.9 3/3 111.0 
30pg/ml 30 30.48 1.39 4.6 3/3 101.6 
40pg/ml 40 41.09 1.95 4.8 3/3 102.7 
60pg/ml 60 62.78 5.20 8.3 3/3 104.6 
80pg/ml 80 75.38 1.56 2.1 3/3 94.2 
100pg/ml 100 94.39 2.78 2.9 3/3 94.4 
200pg/ml 200 202.60 10.63 5.2 3/3 101.3 
400pg/ml 400 401.90 10.86 2.7 3/3 100.5 
500pg/ml 500 498.47 10.36 2.1 3/3 99.7 
 
Table 3.2. Representative standard curve statistics for teriparatide extracted from 200 µL human plasma 
 
 
QC samples were prepared in triplicate in 6 sources of human plasma at 0.02, 0.035, 
0.075, 0.125, and 0.25 ng/ml. The mean accuracies for all QC samples, in all sources of 
matrix, ranged from 90-106%, and mean precision for all levels ranged from 0.7 to 7.7%. 
Representative QC statistics from 6 individual sources (Biological Specialty Corporation lot 

























                
X1793C Mixed  20 20.25 1.50 7.3 3/3 102.2 
82111 Female 20 33.38 1.75 8.6 3/3 102.2 
57298 Male 20 18.30 0.67 3.7 3/3 91.5 
82740 Female 20 20.74 1.59 7.7 3/3 103.7 
57901 Male 20 19.67 0.60 3.0 3/3 98.3 
X1803C Mixed 20 21.27 0.96 4.5 2/3 106.4 




















                
X1793C Mixed  35 33.35 1.99 6.0 2/3 95.3 
82111 Female 35 34.48 1.84 5.3 3/3 98.5 
57298 Male 35 31.64 1.81 5.7 3/3 90.4 
82740 Female 35 33.29 1.73 5.2 3/3 95.1 
57901 Male 35 34.71 0.30 0.9 3/3 99.2 
X1803C Mixed 35 34.24 2.66 7.8 3/3 97.8 




















                
X1793C Mixed  75 75.07 1.17 1.6 3/3 100.1 
82111 Female 75 73.29 4.23 5.8 3/3 97.7 
57298 Male 75 71.92 3.50 4.9 3/3 95.9 
82740 Female 75 70.34 5.14 7.3 2/3 93.8 
57901 Male 75 72.30 5.28 7.3 3/3 96.4 
X1803C Mixed 75 69.63 3.25 4.7 3/3 92.8 




















                
X1793C Mixed  125 131.21 2.73 2.1 3/3 105.0 
82111 Female 125 130.01 1.67 1.3 3/3 104.0 
57298 Male 125 125.82 1.42 1.1 3/3 100.7 
82740 Female 125 117.34 6.94 5.9 3/3 93.9 
57901 Male 125 115.21 5.42 4.7 3/3 92.2 
X1803C Mixed 125 113.70 4.92 4.3 3/3 91.0 




















                
X1793C Mixed  250 262.26 5.14 2.0 3/3 104.9 
82111 Female 250 265.24 1.77 0.7 3/3 106.1 
57298 Male 250 244.54 15.75 6.4 3/3 97.8 
82740 Female 250 221.83 5.72 2.6 3/3 88.8 
57901 Male 250 235.72 12.22 5.2 3/3 93.0 
X1803C Mixed 250 226.60 2.93 1.3 3/3 90.7 
 




Representative chromatograms of an extracted plasma blank and teriparatide at 
various low level concentrations are shown in Figures 3.10A-D. A representative standard 




Figure 3.10. Representative chromatograms from teriparatide extracted from blank human plasma (A) and 















Figure 3.11. Representative standard curve of teriparatide extracted from human plasma, from 15- to 500 
pg/mL. 
 
The necessity for the use of a quadratic fit was explored from various angles. Human 
plasma blanks from all lots were free from interference at the teriparatide retention time. 
Focus on IS performance revealed that IS area counts were consistent across the 
concentration range and across various lots of human plasma. Furthermore, there was no 
interference between the IS and teriparatide in samples containing IS only. Both the nature 
and concentration of the IS were tested with little effect. Rat PTH 1-34, when tested as an 
alternative IS, yielded variable MS background with no change in linearity. An additional 
hypothesis relating to the use of a quadratic fit was that teriparatide might be gradually 
building up on the column and then leaching out slowly, due to inadequate peptide 
solubility. To test this theory, column temperature was increased to 80°C with no impact on 
performance. Another possibility is that a shift in the charge state distribution occurred with 








Finally, the gradient steepness was further reduced in an attempt to uncover any previously 
undetected interferences/co-elutions. None were detected. Assay accuracy and precision met 
accepted criteria for a validated assay[24] , with no CV >8% for any QC level, in any source 
of plasma and an average accuracy of 97.5% for all QC samples. These data suggest that, 
although the calibration curve had this non-linear character, the data fit a weighted quadratic 
function well and the demonstrated accuracy and precision over the assay range were within 
conventional criteria for a validated assay.  
3.3.5 Specificity 
Matrix factors were calculated in six sources of human plasma with a CV across the 
various lots of 5.0 %, easily meeting recommended regulatory criteria[25]. Matrix factors 
for individual lots (N=3 analysis) were 1.24, 1.16, 1.18, 1.24, 1.15, and 1.31. Data for 
individual replicates is presented in Table 3.4. In addition, six sources of plasma were 
assessed for interferences in the blank samples present at the retention time of teriparatide. 
All extracted plasma blanks were found to be free from interference. Accuracy and 
precision of the lowest QC samples (fortified at 20 pg/mL or 4.85 fmol/mL) in 6 sources of 













Lot # Prep 1 
Matrix 
Factor Prep 2 
Matrix 
Factor Prep 3 
Matrix 
Factor 
x1793c 26813.4 1.22 28284.6 1.28 26785.7 1.22 
x1803c 27198.2 1.23 24787.4 1.13 24745.8 1.12 
57298 26619.8 1.21 26493.7 1.20 24550.6 1.11 
57901 28961.7 1.31 26002.6 1.18 27012.8 1.23 
82111 26610.4 1.21 26007.4 1.18 23306.2 1.06 
82740 29942.9 1.36 28104.5 1.28 28307.1 1.28 
 
Table 3.4. Individual matrix factor assessments from 3 replicates each, from 6 sources of human plasma 
 
3.5  Conclusions 
With the global incidence of osteoporosis-related fractures expected to increase by 
50% by 2025 [1], it is reasonable to also expect that the interest in development of treatment 
and monitoring options, and thus the identification and quantification of teriparatide, will be 
increasingly important to the scientific  community. Not only is the interest in teriparatide 
specifically likely to increase, but the trend toward increasing development of peptide 
therapeutics and, interestingly, increasing size of peptide therapeutics[26], makes 
understanding and addressing the specific challenges associated with bioanalysis of large 
peptides particularly relevant.  There are many distinct advantages to quantifying 
teriparatide by LC-MS/MS, and this analysis overcame many analytical hurdles including 
non-specific binding, poor chromatographic peak shape, carry-over, poor linearity, poor 
reproducibility, protein binding and poor MS sensitivity. This chapter presents a novel 
method for differentiating and quantifying teriparatide using µElution SPE and UPLC-
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MS/MS, and highlights the tools and techniques for understanding, identifying, and 
addressing the challenges associated with large molecule analysis by LC-MS in the routine 
bioanalytical labouratory. The combination of a simple, yet highly selective, two-step 96-
well extraction which concentrates without evaporation, chromatography using novel 
charged-surface columns, and detailed investigation of MS transition were key elements 
required to address these issues. The method described herein achieves a quantification limit 
of 15 pg/mL (3.6 fmol/mL) from 200 µL of human plasma, providing the necessary 
sensitivity for analysis of PK studies as well as clinical trials. Accuracy and precision 
measurements all meet FDA criteria for method validation [27] with all CVs for QC 
samples <8%, and average accuracy at all levels of 97.5%. Matrix factor assessment also 
meet industry recommendations for validated assays[25], with a 5% CV of matrix factors 
across 6 lots. To the best of the authors’ knowledge this is the first LC-MS/MS method for 
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4.1 Introduction  
 
The impact of Alzheimer’s disease in terms of mortality rate and cost cannot be 
underestimated financially both on the healthcare system and on the individual. This disease 
currently affects over 35 million individuals worldwide and is expected to affect 115 million 
by 2050[1]. In the US, it is responsible for 500,000 deaths a year and is the 6th cause of 
death in the USA. The cost of Alzheimer's disease is by far the most expensive in the US, 
with the direct costs to Americans totaling an estimated $214 billion in 2014. Of this, $150 
billion are costs to Medicare and Medicaid. In fact, 20% of all Medicare dollars spent is on 
Alzheimer’s related care. Additionally, it is predicted that Alzheimer's will cost the USA, 
alone, approximately $1.2 trillion (in 2014 dollars) in 2050[2], a staggering number. It is no 
surprise that Alzheimer’s research is one of the top focus areas worldwide in academia and 
the pharmaceutical industry.  
One of the main medical challenges centres around the early diagnosis and 
differentiation of Alzheimer’s disease (AD) from various other forms of Mild Cognitive 
Impairment (MCI). While post-mortem analysis remains the definitive determinant of cause 
of death, significant progress has been made in identifying early predictors or markers of the 
disease. An accumulation of research has led to current acceptance that the core indicators 
of AD are tau proteins, hyper-phosphorylated tau, and the amyloid beta peptide 1-42[3-8]. 
Recent publications by a group at Georgetown University also indicate that a panel of ten 
blood-based lipids may be early indicators of AD[9].  A very recent article in the 
Alzmeimer’s and Dementia journal identifies 10 plasma proteins that predict the progression 
from prodromal disease to dimentia[10]. The availability of a fast, reliable, easy to deploy 
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test for these marker compounds could significantly benefit Alzheimer’s diagnosis and 
treatment. 
The work in this chapter focuses specifically on the development of an assay for the 
quantification of three key amyloid beta peptides, including one of the core Alzheimer’s 
markers, amyloid beta (Aβ) 1-42. The method developed and described herein has 
subsequently formed the basis for a joint effort between the Global Biomarker 
Standardization Committee (GBSC) and the Alzheimer’s Association (AA) to develop a 
candidate reference method for LC/MS-based Aβ 1-42 measurement[11, 12]. In fact, Dr. 
Mattsson of the neurochemistry labouratory at the Sahlengrenska University Hospital in 
Sweden describes it as the “first use of selective reaction monitoring quantification of Aβ1–
42 in human cerebral spinal fluid” in his review of  approaches to reference measurement 
procedures for this biomarker[12]. Furthermore, this method is referenced in many of the 
current publications describing LC/MS based Aβ 1-42 quantification [5, 7, 11-19]. 
The pathogenesis of Alzheimer’s is marked by formation and deposition of insoluble 
protein aggregates in the brain[20]. Proteinaceous plaque formation in Alzheimer’s is a 
combination of amyloid beta peptides (A), derived from action of β and γ secretases on the 
amyloid precursor protein, and formation of intracellular neurofibrillary tangles (NFT’s) 
whose major constituent is the microtubule-binding protein tau. A peptides are found in 
both plasma and cerebral spinal fluid (CSF)[21], are 43 amino acids or less in length and 
can polymerize to form long insoluble fibrils consisting of parallel-aligned hydrogen-
bonded β-sheets[22]. The amyloid peptide A1-40 forms the insoluble β-sheet but is seeded 
by A1-42. Amino acid sequence, MW and pI for amyloid peptides studied in this chapter are 





Figure 4.1 Sequence, MW and pI for amyloid beta peptides 1-38, 1-40, and 1-42 
 
 The deposition of these insoluble aggregates from extracellular A deposits as well 
as intracellular NFT’s in the brain are considered the critical event in the development and 
pathology of Alzheimer’s, making A peptides appealing biomarkers of disease severity[23, 
24].  
Therapeutic intervention focuses on modifying the biochemical processes that 
deposit insoluble A plaques in an attempt to slow disease progression or to delay its onset. 
Based on post-mortem examinations, formation of insoluble A deposits are considered the 
critical event in Alzheimer’s progression. Therefore, monitoring A peptide concentrations 
during disease progression or during therapeutic intervention may be an appropriate strategy 
for monitoring therapeutic efficacy of a pharmacological treatment [25, 26]. Current 
methods to quantify amyloid peptides have led to somewhat inconclusive results in 
Alzheimer’s programs due to a combination of non-specificity, lack of selectivity, and the 
inability to multiplex easily. In addition, many different methods have been used, with 
Amyloid β 1-38
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGG 
MW 4132 PI  5.2
Amyloid β 1-40
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV 
MW 4330 PI  5.2 
Amyloid β 1-42
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 
MW 4516 PI  5.2 
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dramatically different quantitative results [27]. Therefore there is a critical need for a more 
accurate and precise, single standardized methodology for the quantification of A species 
in blood samples, and for monitoring ratios of the various isoforms in Alzheimer’s programs 
to elucidate biological processes.  
Enzyme-linked immunosorbant assays (ELISA), western blots or immunoaffinity 
enrichment followed by liquid chromatography mass spectrometry (LC-MS) are the most 
popular assays for A quantitation [28-30]. While immuno assays are sensitive, antibody 
selectivity and various sample handling protocols have created contradictory A findings 
and low throughput assays. Even with newer analytical technologies in place, A 
quantitation by LC-MS is challenging due to low endogenous concentrations, their 
propensity to aggregate and even selecting the appropriate biological matrix for monitoring 
A levels.  
The findings detailed in Chapter 2 provided not only a fundamental understanding of 
the challenges associated with LC-MS of peptides, but also elucidated solutions for many of 
those problems. This knowledge was then applied herein to the quantification of these 
critical Alzheimer’s disease biomarkers.  
Investigators have measured A levels in both plasma and CSF as diagnostic or 
pathogenic biomarkers of Alzheimer’s but, prior to 2014, there was no clear correlation 
between plasma A levels and Alzheimer’s pathology[31, 32]. The work described by 
Mapstone et al[9], however, has now shown that certain lipids may also be appropriate 
biomarkers.  Plasma is a more appealing matrix than CSF for clinical measurements because 
blood collection poses significantly less risk of infection to patients and can be sampled 
over long-term studies. However, Alzheimer’s severity is associated with the inability to 
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clear specific A peptides from the brain that aggregate into plaque deposits[33]. Because 
the brain compartment has reduced A clearance, CSF is likely a more appropriate matrix 
for monitoring A concentrations in the degree of Alzheimer’s severity or during 
therapeutic intervention. Furthermore, at the time of writing, a confident correlation 
between plasma and CSF levels and the relationship to Alzheimer’s progression had not yet 
been definitively established. 
Below is described an alternative sample preparation procedure for A species 
enrichment in CSF without relying upon antibodies. This SPE method had greater than 80% 
extraction efficacy and eliminates selectivity issues associated with antibody based analysis. 
When used in conjunction with the described ultra performance liquid-chromatography 
tandem mass-spectrometry (UPLC-MS/MS) assay, it was possible to accurately and 
reproducibly quantify Aβ1-38, Aβ1-40, and Aβ1-42 from human CSF at the level of 50 pg/mL 
or 0.011 nMol. Enhanced analytical methodologies like the one described herein may 
provide greater insight into amyloid diseases, their progression and therapeutic approaches 
to intervention.  
 
4.2 Experimental  
4.2.1 Chemicals and Reagents  
Human amyloid-beta synthetic peptides A1-38 , A1-40, and A1-42 were purchased 
from American Peptide (Sunnyvale, CA). Nitrogen-15 isotopically labeled human amyloid-
beta peptides [15N51]-A1-38, [15N53]-A1-40, and [15N55]-A1-42 were purchased from 
rPeptide (Athens, GA). Normal, non-diseased human cerebrospinal fluid (CSF) was 
purchased from Biological Specialty Corporation, Colmar, PA (pool 2) and Lampire 
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Biological Labs, Pipersville, PA (pools 1 and 3). Artificial CSF perfusion fluid was 
purchased from Tocris Bioscience (Ellisville, MO). Water for mobile phase and sample 
preparation was obtained from a Milli-Q lab water system, (Millipore, Billerica, MA). 
Acetonitrile, methanol, and ammonium hydroxide (concentrated solution, 28-30%) were 
purchased from Fisher Scientific (Fair Lawn, NJ). All other chemicals and reagents were 
purchased from Sigma (St. Louis, MO) unless otherwise stated.  
4.2.2 Preparation of samples, calibration standards and quality control samples 
A peptides and their isotopically labeled internal standards were corrected for 
purity and prepared at 1 mg/ml in dimethyl sulfoxide (DMSO). Standards were diluted to 50 
µg/ml in DMSO, divided into aliquots for single use and stored at -80 C in 0.5 ml 
polypropylene micro centrifuge tubes (Axygen Scientific; Union City, CA). On the day of 
sample analysis, aliquots of the 50 µg/ml stock of each non-labeled peptide were pooled and 
diluted to 500 ng/ml in 50/50 acetonitrile/water (ACN/H2O) +1% ammonium hydroxide 
(NH4OH), 15N labeled peptides were treated similarly. The internal standard (IS) spiking 
solution was prepared by diluting the 500 ng/ml 15N stock to 20 ng/ml in 50/50 ACN/H2O 
containing 1% NH4OH. For standard and quality control (QC) samples, working solutions 
of pooled A peptides, that were 25X the desired final concentration were made through 
serial dilution of the 500 ng/ml stock. For each intended standard curve point and each QC 
level, 1 ml of artificial CSF containing 5% rat plasma or human CSF was spiked with 40 µl 
of the appropriate concentration of analyte working solution and 50 µl IS spiking solution. 
Quality control samples were prepared in human and artificial CSF matrices at 0.2, 0.8, 2, 
and 6 ng/ml. After addition of standards and prior to extraction, human CSF, calibration and 
quality control samples were equilibrated at room temperature for 30 min. A 200 μl aliquot 
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of each was diluted with 200 μl of 5 M guanidine hydrochloride, shaken at room 
temperature for 45 min and diluted further with 200 μl 4% phosphoric acid (H3PO4) in 
water. The resultant 600 µl sample was extracted by SPE. 
 
4.2.3 Solid-phase extraction conditions  
 Samples were extracted using an Oasis MCX μElution plate (Waters Corp., 
Milford, MA). The plate was conditioned with 200 μl of methanol followed 200 μl of 4% 
H3PO4 in water. The 600 μl pretreated CSF, standards and quality control samples were 
loaded onto the SPE plate and washed with 200 μl of 4% H3PO4 in water followed by 200 μl 
of 10% acetonitrile. Amyloid beta peptides were eluted with two 25 μl aliquots (collected 
together) of 75/15/10 (v/v/v) ACN/H2O /concentrated NH4OH solution. Samples were then 
diluted with 25 μl of water and placed in the autosampler for analysis. 
 
4.2.4 Ultra-performance liquid chromatography tandem mass spectrometry  
A 10 μl aliquot was injected onto an ACQUITY UPLC BEH300 C18 column (2.1 x 
150 mm, 1.7 µm) using a Waters ACQUITY UPLC system. The column temperature was 
50°C. The chromatography system was operated in reversed-phase gradient mode where 
mobile phase A consisted of 0.3% NH4OH (by volume) in water and mobile phase B 
consisted of 90/10(v/v) acetonitrile/mobile phase A. After an initial 1 minute hold, A 
peptides were eluted using a linear gradient from 10% B to 45% B over 5.5 min at 0.2 
ml/min, which was directly introduced into the MS, without splitting. For each peptide and 
IS, collision induced dissociation (CID) products of 4+ precursors were detected in positive 
ion multiple reaction monitoring (MRM) mode using a Waters Xevo™ TQ mass 
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spectrometer (Milford, MA.) The electrospray voltage, source temperature,  desolvation 
temperature and desolvation gas flow rate were 2.5 kV, 120 °C, 450 °C and 800 L/Hr, 
respectively. MRM transitions and charge states for each peptide and IS as well as their 
respective cone voltages and collision energies are summarized in Table 4.1. MassLynx 
instrument control software was used for data acquisition. All peak area integration, 
regression analysis and sample quantification was performed using TargetLynx. Peak area 
ratios (PARs) of the A peptides and their isotopically labeled internal standards were 
determined and calibration curves for each of the A peptides were constructed using PARs 
of the artificial CSF calibration standards. A concentrations in CSF were determined from 
their PARs against their respective calibration line. 
 
 
















Aβ1-38 1033.5 1000.3 b 36 33 23
[15N51]-A1-38 1046.0 1012.5 30 22
Aβ1-40 1083.0 1053.6 b 39 33 25
[15N53]-A1-40 1096.0 1066.5 35 22
Aβ1-42 1129.0 1078.5 b 40 28 30
[15N55]-A1-42 1142.5 1091.5 35 28
226 
 
4.3 Results  
4.3.1 Sample pre-treatment and solid-phase extraction recoveries  
During early method development using artificial CSF as a surrogate matrix, lower 
A recovery was observed relative to that in human CSF (though neither was optimal) and 
characterized as non-specific binding. Subsequently, Aβ peptide standards were diluted in 
artificial CSF containing 5% rat plasma to act as a carrier in order to address this issue and 
decrease non-specific binding. Rat plasma was chosen as a carrier because rat Aβ peptides 
differ in amino acid composition by substitution at arginine-5, tyrosine-10 and histidine-13 
for glycine, phenylalanine and arginine, resulting in different molecular weights from 
human Aβ species, thus eliminating any possible cross talk.  Although the addition of carrier 
protein improved recovery in general, absolute recovery from both the artificial CSF + rat 
plasma and spiked human CSF were still lower than desired (<50%). Earlier studies in 
Chapter 2 and the HPLC index of these peptides led to the suspicion that protein binding 
was occurring. In addition, the knowledge that Aβ 1-42 aggregates necessitated an especially 
aggressive approach to eliminating this binding. Therefore, for standard, quality control, and 
samples in human CSF matrix, a final concentration of 5 M guanidine hydrochloric acid was 
used as a denaturant to further reduce non-specific interactions between proteins and Aβ 
species as well as aggregation, which improved the assay reproducibility. Analyte retention 
on the SPE sorbent was enhanced by adding 4% H3PO4 to the samples prior to loading.  
After loading samples onto the SPE plate, varying percentages of acetonitrile were 
examined as wash solutions to reduce matrix interferences. A 10% acetonitrile (ACN) wash 
was incorporated to remove matrix interferences without sacrificing amyloid beta peptide 
recovery. Increasing the wash solution to 20% ACN decreased A1-38 recovery, being the 
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least hydrophobic of the amyloid peptides investigated. Optimum Aβ recovery was obtained 
using 75% ACN containing 10% NH4OH as the eluting solution This provided both the 
elutropic strength and the required solubility to fully elute A1-42, the least soluble and most 
hydrophobic of these 3 peptides. Reducing the organic and the basic modifier percentages to 
65% ACN and 5% NH4OH decreased recovery for both A1-40 and A1-42. When the 
organic solvent was increased to 75% ACN with 5% NH4OH the elutropic strength was 
sufficient to improve the recovery for A1-40 but not for A1-42. The need for 10% base to 
fully elute A1-42 may be explained several ways. It is possible that aggregation occurs 
during SPE processing and a higher concentration of base is able to disrupt aggregation 
whereas the lower concentration cannot. Alternatively, higher base content may disrupt 
additional protein binding and/or ionic bonding. SPE extraction efficiency was determined 
by comparing average areas from a 1 ng/ml mixture of peptides in matrix taken through the 
described extraction procedure to average area counts from a blank extracted matrix which 
was then spiked post-extraction at 1 ng/ml. Recovery of A1-38, A1-40, A1-42 standards in 
artificial CSF without rat plasma were approximately 60%. Recoveries of A1-38, A1-40, 
A1-42 in artificial CSF containing 5% rat plasma were 94, 92 and 90% and for human CSF 
(using Guanidine HCl denaturation) were 88, 92, and 80%, respectively. Higher recovery 
leads to greater confidence in results and improved accuracy due to increased signal to 
noise.  
4.3.2 LC-MS/MS Analysis of Aβ Peptides 
Linear dynamic range and assay precision were determined using Aβ standard 
curves prepared in artificial CSF as described and quality control samples spiked into 
human CSF. The (M+H)4+ precursor to b4+-ion fragment transitions of A1-38, A1-40, and 
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A1-42  that were chosen for quantification were based on relative intensity and specificity, 
with “b” ions being chosen in all cases. Although 5+ precursors were present, the chemical 
background was significantly lower when the 4+ precursors were used (see Figure 2.14). 
Therefore transitions based on fragmentation of the 4+ precursors were used in this assay. 
The highest intensity product ion was selected for use as the primary quantitative transition, 
although other products were also detected (Figures 4.2-4.4), namely a series of b sequence 
ions including b31 through b40, corresponding to sequential cleavage of amino acids from 
the N-terminus. 
 













































Figure 4.3 ESI+ MSMS spectra for Aβ 1-40 
 
 
Figure 4.4 ESI+ MSMS spectra for Aβ 1-42 
 
Chromatographic retention times for A1-38, A1-40, and A1-42 were 5.6, 5.85 and 
6.03 minutes and the peptides were easily quantified in control CSF (Figure 4.5). Gaussian 
peaks were obtained and peak widths were 2-3 seconds wide at base. The amyloid peptides 
were baseline separated from each other. Peak intensity suffered at lower temperature, 
M+4H4+
m/z

















































higher flow rate, and/or when a steeper gradient was used. In addition, the use of a 150 mm 
length column was necessary to remove co-elution with endogenous interferences. 
 
Figure 4.5 Representative chromatographic separation of amyloid beta isoforms 1-38, 1-40, and 1-42 
 
Calibration standards used for quantification of A1-38, A1-40, and A1-42   were from 
100 to 10,000 pg/ml. The r2 values for all curves, for all amyloid peptides were > 0.98. For 
standard curves prepared in artificial CSF with rat plasma (Figures 4.6-4.8), the average 
percent deviation for all standard curve points was 3.8%, 3.2%, and 7.2% for A1-38, A1-40, 

























Figure 4.7 Representative standard curve for Aβ 1-40 extracted from artificial CSF 
Com pound nam e: 1-38
Correlation coefficient: r = 0.996956, r^2 = 0.993921
Calibration curve: 0.333755 * x + -0.0119724
Response type: Internal Std ( Ref 2 ), Area * ( IS Conc. / IS Area )
Curve type: Linear, Origin: Exclude, Weighting: 1/x, Axis  trans : None
ng/m L


















Com pound nam e: 1-40
Correlation coefficient: r = 0.993003, r^2 = 0.986055
Calibration curve: 0.60165 * x + -0.0184937
Response type: Internal Std ( Ref 2 ), Area * ( IS Conc. / IS Area )
Curve type: Linear, Origin: Exclude, Weighting: 1/x, Axis  trans : None
ng/m L
























Figure 4.8 Representative standard curve for Aβ 1-42 extracted from artificial CSF 
 
For standard curves prepared in human CSF, the average % deviation for all 
standard curve points was 6.1%, 2.2%, and 2.8% for A1-38, A1-40, and A1-42 respectively. 
To demonstrate parallelism and to confirm that artificial CSF (+ rat plasma) was a suitable 
surrogate matrix, a comparison of Aβ1-42 prepared in artificial vs. human CSF was 
performed. The data correlated with an r2 of 0.99 and slope of 1.1 (data for Aβ 1-42 shown in 
Figure 4.9); this was also true for the two additional peptides of interest. Artificial CSF was 
chosen as a surrogate matrix for CSF because of lower cost and higher availability. The 




Figure 4.9 Correlation between Aβ 1-42 concentrations determined using standard curves prepared in either 
spiked human CSF or artificial CSF + rat plasma carrier protein 
 
During method development, positive ion electrospray MS was compared to 
negative ion electrospray for CSF extracted Aβ peptides. Although fragmentation in 
negative ion produces a very intense water loss as shown in Figure 4.10, studies in extracted 
human CSF highlighted the lack of specificity of such an approach. As evident with the 
A1-42 species, negative ion mode produced a signal 1.6-fold higher than positive but was 
characterized by significant matrix interferences (Fig 4.11). This was also observed with the 
other A species of interest. Though plasma was not the matrix of interest for this study, the 
difference in specificity is even more pronounced, as in the example of Aβ 1-40 shown in 
Figure 4.12. Regardless, intensity of positively charged ions was more than sufficient to 




Figure 4.10 ESI- MSMS spectra for Aβ 1-42 
 
 
Figure 4.11 Comparison of LC-MS/MS analysis of Aβ 1-42, extracted from human CSF, using negative 
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Figure 4.12 Comparison of LC-MS/MS analysis of Aβ 1-40, extracted from human plasma, using negative 
ionization (top) and positive ionization (bottom) 
 
Basal levels of A1-38, A1-40, and A1-42 were determined by analyzing six independent 
extractions from three sources of pooled human CSF and a pooled lot of cynomalgous 
monkey CSF. These results are summarized in Figure 4.13. Mean basal ng/ml levels of Aβ 
from 3 human CSF pools were: Aβ1-38:1.64, 2.17 and 1.26; Aβ1-40:3.24, 3.63 and 2.55; Aβ1-
42: 0.50, 0.63 and 0.46 ng/mL, respectively. Levels for the monkey pool were 1.7, 3.7, and 
0.7 ng/mL for Aβ 1-38, 1-40, and 1-42, respectively. Representative chromatograms of basal 
levels of Aβ 1-42 extracted from 3 pooled lots of human CSF and one pooled lot of monkey 
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Figure 4.13 Summary of basal levels of Aβ 1-38, 1-40, and 1-42 extracted from three lots of pooled human CSF 
and a single lot of pooled monkey CSF. 
Amyloid Beta 1-38 Amyloid Beta 1-42
Replicate #
Human 























1 1.58 2.35 1.01 1.71 1 0.52 0.62 0.42 0.67
2 1.65 2.10 1.37 1.61 2 0.42 0.66 0.48 0.62
3 1.61 2.46 0.95 1.95 3 0.54 0.64 0.53 0.62
4 1.66 1.94 1.61 1.54 4 0.47 0.57 0.35 0.66
5 1.82 2.16 1.47 1.68 5 0.48 0.57 0.49 0.70
6 1.49 2.00 1.17 1.64 6 0.56 0.71 0.51 0.69
Mean 1.64 2.17 1.26 1.69 Mean 0.50 0.63 0.46 0.66
Std. 
Deviation 0.11 0.20 0.26 0.14 Std. Deviation 0.05 0.05 0.07 0.03















1 3.08 4.03 2.54 3.70
2 3.39 3.78 2.59 3.99
3 3.29 3.60 2.58 3.52
4 2.88 3.53 2.61 3.96
5 3.13 3.23 2.51 3.28
6 3.66 3.62 2.49 3.59
Mean 3.24 3.63 2.55 3.67
Std. 
Deviation 0.27 0.27 0.05 0.27




Figure 4.14 Representative chromatogram of Aβ 1-42 extracted from 3 pooled lots of human CSF and one 
pooled lot of monkey CSF 
 
  A peptide concentrations were significantly different (p < 0.05) using a t-test 
comparison for the 3 pooled CSF sources except for CSF pool one and three in the Aβ1-38 
and Aβ1-42 fractions. This demonstrated some variability in commercial sources of CSF that 
are representative of the normal population. The coefficient of variation (CV) was less than 
20% for all replicates within the pooled CSF sources. 
Quality control samples prepared in human CSF matrix were used to assess intra-
sample precision and reproducibility. QC samples were prepared in triplicate in the three 
separate human CSF pools and one monkey pool, as previously described, at 0.2, 0.8, 2, and 
6 ng/ml. The concentrations were determined by subtracting average basal levels from the 
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2.09 4.76 4.91 5.94 6.36 6.47 7.866.88 7.507.24
Human CSF, pooled sample 1
Human CSF, pooled sample 2
Human CSF, pooled sample 3
Monkey CSF, pooled sample 1
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CSF source to provide the corresponding QC level and are represented in Tables 4.2A 
through 4.2D.  
 
 















0.2 1.88 2.00 0.13 6 2/3 106.6
0.8 2.48 2.40 0.20 8 3/3 96.9
2 3.68 3.59 0.09 2 3/3 97.7
6 7.68 7.43 0.63 8 3/3 96.7
Amyloid β 1-40
Over-spike 











0.2 3.44 3.29 0.25 8 3/3 95.7
0.8 4.04 3.61 0.25 7 3/3 89.3
2 5.24 4.70 0.39 8 2/3 89.8
6 9.24 8.84 0.33 4 3/3 95.6
Amyloid β 1-42
Over-spike 











0.2 0.698 0.71 0.06 8 3/3 101.3
0.8 1.298 1.26 0.18 15 2/3 97
2 2.498 2.35 0.17 7 2/3 94





















0.2 2.41 2.29 0.21 9 3/3 96.7
0.8 3.01 2.69 0.24 9 2/3 89.3
2 4.21 3.92 0.10 3 3/3 93.2
















0.2 3.83 3.72 0.15 4 3/3 98.5
0.8 4.43 4.24 0.01 0 3/3 95.7
2 5.63 4.98 0.29 6 3/3 88.4
















0.2 0.828 0.86 0.08 9 3/3 103.8
0.8 1.428 1.32 0.12 9 3/3 92.4
2 2.628 2.28 0.30 13 2/3 90





















0.2 1.49 1.36 0.07 5 3/3 90.9
0.8 2.09 1.84 0.12 6 3/3 88.2
2 3.29 3.29 0.32 10 3/3 99.9
















0.2 2.75 2.36 0.02 1 2/3 85.8
0.8 3.35 3.05 0.02 1 2/3 91.2
2 4.55 3.93 0.01 0 3/3 86.4
















0.2 0.66 0.66 0.07 11 3/3 98.8
0.8 1.26 1.15 0.06 5 3/3 90.7
2 2.46 2.40 0.12 5 3/3 97.5




Table 4.2D Summary of QC statistics for Aβ peptides in cynomalgous monkey CSF pool 1 
 
Mean accuracy values for A1-38, A1-40, and A1-42 in all three pooled human CSF 
sources were within 15% of expected values demonstrating high method precision and 
accuracy. As is typical for endogenous compounds, determination of the LLOQs for each 
analyte is based on the lowest concentration that can be accurately and precisely quantified. 
In this particular case, the LLOQs in human CSF were better than or equal to 0.1 ng/ml, 

















0.2 1.92 1.95 0.04 2 3/3 101.6
0.8 2.52 2.56 0.30 12 3/3 101.4
2 3.72 3.69 0.43 12 3/3 99.2
















0.2 3.87 3.73 0.24 6 3/3 96.3
0.8 4.47 4.15 0.17 4 3/3 92.8
2 5.67 4.94 0.23 5 3/3 87.1
















0.2 0.861 0.81 0.06 7 2/3 93.7
0.8 1.461 1.38 0.14 10 3/3 94.6
2 2.661 2.36 0.14 6 2/3 88.7
6 6.661 5.89 0.05 1 2/3 88.5
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4.4 Discussion  
Interest in quantifying peptides and proteins to help elucidate biological processes in 
disease and during therapeutic programs has increased steadily over the past decade. This 
current work was precipitated by the need for a high-throughput and cost effective assay 
that could accurately and reproducibly quantify A peptides in the CSF of human donors. 
Current quantitative assessments of Aβ species in biological fluids have relied heavily on 
immunological methods such as Western blots and ELISA. However, these assays require 
highly specific antibodies and reagents that can result in assays with limited dynamic 
ranges, various matrix interferences and dilution linearity problems[34]. Non-commercial 
immunoassays are especially subject to high intra- and inter-assay variability since they are 
not subject to more stringent manufacturing controls. Combinations of these factors make 
immunoassays more labour intensive and often challenging to validate in support of clinical 
studies. The assay described here utilized an SPE and UPLC-MS/MS workflow.  Recent 
advances in SPE mixed-mode sorbents have facilitated improvements in assay selectivity 
and analyte recovery and this has been helped by the fact that mass spectrometry platforms 
have improved significantly in recent years. Not only does LC-MS give a  higher throughput 
than ELISA based methods, the ability to simultaneously quantify a heterogeneous 
population of A species by mass spectrometry is advantageous because it reduces the 
sample requirements associated with running duplicate ELISA assays, minimizes reagent 
consumption and in this case is more economical. Furthermore, the greater accuracy and 
precision of LC-MS/MS methods relative to affinity-based methods should allow for more 
definitive differentiation of subtle changes between normal and AD populations. 
Immunoprecipitation liquid chromatography mass spectrometry (IP-LC/MS) is another 
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popular enrichment method, which also relies on antibodies[35]. Based on this work, 
antibody enrichment or immunochemical assays are not necessary to accurately quantify 
A1-38, A1-40, and A1-42  in human CSF. 
Selectively lowering or enhancing the clearance of A peptides has emerged as a 
therapeutic strategy for the treatment of Alzheimer’s [36]. The diagnostic power of A 
peptides as well as other Alzheimer’s biomarkers depends on the pre-analytical handling of 
the CSF sample, the assay platform and the test group[37]. Goda et al. describe sample 
pretreatments with acetic acid to minimize non-specific interactions of A peptides with 
surfaces and proteins but their recovery was 80% or less [38, 39]. As Aβ species have a 
propensity for aggregation, poor solubility and also nonspecifically bind to proteins / 
surfaces, the CSF samples were pre-treated with a denaturant and phosphoric acid to 
minimize enzyme activities, non-specific protein interactions as well as to to induce charge 
prior to SPE. Using this methodology the recovery was approximately 90% for the three Aβ 
species investigated. The key to obtaining high recovery was attributed to meticulously 
altering and optimizing the elutropic composition and ion-pair strength of SPE solvents until 
the optimal combination (75% ACN/10% NH4OH) was established, delivering the best 
recovery. Proteins, salts and other endogenous components within CSF typically interfere 
with quantification in both immuno-based and MS-based assays, thus requiring highly 
selective sample preparation. Mixed-mode SPE was chosen for this application primarily 
due to the selectivity benefit derived from dual, orthogonal retention mechanisms on a 
sorbent which has both reversed-phase and ion-exchange properties. While high Aβ 
recovery was achieved, it is not entirely clear if this methodology incorporates only free Aβ 
or total free Aβ; since total free Aβ includes species bound to proteins. As the analyte 
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recovery is high (>90%)  and QC samples are within acceptable coefficients of variation, it 
is believed that the assay is quantifying total and free Aβ, but this was not examined further.  
Recent advancements in mass spectrometry technologies, both in sensitivity and 
capability, have allowed deeper large- biomolecule investigation and facilitated the 
development of more robust LC-MS methodologies for their quantification. While LC-MS 
is an appealing platform for quantifying Aβ peptides, it is not without challenges. Aβ 
peptides have an isoelectric point of ~ 5.2, are large and contain various acidic, neutral and 
basic amino acid residues. Aβ peptides can ionize negatively or positively during 
electrospray and produce multiply charged species. During flow injection optimization with 
standards in negative ion mode, the major observed mass transition from fragmentation of 
Aβ was loss of water. While negative ion mode produces an intense transition ion, it does 
not produce the additional ions needed for assay selectivity when working in complex 
matrices.  In contrast the positive-ion mode electrospray MS fragmentation ions produced 
an abundance of b- and y-ions but overall intensity was lower that negative ion MS. Others 
noted similar observations; positive ion electrospray was selective for A analysis in matrix, 
but collision cell fragmentation resulted in an overall loss of sensitivity due to mass-charge 
issues and fragmentation signal dilution[30, 35, 40].  
Dillen et al. recently reported a negative ion mode assay with similar sensitivity to 
the described method. However, their coefficient of variation for low QC’s was 
approximately 40% using an MS system with limited scanning capabilities[40]. The MS 
platform used in this work allowed the simultaneous detection and quantification of three 
Aβ species and their internal standards without sacrificing accuracy or precision. Dillen et 
al. also described challenges associated with choosing an appropriate surrogate matrix and 
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reported that artificial CSF might not be a good substitute. Matrix interferences and 
recovery problems were also observed in this study when working in artificial CSF, but the 
addition of 5% rat plasma improved detection and reproducibility and increased recovery to 
90% or greater. Reduced SPE recovery in artificial CSF without carrier protein is most 
certainly due to the hydrophobic nature of Aβ peptides and their propensity to stick to 
surfaces especially in aqueous solution. In addition, this work takes advantage of highly 
selective sample preparation based on mixed-mode SPE and the added specificity obtained 
using positive ion MS to enable the use of artificial CSF as a surrogate matrix. A surrogate 
matrix for Aβ quantification is ideal because it is cost effective, more readily available than 
CSF and does not require data manipulation such as standard addition or background 
subtraction for absolute quantification experiments.  
An accumulation of reports put together by Bates et al highlight published Aβ1-42 
peptide concentrations in the CSF healthy and AD human donors[27]. The Aβ1-42 range in 
healthy subjects is reported as 75 - 2000 pg/ml. The large discrepancy in Aβ1-42 
concentrations is also apparent within the AD population (100-2000 pg/ml). When these 
studies are viewed as a whole, it does not appear that control Aβ1-42 is significantly different 
than AD groups since the reported range of Aβ1-42 levels are so vast in CSF. However 
within a test group of control vs. AD patients, Aβ1-42 is significantly different[41, 42]. Since 
published concentrations of Aβ1-42 and other Aβ peptide species are routinely analyzed or 
enriched by immuno-assays, reported Aβ concentrations are subject to assays with high 
coefficient of variation leading to misrepresentation of Aβ levels. In the LC-MS based 
experiments described herein, relative Aβ peptide levels trended similarly between pooled 
CSF lots, but significant differences in Aβ peptide levels between CSF lots were observed. 
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This observation is interesting because it shows high heterogeneity in pooled CSF lots, 
similar to that reported by other groups. However, one might expect less Aβ variability 
between population groups using this described method as it has a tight coefficient of 
variation (< 15%) that cannot be duplicated with ELISA which can be 25% or greater.      
Although this work pertains to quantification of Aβ1-38, Aβ1-40, and Aβ1-42 in human CSF, a 
similar approach could be used for smaller human Aβ peptides or nonhuman primate[43]. 
Rat Aβ could also be measured but masses and fragmentation patterns will need 
consideration[44].  
More recently, efforts have focused on extending application of this work to take 
advantage of a more sensitive MS platform to improve detection limits and reduce required 
sample size. By replacing the original MS platform (Xevo TQ MS) with a more sensitive 
“next generation model” (Xevo TQ-S) triple quadrupole mass spectrometer the preliminary 
data showed a 5-fold improvement in detection limits using four-times less sample (50 µl 
instead of 200 µl.) Using 50 µl aliquots, QC samples were successfully quantified down to 
40 pg/mL, with CVs less than 5%. A summary of QC and standard curve statistics using 50 
µl of sample and the newer MS system are compiled in Tables 4.3 and 4.4. 
 
 
Table 4.3 Average QC values for Aβ peptides extracted from 50 µL human plasma (N=3 in each of two pooled 















Amyloid β 1-38 Human 
CSF 1 and 2 2.3 5.8 -3.2 7.3 14.8 5.1 13.1
Amyloid β 1-40 Human 
CSF 1 and 2 -0.8 -3.2 -1.9 2.5 -2.6 -4.2 -3.8
Amyloid β 1-42 Human 





Table 4.4 Representative standard curve statistics for Aβ 1-42 from 50 to 10,000 pg/mL extracted from 50 µL 
artificial CSF 
 
4.5 Additional Investigations in Support of Candidate Reference Method Development 
and Progression 
As described in the introduction to this chapter, since the completion and initial 
publication of this work in 2011, a collabouration between the Alzheimer’s Association 
(AA) and the Global Biomarker Standardization Committee (GBSC) was created in order to 
develop and progress a candidate reference method for quantification of Aβ 1-42 using 
LC/MS. The assay developed here was employed to participate in both a round robin and a 
ring trial study, towards that end. Four labs were expected to partake in the initial round 
robin study. The aim of which was to have each lab quantify unknowns using their 
respective versions of the method put forth in this research.The results of this round robin 
have been submitted as a short communication to the Journal of Alzheimer’s and Dementia. 
Although all labs employed the extraction scheme described in this chapter and largely the 
LC and MS conditions, there were some slight variations amongst the labs, primarily the 
nature of the surrogate matrix and the use of 1D versus 2D chromatography. This led to a 
separate study in our labs aimed at comparing the assay variables and summarizing the 
Name Type Std. Conc RT Area IS Area Response Conc. %Dev
blank artificial CSF 5.73 19.7 7.0
50 pg/mL artificial CSF Standard 0.05 5.71 230.4 3620.5 0.06 0.06 14
100 pg/mL artificial CSF Standard 0.1 5.71 390.8 3585.1 0.11 0.11 8.1
250 pg/mL artificial CSF Standard 0.25 5.71 778.3 3737.3 0.21 0.22 -12
350 pg/mL artificial CSF Standard 0.35 5.71 1267.3 3693.8 0.34 0.37 6.2
500 pg/mL artificial CSF Standard 0.5 5.71 1494.7 3566.8 0.42 0.46 -8.5
750 pg/mL artificial CSF Standard 0.75 5.71 2733.5 4152.0 0.66 0.73 -3.1
1 ng/mL artificial CSF Standard 1 5.71 3166.8 3792.5 0.84 0.93 -7.4
5 ng/mL artificial CSF Standard 5 5.72 14773.9 3148.3 4.69 5.27 5.4
7.5 ng/mL artificial CSF Standard 7.5 5.72 24576.9 3877.0 6.34 7.12 -5
10 ng/mL artificial CSF Standard 10 5.72 33343.3 3662.5 9.10 10.24 2.4
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results. This allows the evaluation of the intra-lab variability of these differences relative to 
the inter-lab variability of the same.  
To investigate the influence of surrogate matrix, three different surrogates will be 
compared to standard addition using human CSF. The three surrogates are as follows: 
artificial CSF + 5% rat plasma by volume, (the original surrogate, deemed matrix 1), 
artificial CSF + 4 mg/mL BSA (roughly equivalent protein content in a 5% by volume 
plasma solution, deemed matrix 2) and a homemade artificial CSF salt solution (containing 
NaCl, KCl, CaCl2, MgCl2, Na2HPO4, and NaH2PO4) containing 4 mg/mL human serum 
albumin, 0.05 mg/mL IgG, and 0.8 mg/mL glucose (deemed matrix 3). The latter matrix 
attempts to mimic human CSF with the addition of appropriate proteins and sugar. Human 
CSF will be referred to as matrix 4. Standard curves were prepared in each of the four 
matrices as detailed in the experimental section of this chapter, and used to quantify basal 
levels of the three Aβ peptides in normal, non-diseased pooled human CSF. In addition, 
quantification using the four matrices was carried out on two LC/MS platforms: the standard 
1D platform described in the experimental section and a multidimensional platform 
(referred to as “2D”) which includes at-column-dilution (ACD) and a trap and back elute 
component. ACD enables the injection of a larger volume than our initial work. Trapping of 
the peptides is achieved with a 2.1 X 20mm XBridge C18 column. As this trapping 
configuration does not provide orthogonality, but simply re-focusing capability, significant 
additional clean-up is not expected, though a modest degree may occur. (A more detailed 
description and schematics of the analytical configuration can be found in Chapter 5 where 
this platform provides significant benefits to the quantification of intact insulins in human 
plasma). A summary of the results from this investigation is presented in Table 4.5. A 
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representative chromatogram of a 50 pg/mL sample analyzed on an LC/MS system 
equipped with either a 1D or 2D ACQUITY UPLC is shown in Figure 4.15. 
 
 
Table 4.5 Summary of basal Aβ 1-42 levels in human CSF, as determined from standard curves prepared in four 
different matrices (three surrogates compared to human CSF) and analyzed on LC/MS platforms utilizing 
either a 1D or a 2D LC system 
 
Baseline Concentrations (ng/mL) of Abeta 1-42
in Normal Pooled Human CSF (BioChemed)
2D 1D Matrix 1  Matrix 2 Matrix 3 Matrix 4
% CV 4.5 4.0 5.8 5.4 5.0 6.3
%CV by Variable
2D 2D 2D 2D 1D 1D 1D 1D
Matrix 1 Matrix 2 Matrix 3 Matrix 4 Matrix 1 Matrix 2 Matrix 3 Matrix 4
Analyst 1 0.42 0.41 0.45 0.41 0.45 0.43 0.47 0.47
0.39 0.38 0.41 0.40 0.45 0.43 0.47 0.43
Analyst 2 0.40 0.39 0.43 0.39 0.43 0.42 0.45 0.41






   
Figure 4.15 Comparison of 50 pg/mL Aβ peptides separated using either a 1D or 2D ACQUITY UPLC 
system; 30 µL of sample are injected in the 2D system and 15 µL on the 1D system 
 
The data clearly validate the use of any one of the three possible surrogate matrices 
or standard addition using human CSF for quantification of Aβ 1-42, on either a 1D or 2D LC 
platform. The overall CV of the measurements, incorporating all variables, is only 6%, 
indicating that highly precise and consistent measurement is achieved regardless of standard 
curve matrix or analytical platform. The precision within the measurements, by independent 
variable, is also excellent, averaging 4-6%. The primary benefit of the multi-dimensional 
LC system is to enable the injection of larger volumes of extract without breakthrough. The 
final injection solvent for amyloid peptides, using the extraction scheme outlined in the 
experimental section, contains approximately 37.5% organic and 5% ammonium hydroxide. 
During initial method development, it was discovered that it was not possible to inject more 
than10-15 µL of extract without substantial breakthrough on the standard 1D configuration. 
50pg/mL PPD
Time





























Use of ACD and subsequent focusing on the trap column facilitated injections of  >45 µL, 
resulting in significant sensitivity improvements. This cursory examination of the benefits 
of multi-dimensional chromatography warrant a more thorough study of  its value in peptide 
quantification and  therefore are examined in greater detail in the subsequent chapter of this 
thesis.    
 
4.6 Conclusions 
 In spite of the acknowledged obstacles to high sensitivity, the highly selective 
measurement of Aβ peptides was achieved using LC-MS without affinity-based 
purification. 
The methodology described above allowed the simultaneous quantification of 
multiple Aβ species in CSF. This LC-MS/MS assay approaches the sensitivity of ELISA or 
IP LC-MS/MS methods, but is higher throughput and more cost effective. Quantification of 
multiple Aβ species in pooled CSF from a heterogeneous control population was possible 
with this method using mixed-mode solid-phase extraction, sub-2 micron particle column 
technology and positive ion MRM to achieve an accurate, precise and quantitative assay that 
can be validated to support studies in large cohorts of clinical samples. As new strategies 
emerge for AD treatment, accurate and reproducible quantification of known and unknown 
Aβ species will play a crucial role in understanding amyloid disease progression and 
intervention. The method described herein shows promise for adaptation to quantify 
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This chapter will be presented in two sections. The first establishes proof of concept for 
direct quantification of four intact insulins in human plasma. This section describes the 
fundamental research endeavours aimed at overcoming the challenges of working with large 
peptides such as insulin and proposes a starting point methodology. The second section 
builds on the proof of concept work by incorporating multidimensional LC and more 
specific sample preparation to extend the number of insulins in the assay and to improve 
assay sensitivity and specificity. The second section also presents results from a blind study 
of 22 diabetic patients on combination therapies and a unique insulin overdose case, thereby 




Section I:  Initial Proof of Concept Investigation 
5.1 Introduction 
Over recent years the proportion of new drug entities (NDEs) being developed has 
seen increased interest in large biomolecules such as proteins and peptides.  Of these 
biopharmaceuticals, insulin is one of the oldest and perhaps best known, and to this day, 
remains one of the primary treatments for diabetes [1, 2]. In addition to recombinant human 
insulin, a number of closely-related analogs with improved pharmacokinetics have been 
developed, resulting in several long, fast, and intermediate acting versions.  Insulin glargine 
and insulin detemir are two popular long-acting analogs, effectively stabilizing blood 
glucose for 24 and 16 hours, respectively [3]. Glargine is homologous to insulin except for 
the substitution of glycine for asparagine at position 21 of the A-chain and the addition of 
two arginines to the C-terminus of the B-chain. Structures and sequences of insulins are 




Figure 5.1 Amino acid sequences and structures for human insulin and five analogs 
 
These changes shift the isoelectric point (pI) from 5.4 (pI of endogenous insulin) to 
approximately 6.7. This results in reduced solubility at physiological pH which causes 
formation of a microprecipitate when the acidic solution is injected. It is the slow release of 
the drug from this precipitate that elongates the half-life of glargine. It is believed that these 
sequence changes also increase the natural propensity of insulin to form hexamers, which 
further prolongs bioavailability. Detemir is modified through acetylation and addition of a 
fatty acid chain to lysine 29 on the B-chain. In addition to increased hexamer formation, 
detemir rapidly binds to human albumin, slowing its release into the bloodstream.  Insulin 
glulisine and insulin aspart are two widely prescribed fast acting analogs. The sequence 































reduced hexamer formation, which yields bioavailability within approximately 10-15 
minutes [4].  
As control of both short-term, meal-time and long-term basal levels of blood glucose 
are critical, many diabetic patients are prescribed a combination of these analogs for the 
maintenance of near-normal glycemic profiles.   
To date, most biological measurement of insulins has been carried out using ligand-
binding assays (LBAs). For example, in 2007, there were at least 12 different commercial 
assays for human insulin[5], including radio-immunoassays (RIAs) and enzyme-linked 
immunosorbent assays (ELISAs). The short comings of LBAs in general are exemplified in 
human insulin assays and are well documented[5-10]. Of these, perhaps one of the greatest 
challenges for accurate quantification of insulins and analogs using LBAs is cross-
reactivity. Performance of LBAs, in particular the degree of cross-reactivity between and 
amongst analogs as well as with endogenous insulin, is entirely dependent on the choice of 
specific monoclonal antibody that comprises the commercial reagent. Numerous papers 
exist detailing the different cross-reactivities of “commercially available” insulin kits with 
analogs [5-10]. It is not uncommon to observe 50-100% cross-reactivity of most of the kits 
with one or more analogs. It has also been shown that the degree of cross-reactivity can be 
concentration dependent[7]. Furthermore, there appears to be high variability between 
commercial assays. Manley et al reported that when different assays were used to quantify 
the same samples, results differed by as much as 2-fold [7].  
Since patients will often take a combination of these analogs to stabilize blood 
glucose, it is important to have an analytical methodology capable of simultaneously 
differentiating and quantifying the various analogs. When trying to determine 
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pharmacokinetic parameters for a discrete insulin analog by LBA, it can be near impossible 
to quantify the absorption endpoint due to basal levels of other analogs present, which react 
equally with the assay. Use of multiple assays has been described [4] to obtain 
concentrations for individual analogs, using subtraction or multiplication factors based on 
known cross-reactivity. 
Interest in insulin analog quantification extends beyond diabetes treatment and 
monitoring. Due to the suspected performance enhancing properties of insulin, the use of 
insulins in non-diabetic athletes has been prohibited by both the International Olympic 
Committee (IOC) and the World Anti-Doping agency (WADA)[11]. There is therefore a 
need to be able to screen for and unambiguously identify any of the insulin analogs possibly 
used in sports doping. Methods which quantify and differentiate amongst the analogs are 
also needed in the identification of the specific insulin responsible for wrongful death cases 
or in the study of hypoglycemia. Finally, patent protection for many of the current 
formulations will expire by 2017 (Figure 1.1). As such, the development of bioequivalence 
methods for these compounds is already actively in progress. These methods need to be very 
accurate and precise to meet regulatory requirements; they should also be capable of facile 
implementation in conventional bioanalysis labouratories. 
Coinciding with the increased development of biologically based therapies, there has 
been an increase in the use of LC-MS/MS for quantification of biopharmaceuticals. LC-
MS/MS has been the technique of choice for small molecule quantification for many years, 
and as such, is the platform that dominates most discovery-stage, pre-clinical and clinical 
bioanalytical labouratories[12, 13]. It now shows promise in overcoming the shortcomings 
of LBAs for large molecule quantification in biofluids. As previously discussed, in contrast 
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to LBAs, LC-MS/MS assays offer a higher degree of accuracy and precision, high 
specificity, the ability to multiplex, broader linear dynamic range, fast development times 
and freedom from reagent reproducibility and reliability issues. LC-MS based approaches 
are not without their challenges. Chapters 1 and 2 have outlined these challenges, examined 
them in detail and proposed solutions where possible. 
To date a few LC-MS methods exist for the quantification of insulin and its 
analogs[11, 14-24]. Many methods employ a multi-step affinity purification and/or 
multidimensional or nano-flow chromatography to achieve adequate specificity and 
sensitivity. Though most methods quantify the intact insulin, some require reduction of 
disulfide bonds in order to release the A and B chains[25]. In the latter case, the B chain was 
used to represent the intact molecule.  The most sensitive of these methods was developed 
for urine sample analysis and employed a sample prep process taking several hours and 
involving a 4-step SPE isolation followed by an 8-step immunoaffinity chromatography 
(IAC) method, and finally an additional 4-step SPE clean up prior to LC/MS analysis[11]. 
The subsequent overall analytical run time was 40 minutes. A similar three- stage, multi-
step sample prep method was also described for insulin quantification in serum[17]. In this 
methodology up to 4 mL of serum was required, and the analytical run time was 15 minutes. 
Additional serum methods have been developed using nano-flow or 2D LC. Here the 
sample volume required was up to 1 mL  (serum) and run times ranged from 10 to 40 
minutes[23, 25]. A very sophisticated approach for quantifying human insulin uses 3D 
nano-LC, an overnight immunoprecipitation (IP) extraction, and in-house prepared anti-




A common requirement with methods that employ some form of sample preparation 
is evaporation and reconstitution of the extracted sample prior to LC-MS analysis. This 
increases the analyte concentration and allows the injection solvent to be optimized. For 
many peptides, this evaporation step is associated with significant adsorptive losses. In 
addition, the minimum run time recorded is 10 minutes and the average sample prep time is 
several hours to overnight. These characteristics are not suited for the routine bioanalytical 
labouratory where it is typical to process several hundred samples each day and to require 
that the data be available by start of business the following day.  
Section I of this chapter describes the efforts to develop a simple LC-MS method 
utilizing 250 µL of plasma for the simultaneous differentiation and rapid quantification of 4 
synthetic insulin analogs. In addition, the sample prep described herein requires 
significantly less sample than previously published methods and can be accomplished in 
under 30 minutes for a 96-well plate, an average of 6-10 times faster than current methods 
achieving detection limits in the hundreds of pg/mL range. The reduction in sample prep 
time is achieved through a combination of eliminating evaporation and significantly 
reducing the complexity and number of steps required for the sample clean-up. Finally, the 
method employs conventional analytical flow LC and triple quadrupole MS, a common 
comfortable platform for the vast majority of bioanalytical scientists. This has the 
advantages of much shorter run times, greater system robustness, and is more readily 




5.2 Experimental  
5.2.1 Chemicals and Reagents  
Lantus® (insulin glargine) and Apidra® (insulin glulisine), both manufactured by 
Sanofi-Aventis, were used as formulated. Levemir® (insulin detemir) and NovoLog™ 
(insulin aspart), both manufactured by Novo Nordisk, were also used as formulated. 
Normal, non-diseased human plasma was purchased from Lampire Biological Labs, 
Pipersville, PA. Rat plasma was purchased from Equitech Bio, Kerrville, TX. Water for 
mobile phase and sample preparation was obtained from a Milli-Q lab water system, 
(Millipore, Billerica, MA). Acetonitrile, methanol, and formic acid (concentrated solution, 
99%) were purchased from Fisher Scientific (Fair Lawn, NJ). All other chemicals and 
reagents were purchased from Sigma (St. Louis, MO) unless otherwise stated.  
5.2.2 Preparation of samples, calibration standards and quality control samples 
The concentration of the insulin analog in each formulation was first converted from 
IU/mL into mg/mL in order to facilitate dilution calculations. For all formulations, 
respective insulin analogs are present at 100 IU/mL. For Lantus, Apidra, and NovoLog, 100 
IU is equal to 3.638, 3.49, and 3.5 mg insulin glargine, insulin glulisine, and insulin aspart,  
respectively, per mL. (These values were taken from product inserts). For Levemir, 100 U 
insulin detemir is equivalent to 14.2 mg. This value was obtained from the European 





A diluent consisting of 30/10/60 MeOH/CH3COOH/H2O plus 0.05% rat plasma was 
prepared. The various insulin formulations were diluted serially in the above diluent and 
then combined to generate a working solution containing the four analogs, each at a 
concentration of 1 µg/mL. Separate working solutions were produced for preparation of 
quality control samples and standards. Bovine insulin was used as the internal standard (IS) 
and was prepared in the above diluent at a concentration of 500 ng/mL to be used for 
spiking. For standard curve and quality control (QC) samples, spiking solutions of pooled 
insulin analogs were made through serial dilution of the 1 µg/mL stock. For each intended 
standard curve point and each QC level, 1 mL of control human plasma was spiked with an 
appropriate volume of the appropriate concentration of analyte spiking solution (combined 
insulin solutions), and 20 µL of 500 ng/mL IS spiking solution. Standard curve points were 
prepared at 0.2, 0.5, 1, 5, 10, and 25 ng/mL in human plasma. Quality control samples were 
prepared in human plasma at 0.35, 0.75, 2, 8, and 20 ng/mL. Blank human plasma samples 
were also extracted for determination of limit of detection (LOD). A 250 μL aliquot of each 
sample was diluted with 250 μL of 10 mM TRIS base and vortex mixed. The resultant 500 
µL sample was extracted by SPE. 
5.2.3 Solid-phase extraction conditions  
Samples were extracted using an Oasis® HLB μElution plate (Waters Corp., Milford, 
MA). The plate was conditioned with 200 μL of methanol followed by 200 μL of water. The 
500 μL pre-treated standard curve, blank, and quality control samples were loaded onto the 
SPE plate and washed with 200 μL of 1% acetic acid in 5% methanol in water. Insulin 
analogs were eluted with two separate  25 μL aliquots (collected together) of 10% acetic 
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acid in 60% methanol. The eluates were then diluted with 50 µL water and placed in the 
autosampler for analysis. 
5.2.4 Chromatographic Conditions  
A 20 μL aliquot of the diluted SPE eluate was injected onto an ACQUITY UPLC 
CSH C18 column (2.1 x 50 mm, 1.7 µm) using a Waters ACQUITY I-Class UPLC system 
equipped with a flow-through needle (FTN) autosampler. Samples were kept cooled at 10°C 
and the column temperature was maintained at 60°C. Mobile phase A consisted of 0.1% 
formic acid (by volume) in water and mobile phase B consisted of 0.1% formic acid (by 
volume) in acetonitrile. Insulin analogs were eluted using a linear gradient from 20% B to 
65% B over 2 min at 0.25 mL/min, which was directly introduced into the MS, without 
splitting. Mobile phase B was then ramped from 65 to 98% over 0.1 min and held for 0.5 
min to clean the column. This was followed by an equilibration at initial conditions. Total 
cycle time was 3.5 minutes. 
5.2.5  Mass spectrometry and Software 
For each peptide and the IS, collision induced dissociation (CID) products of 
multiply charged precursors were detected in positive ion multiple reaction monitoring 
(MRM) mode using a Waters Xevo™ TQ-S mass spectrometer (Milford, MA). The 
electrospray voltage, source temperature,  desolvation temperature and desolvation gas flow 
rate were 3.0 kV, 150 °C, 500 °C and 1000 L/Hr respectively. MRM transitions and charge 
states for each peptide and the IS as well as their respective cone voltages and collision 
energies are summarized in Table 5.1. MassLynx instrument control software was used for 
data acquisition. All peak area integration, regression analysis and sample quantification 
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was performed using TargetLynx. Peak area ratios (PARs) of the insulin analogs and the 
bovine insulin internal standard were determined and calibration curves generated for each 
of the analogs. Insulin analog concentrations in QC samples were determined from their 
PARs against their respective calibration lines. 
 
 
Table 5.1 MS conditions for human insulin, 5 analogs, and the internal standard bovine insulin; highlighted 
transitions correspond to the primary quantitative transition, other transitions are confirmatory 
 
5.3 Results and Discussion 
5.3.1 Development of sample pre-treatment and solid-phase extraction  
Obtaining adequate specificity and recovery for insulin analogs in human plasma 
matrix is not a trivial task. As with all peptides, insulins are zwitterionic and their behaviour 
is difficult to predict. They also need to be separated from thousands of other, potentially 
isobaric, peptides found in a sample. Experimentation during development of this method 





Glargine 1011->1179 60 25
867->984 60 18
Lispro 1162-> 217 50 40
968.5->217 50 40
Detemir 1184-> 454.4 60 20
1184-> 1366.3 60 20
Aspart 971.8 -> 660.8 60 18
971.8 -> 1139.4 12 18
Glulisine 1165 -> 1370 14 22
1165 -> 346.2 14 22
Bovine (IS) 956.6 -> 1121.2 60 18




found that many of the recovery and poor reproducibility issues encountered with insulins 
are related to non-specific binding (NSB), protein binding, and solubility. Careful and 
systematic evaluation of various pretreatment options as well as wash and elution 
compositions was critical to the overall specificity and high recovery of the method. In all 
cases described herein, extraction efficiency was determined by comparing average peak 
areas from a 1 or 10 ng/mL mixture of peptides in matrix after the described extraction 
procedure to average area counts from blank SPE extracted matrix which was then spiked 
post-extraction at 1 or 10 ng/ml.  Initial extraction studies were performed with insulin 
glargine only. Other analogs were added once preliminary method development was 
complete.  An experiment comparing reversed-phase SPE to protein precipitation (PPT) 
methods confirmed that the endogenous background from samples extracted with simple 
precipitation was too high to allow quantification in the sub-ng/mL range. This is not 
surprising as it is identical to the findings during teriparatide method development described 
in Chapter 3.  In order to concentrate the samples without evaporation, a step that often 
leads to adsorptive losses for peptides, method development was performed in 96-well 
µElution plates as discussed in Chapter 2. These plates are characterized by high loading 
capacity and low elution volumes, facilitating as much as a fifteen-fold concentration 
without dry-down.  To simplify interpretation of retention behaviour, a polymeric reversed-
phase only SPE (Oasis HLB) was evaluated, rather than mixed-mode sorbents, using the 
generic SPE screening protocol described in Chapter 2, which had been developed 
specifically for peptides.  It was necessary to make minor changes to the generic protocol 
based on knowledge of insulin properties. These included diluting the sample with TFA (to 
improve solubility) and reducing the organic content of the elution solvent from 75% 
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acetonitrile  (+ 1% TFA) to 50% acetonitrile (+1% TFA). The latter change was made based 
on the fact that the insulins elute with <50% acetonitrile from the LC column. Large 
peptides such as insulin precipitate at lower concentrations of organic than smaller peptides 
do (Chapter 2), as such, the reduction and change in organic concentration was intended to 
reduce the likelihood of precipitation as well. This basic method yielded a reasonable 
insulin glargine recovery of 70%, however specificity was poor. In an attempt to improve 
specificity, similar methodologies were tested on mixed-mode anion and cation exchange 
sorbents, resulting in equal or lower recovery and little benefit to specificity. At this stage, 
in order to minimize uncontrolled variables potentially contributed by unexpected 
interactions with mixed-mode sorbents, further development proceeded with the reversed-
phase sorbent only and focused on optimization of the pre-treatment and wash solutions to 
reduce interferences while improving and maximizing recovery.  Plasma pre-treatment was 
optimized first in order to eliminate protein-binding, adjust pH, and selectively retain 
insulins relative to undesired plasma components. Various acidic pre-treatments were 
assessed including TFA, H3PO4, FA and precipitation with HCl or TCA. There was no 
improvement in specificity using any of these pre-treatments, and of these options, the TFA 
dilution still provided the best recovery. In order to change the retention characteristics of 
the insulins, the samples were diluted with 10 mM TRIS base at approximately pH 9- 9.5.  
Not only did recovery improve significantly (insulin glargine recovery was >95%) but the 
endogenous background was reduced. The combination of reduced background and 
increased recovery resulted in a 50% increase in signal. Chromatograms from the final 
eluates from samples pretreated with TFA (Figure 5.2B, top panel) contained a broad, 
intense interference peak at 5.76 minutes that was absent in the eluates from samples 
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pretreated with TRIS (Figure 5.2A, top panel). These samples were further analyzed using 
full scan MS to elucidate the nature of the peak. Spectra were summed from 5.5 to 6.25 
minutes samples from both pre-treatments, and the resultant data are shown in the bottom 
panels of Figures 5.2A and 5.2B. Deconvolution of the protein envelope in the samples pre-
treated with TFA produced an intact MW of approximately 66,400, providing putative 
identification as human serum albumin (HSA). HSA is typically present at approximately 
35-50 mg/mL and must be efficiently removed and separated from the insulin analytes. Pre-
treatment with TRIS efficiently achieved this goal, as evidenced by the absence of the large 
protein peak at 5.76 minutes.  
 
Figure 5.2 LC chromatograms of final SPE eluates resulting from plasma samples initially pretreated with 
TRIS (panel A, top) or TFA (panel B, top) prior to SPE; bottom panels are summed spectra from 5.5 to 6.25 
minutes 
 
The experiments in Chapter 2 highlight the importance of screening of various 
injection solvents. This is particularly important for peptide compounds as it may provide 
valuable information pertaining to solubility, which can heavily influence carryover, 
linearity, sensitivity and peak shape. The information resulting from this investigation 
showed that the combination of methanol and acetic acid produced the sharpest and most 
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intense chromatographic peaks for insulin analogs. The composition of the final SPE elution 
solvent was derived from these results. Specifically, the final elution solvent was changed to 
methanol and acetic acid, resulting in an additional 50% increase in signal for insulin 
glargine relative to that seen using the original TFA/ACN based elution solvent. The 
proportion of methanol (60%) was derived from the chromatographic elution profile for 
glargine plus an additional 10% to ensure adequate recovery off of the SPE sorbent, which 
was believed to be more retentive than the chromatographic column. The final acetic acid 
content (10%) was optimized. Lower percentages yielded lower recovery for some of the 
insulin analogs. It is possible that the high concentration of acetic acid required is related to 
modifier strength. Just as formic acid is a weaker modifier than TFA (and thus higher 
concentrations are typically required), acetic acid is a weaker modifier than formic acid, 
requiring even higher concentrations to disrupt secondary interactions with the sorbent and 
improve recovery. An additional theory is that insulin solubility is also improved by 
increasing acetic acid content in the elution solvent. Tuning solutions prepared with 
identical organic content and different modifiers (formic versus acetic acid) were compared 
in terms of peak response, and the acetic acid modified solution yielded a two-fold increase 
in the area of the solution compared to that obtained with formic acid. One possible 
explanation is that the acetic acid somehow improves solubility for insulin relative to formic 
acid or that ionization efficiency is improved under acetic acid conditions. 
Using the method described in the experimental section, final absolute recoveries of 
glargine, detemir, glulisine, aspart and bovine insulin (the internal standard) from human 
plasma were 84, 62, 87, 83, and 94%, respectively.  Although absolute recovery for glargine 
was ~10% higher using ACN and TFA in the  SPE elution solvent, area counts were ~50% 
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lower than when acetic acid and methanol were used to elute the analytes. This is possibly 
due to improved selectivity of the acetic acid/methanol based elution solvent, resulting in a 
reduction in co-eluting interferences, ultimately yielding higher area counts even if the 
absolute recovery was lower. The lowest recovery was obtained for insulin detemir, which 
elutes significantly later chromatographically than the other analogs. This suggests that a 
higher organic composition in the final SPE eluate might increase detemir recovery. 
Increasing the organic content might also elute more interferences, however. To evaluate 
this theory, various extraction conditions were tested. The organic solvent content of the 
SPE eluent was changed from 60% to 80% methanol; the same was tried using isopropanol 
or acetonitrile. These failed to increase recovery for detemir. The additional organic content 
merely served to elute an additional, closely related isobaric interference from the SPE bed, 
which was evident in the subsequent LC/MS analysis and MRM data for detemir. 
Consequently, the methanol composition was maintained at 60%. 
Larger format SPE plates were also evaluated with larger sample volumes. The 
necessity to evaporate and reconstitute eluates from these larger plates resulted in insulin 
losses of up 50%, presumably due to NSB to the collection plates during dry down. This 
phenomenon was studied extensively by Pezeshki et al, where they found up to 40% loss 
during dry down for a variety of peptides under different conditions[26]. A second 
experiment was attempted wherein 20 µL of DMSO was added to the eluate prior to 
evaporation to keep the sample from going to complete dryness. Peptide losses were still 
evident and the chromatographic peak shape deteriorated due to the presence of DMSO, 
rendering this an unattractive option. These experiments confirmed the value of the µ-plates 
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to simultaneously extract and concentrate the samples without evaporation and 
reconstitution. 
5.3.2 Mass Spectrometry of Insulin Analogs 
Peptides such as the insulin analogs, which are not only large (>4000Da), but also 
stabilized by multiple disulfide bridges, can make it particularly difficult to optimize the MS 
detection conditions using the traditional small molecule approaches. The determination of 
optimal MS parameters for these compounds highlights several major differences between 
peptide and small molecule tuning processes.  Though it is best practice to tee the analyte 
stream into the LC effluent for MS optimization, this may not always be carried out, for a 
variety of reasons. For small molecule tuning, neither the actual flow rate at which tuning 
occurs nor the % of the acidic modifier in the solvent (typically) impacts the observed 
precursor m/z. One usually expects M+1, M-1, or adducts from solvents or cations. 
However, for peptides, both flow rate and organic/modifier composition dramatically 
influence not only the specific multiply charged precursors formed, but also their relative 
abundances. Data obtained from experiments conducted during this study, highlighted 
differences between a simple infusion of human insulin at 10 µL/min and teeing into the 
mobile phase at 200 µL/min (Figure 5.3). The most abundant and highest intensity precursor 
ion (a common choice for obtaining optimal assay sensitivity), is distinctly different 
depending on the tuning condition. For example, at 10 µL/min, the highest intensity 
precursor is the 4+ precursor at m/z 1452, while the 5+ precursor at m/z 1162 is most 
intense at 200 µL/min. Interestingly, this phenomenon is not observed for all peptides, 
making it difficult to explain. A theory was proposed in Chapter 2 relating to dilution within 
the droplet. An additional theory is that initial droplet size at nano/micro flow is smaller 
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than at analytical flow, reducing the surface available for charge residence, thus reducing 
the number of charges present/accessible to the peptides within the droplet.   
 
 
Figure 5.3 MS spectra for human insulin at either 200 µL/min (top) or 10 µL/min (bottom) 
 
While one typically relies on a single precursor to generate fragments for small 
molecule analyses, there are advantages to selecting multiple precursors to attempt 
fragmentation of a peptide analyte. Not only do the various charge states fragment 
differently, but it can also be difficult to predict the specificity of a particular MRM when 
the sample is derived from a biological matrix. Furthermore, there exists some question as 
to whether or not the relative abundance of the various charge states changes during analysis 
and with concentration (this phenomenon was seen by Darby et al[14]), driving the 
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recommendation (Chapter 2) to monitor and possibly sum MRMs arising from distinct 
precursors. An MS spectrum for each of the analogs is displayed in Figure 5.4. Each analog 
yields a unique selection and pattern of precursors, despite their closely related nature. For 
each analog, the two or three most abundant precursors were chosen for fragmentation.  
 
 
Figure 5.4 MS spectra for insulin aspart (A), detemir (B), glulisine (C) and glargine (D) 
 
Collision induced dissociation (CID) of the chosen precursors was performed over 
the range of m/z 100-1800. Both the 6+ and 7+ insulin glargine precursors yielded multiple 
possible fragments, whereas only the 6+ charge state of insulin aspart and the 5+ of glulisine 
and detemir resulted in fragment ions with sufficient intensity for meaningful quantification. 
Representative MSMS spectra for each insulin analog, at its optimum collision energy, is 
shown in Figure 5.5. Fragments chosen for quantification are highlighted with an asterisk.  
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Figure 5.5 Representative MSMS spectra for insulin analogs 
 
Under nominal mass MS resolution conditions, there is overlap between the isotope 
patterns of the 5+ and 6+ multiply charged precursors of aspart and glulisine (see Figure 
5.4). This was previously reported by Thomas et al[27], and may lead to a lack of specificity 
if unique fragments are not chosen. These same precursors also overlap with human insulin. 
However, certain fragments arising from human insulin (at m/z 561, 653, and 226) were 
determined to be unique. At higher collision energies, each of the insulin analogs readily 
produces immonium ion fragments which exhibit high intensities.  Most yield an intense 
peak m/z 136, for example, corresponding to a tyrosine immonium ion. These spectra are 
simpler than the MSMS spectra for the insulins at their optimal, lower collision energies. 
The higher energy spectra are dominated by a single intense fragment at m/z 136 (Figure 
5.6, bottom), rather than several low intensity fragments (Figure 5.6, top). Though it is 
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Figure 5.6 MSMS of the 7+ insulin glargine precursor using a collision energy of 18 eV (top) or 35 eV 
(bottom) 
 
Due to the nominal mass resolution limitations of triple quadrupole instruments, the 
high concentration of other peptides in the sample (possibly closely related), and the high 
chemical background associated with low m/z fragments, specificity in the endogenous 
matrix was the critical deciding factor. The chromatograms for insulin glargine in Figure 5.7 
demonstrate the dramatic difference in specificity obtained from a transition based on a 
lower intensity b or y ion fragment such as m/z 984, versus the higher intensity immonium 
fragment at m/z 136 seen in Figure 5.6. The mass spectrometer used in this work had a mass 
range of 50 - 2048 amu on both quadrupoles, facilitating improved sensitivity at higher mass 
ranges, which enabled the use of fragments such as the m/z 984 for glargine and m/z 1370 
Collision Energy = 18 eV
Collision Energy = 35 eV
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for glulisine in quantification. The observed specificity benefit derived from these larger 
fragments was central to reducing the overall demand on the sample preparation. In this 
application, it has contributed substantially to the use of a significantly simpler and faster 
sample prep scheme than previously published methods. In summary, it is recommended 
that one always choose the highest m/z precursor and/or product ions possible and that 
immonium and other low m/z ions be avoided.  
 
 
Figure 5.7 Specificity difference for insulin glargine extracted from human plasma observed when monitoring 
an immonium ion fragment (top) versus the more specific sequence ion at m/z 984 (bottom); inset shows a 
typical immonium ion structure 
 
5.3.3 Liquid Chromatography 
The value of  wide (300 Å) pore size LC columns for the separation of peptides has 
been documented previously[28, 29] and was demonstrated in Chapter 2. These columns 
produced significantly narrower analyte peak widths, particularly for large peptides. The 
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data presented in Chapter 2 established that transitioning from columns packed with the 
typical 3.5 µm particles to the newer <2 µm particle columns extends the flow rate range for 
optimal chromatographic performance for larger peptides into the desired bioanalytical 
range of several hundred µL/min, due to improved efficiency resulting in a broader optimal 
linear velocity operating range.. Therefore, the initial test conditions for the insulin analysis 
consisted of LC method development with a C18, 1.7µm, 300 Å column. Unexpectedly, and 
specifically for insulin and its analogs, this column produced peaks characterized by severe 
tailing and widths of approximately 6-8 seconds wide at base. One of the major sources of 
tailing for peptides is thought to be interaction of the analyte with the stationary phase 
surface. A recently introduced column chemistry, the Charged Surface Hybrid (CSH) 
column (described in Chapter 2), claims improved peak shape under formic acid conditions, 
mimicing performance expected when using TFA under certain conditions. Peptides, 
historically, have primarily been chromatographed using TFA mobile phases in order to 
improve peak shape, making this novel column a particularly intriguing option. Figure 5.8 
shows that this charged surface column improved the peak shape for insulin versus a 





Figure 5.8 Chromatographic separation of bovine insulin using a traditional C18 300Å (ACQUITY UPLC 
BEH 300 C18) column (top) and a charged surface (ACQUITY UPLC CSH C18) column (bottom) 
 
  In general, the isoelectric points (pI) for most insulin analogs are in the 5-7 range, 
making them positively charged under the low pH mobile phase conditions employed. The 
observed improved peak shapes could be due to the stationary phase also being positively 
charged, in this way minimizing secondary interactions through charge repulsion. During 
the method development process, various organic solvents and modifiers as well as LC flow 
rates were tested in order to obtain the best peak shape and sensitivity. As the best SPE 
recovery (and presumably, solubility) of the insulin analogs was obtained using methanol 
and acetic acid, this combination was tested and investigated as an LC mobile phase. 
Experimental results yielded reduced MS sensitivity and broad LC peaks. It is possible that 
acetonitrile improves MS ionization and/or that acetic acid is not as good a buffer as formic 
acid, or finally that the mobile phase pH is not as low with acetic acid as it is when using 
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formic, resulting in a change in peak shape. However, acetic acid and methanol were 
incorporated into the sample manager wash solvents, and were effective at eliminating 
carry-over.   
Initial LC method development was performed using solvent-only standards in 
methanol/acetic acid. Chromatographic performance was unpredictable, with peak areas 
varying as much as 50-200% injection to injection. The Insulin peaks were also 
undetectable in many of the injections. In addition, serial dilution of a high level standard 
yielded poor linearity, particularly at lower concentrations. This behaviour is symptomatic 
of non-specific binding (NSB), which is a common attribute of many peptides, particularly 
larger ones containing lengthy hydrophobic regions. In Chapter 2, it was demonstrated that 
addition of a carrier protein can be an effective way to minimize NSB. In this case, for 
simplicity, 0.05% rat plasma was added to the sample diluents (described in the 
experimental section), resulting in improved linearity in solvent standards. NSB can also 
occur between peptide analytes and the chromatographic columns. To alleviate this effect, 
LC columns may have to be “pre-treated” in order to obtain the best performance for 
biomolecules such as insulin. Figure 5.9 highlights the difference between injections of 
insulin onto a column which has been subject only to solvent standards versus the same 
column after 9 injections of protein precipitated plasma. The plasma components 
presumably coat the column surface and effectively minimize NSB. These changes resulted 
in reproducible peak areas and a broad linear dynamic range in solvent standards as well as 





Figure 5.9 Change in chromatographic performance for insulin glargine from the first two injections (bottom 
and middle panels) and after injections of precipitated plasma (top) 
 
The optimized separation conditions were formic acid (0.1%) in water and 
acetonitrile at a flow rate of 0.25 mL/min (shown in Figure 5.10) where retention times for 
the various analogs and IS range from 1.17 to 1.74 minutes. Peaks widths were ≤ 2.8 
seconds wide at base for all insulin analytes and Gaussian peak shapes were obtained. Table 
2 summarizes representative peak statistics from solvent-based standard curves for several 
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50 pg/mL 0.05 483.06 0.051 2.4 
100 
pg/mL 0.1 777.31 0.094 -6.4 
500 
pg/mL 0.5 3748.09 0.522 4.3 
1 ng/mL 1 6955.55 0.984 -1.6 
2 ng/mL 2 15881.66 2.27 13.5 
5 ng/mL 5 38498.98 5.528 10.6 
10 ng/mL 10 74175.04 10.668 6.7 
20 ng/mL 20 143202.70 20.612 3.1 










Table 5.2 Representative standard curve statistics for insulin glulisine (A) and insulin glargine (B) from 50 









50 pg/mL 0.05 246.6 0.045 ‐9.5
100 pg/mL 0.1 563.7 0.101 1
200 pg/mL 0.2 1090.0 0.194 ‐3.2
500 pg/mL 0.5 2642.8 0.467 ‐6.7
1 ng/mL 1 5544.9 0.977 ‐2.3
2 ng/mL 2 11120.5 1.957 ‐2.1
5 ng/mL 5 28094.9 4.942 ‐1.2
10 ng/mL 10 61467.9 10.811 8.1
20 ng/mL 20 117881.6 20.731 3.7
50 ng/mL 50 298668.7 52.523 5
100 ng/mL 100 625570.8 110.009 10
500 ng/mL 500 2764219.3 486.092 ‐2.8
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5.3.4  Human Plasma Standard curve and Quality Control Data 
Following the testing in solvent standards, samples were prepared in human plasma. 
Linear dynamic range and assay accuracy and precision were determined using standard 
curves and quality control (QC) samples prepared in human plasma spiked with a mixture of 
the insulin analogs and a fixed concentration of the IS as described. Calibration standards 
used for quantification of the various insulin analogs ranged from 0.2 to 25 ng/ml. Using a 
1/x weighting and linear fit, the r2 values for all curves, for all insulin analogs were > 0.997. 
The mean accuracies for all standard curve points extracted from human plasma were 
93.4%, 91.6%, 96%, and 95.1% for glargine, detemir, aspart, and glulisine, respectively.  
QC samples were prepared in triplicate in pooled human plasma, as previously described, at 
0.35, 0.75, 2, 8, and 20 ng/ml. The mean accuracies for all QC samples were 94.2%, 94.6%, 
and 91.5% for glargine, detemir, and glulisine, respectively. Statistics for aspart QC samples 
were not as accurate nor as precise; this is explained by overall lower area counts and higher 
endogenous background in extracted plasma samples. To improve this performance, a more 
specific extraction and/or modified LC strategy will be needed. This will be the subject of 
Section II of this chapter. Representative standard curve and QC statistics are presented for 
insulin detemir and glulisine in Tables 5.3 and 5.4, respectively. Representative 
chromatograms of an extracted plasma blank and insulin glulisine and insulin glargine at the 















Blank plasma   31.5         
200 pg/mL plasma 0.2 153.3 0.012 13239.5 16.6 0.23 
500 pg/mL plasma 0.5 375.6 0.03 12437.3 -4.6 0.48 
1 ng/mL plasma 1 750.2 0.06 12419.1 -12.7 0.87 
5 ng/mL plasma 5 4714.5 0.399 11801.8 6.3 5.31 
10 ng/mL plasma 10 8984.8 0.696 12907.3 -8 9.20 
25 ng/mL plasma 25 25007.1 1.948 12836.3 2.4 25.60 
              
QC 350 pg/mL plasma 0.35 241.6 0.02 12200.7 -2.6 0.34 
QC 750 pg/mL plasma 0.75 733.6 0.058 12560.6 12.9 0.85 
QC 2 ng/mL plasma 2 1969.4 0.141 13954.4 -3.5 1.93 
QC 8 ng/mL plasma 8 7486.7 0.615 12168.7 1.8 8.14 
QC 20 ng/mL plasma 20 20549.6 1.616 12712.9 6.3 21.26 
 
Table 5.3 Representative standard curve and QC sample statistics (n=3) for insulin detemir from 200 pg/mL to 

























Blank plasma   36.9         
0.2 ng/mL plasma 0.2 230.3 0.013 17486.8 7.4 0.22 
0.5 ng/mL plasma 0.5 1017.4 0.057 17807.0 5 0.53 
1 ng/mL plasma 1 2068.0 0.12 17249.8 -3.2 0.97 
5 ng/mL plasma 5 11330.0 0.61 18563.8 -11.4 4.43 
10 ng/mL plasma 10 23803.2 1.396 17051.6 -0.2 9.98 
25 ng/mL plasma 25 57342.0 3.606 15903.8 2.3 25.58 
              
QC 0.35 ng/mL 
plasma 0.35 626.1 0.035 17654.8 6.3 0.37 
QC 0.75 ng/mL 
plasma 0.75 1700.4 0.101 16856.5 11.2 0.83 
QC 2 ng/mL plasma 2 4744.9 0.31 15317.0 15.5 2.31 
QC 8 ng/mL plasma 8 18609.8 1.013 18366.4 -9 7.28 
QC 20 ng/mL plasma 20 47779.3 2.828 16894.6 0.5 20.09 
 
Table 5.4 Representative standard curve and QC sample statistics (n=3) for insulin glulisine from 0.2 ng/mL to 
25 ng/mL in human plasma 
 
Figure 5.11A Representative chromatogram of insulin glulisine at the LOD (B) and LLOQ (C) in human 
plasma; blank extracted human plasma is also shown (A) 
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Figure 5.11B  Representative chromatogram of insulin glargine at the LOD (B) and LLOQ (C) in human 
plasma; blank extracted human plasma is also shown (A) 
 
Figure 5.11A clearly shows that a limit of detection, and perhaps even 
quantification, of 0.2 ng/mL for insulin glulisine is readily achieved using this method. 
However, for insulin glargine, the data in Figure 5.11B indicates that even detection at 0.2 
ng/mL may be difficult to achieve in other sources of plasma matrix due to the high 
background and closely-eluting interferences. Section II of this chapter focuses on 
improving detection limits and reducing matrix interferences for all analogs, especially 
insulin glargine, one of the most widely sold insulin analogs and coincidently, one in which 
there is great interest due to patent expiry (Figure 1.1). 
5.3.5 Specificity 
For a method such as this, where several closely related large peptides (with multiple 
possible molecular ions) are being analyzed in complex matrix using low resolution mass 
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spectrometry, the risk of interference from the MRM of one insulin channel into another is 
high. Therefore, one must assess the contribution of analytes present individually at high 
concentration, to the response in other channels. In order to evaluate the specificity of the 
method, samples were fortified individually with one of the four analogs at a concentration 
of 500 ng/mL, which is 20X the plasma ULOQ of 25 ng/mL. In addition, samples were 
fortified with human insulin only at 500 ng/mL and 1 µg/mL to assess the impact and 
potential interference of high levels of endogenous insulin (as might be present in Type 2 
diabetics) on assay specificity.  
The specificity experiments highlighted several positive attributes as well as certain 
limitations of this method, if the method were employed as-is. When human insulin is 
present at 1 µg/mL there is no detectable response in the primary MRMs for Levemir, 
Lantus and Novolog. There is a low level response (roughly equivalent to 0.5-1 ng/mL) in 
the 2 MRM transitions for Apidra. This is easily attributable to the overlap of precursor 
molecular ions experienced under low resolution conditions, coupled to the high sequence 
homology. In samples containing either Lantus only or Levemir only, the method 
demonstrated complete specificity as there was no detectable response in the primary 
channel for any of the other analogs or for human insulin. However, when Apidra or 
Novolog are present at 20X of the plasma ULOQ of 25 ng/mL, a response close to the LOD 
is detected in the channels for Novolog and Apidra, respectively, limiting the practical 
quantification limit for those analytes, if Novolog or Apidra were present at such extreme 
levels. Furthermore, Novolog, at 500 ng/mL, does trigger a response in the MRM channels 
for human insulin arising from the 6+ precursor. This presents a challenge as these analytes 
nearly co-elute under the gradient conditions proposed. The test run here, where individual 
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analogs are present at such high concentrations, represents an extreme circumstance. When 
these analogs are present at 2X the plasma ULOQ, the assay is completely specific for all 
analogs, as well as for human insulin. 
 
5.4  Conclusions from Initial Proof of Concept Studies 
With the global incidence of diabetes having grown dramatically over the past 
decade [30], it is expected that the interest in development of treatment and monitoring 
options, and thus potentially the identification and quantification of insulins, will be 
increasingly important to the scientific  community. Though there are many distinct 
advantages to quantifying insulin and other large hydrophobic peptides by LC-MS/MS, this 
technique presents many analytical challenges including non-specific binding, poor 
chromatographic peak shape, carry-over, poor linearity, poor reproducibility and poor MS 
sensitivity. Section I of this chapter has presented proof of concept for a novel method for 
differentiating and quantifying therapeutic insulin analogs using µ-Elution SPE and UPLC-
MS/MS, and   highlights the tools and techniques for understanding, identifying, and 
addressing the challenges associated with large peptide/small protein analysis in the 
bioanalytical labouratory. The figures throughout this section illustrate these behaviours, 
many of which may be new to bioanalytical researchers previously focused on small 
molecule development. Although full validation was not performed, the data show distinct 
promise for the direct, simultaneous quantification and differentiation of multiple, intact 
long and fast acting insulin analogs in human plasma. This UPLC-MS/MS analysis can be 
readily implemented, is simpler, and has a higher throughput than other published LC-
MS/MS methods, which are considerably more complex and typically use multi-
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dimensional and/or nano LC or time consuming affinity purification. The run time of 3.5 
minutes is 5-10X faster than other publications. In addition, this is the first study that 
simultaneously analyzed several long and fast acting analogs. Although this proof of 
concept work is not as sensitive as the ultrasensitive IP/nano-LC/high, resolution method 
recently published by Thomas et al[31] for urine, its speed, simplicity and adequate 
detection limits make it attractive to high throughput bioanalytical labouratories and provide 
the foundation for the further research described in Section II of this chapter. In contrast to 
ligand-binding assays, there is no concern with cross-reactivity between human insulin and 
the analogs, using the LC/MS method described herein, as this MRM approach readily 
differentiates the glargine, detemir, and glulisine analogs from endogenous insulin. The 
primary limitation of the current method is that there is a lack of adequate specificity 
between glulisine and aspart, when either is present at extremely high concentrations (20X 
the plasma ULOQ) as they co-elute chromatographically. Fortunately, they are not expected 
to be present in the sample as both are fast acting analogs and would not likely be co-
administered. Furthermore, when aspart is present at 20X the plasma ULOQ, there is a 
detectable response in the human insulin channels chosen. An additional limitation of the 
proof of concept study is that it does not include validated quantification of human insulin 






Section II Improved Sensitivity and Specificity Using Multidimensional LC and 
Mixed-mode SPE 
 
As mentioned in section 5.1, recombinant human insulin and the many long and fast 
acting analogs that have been developed represent the primary treatment for insulin 
dependent Type I and, with an increasing trend, these are also prescribed to Type II diabetes 
patients. Dosage is normally in combination with oral therapy or after failure of diet or oral 
agents to exhibit glycemic control [32]. Section I of this chapter presented proof of concept 
for insulin quantification using LC/MS, however full validation was not performed and 
human insulin and its most closely related analog, lispro, were not included. In addition, 
detection limits were not adequate for current research efforts or for monitoring fasting 
levels. Therefore, alternative techniques were investigated to resolve these shortcomings, 
the results of which are discussed in Section II. 
 
5.5 Introduction  
Several factors highlight interest in quantification methods for insulin and analogs, 
and justify further development beyond the proof of concept work detailed in Section I of 
this chapter. The global incidence of diabetes mellitus (DM) continues to increase and 
therefore also the number of patients requiring daily insulin treatment. Additionally, patent 
protections have expired or are due to expire shortly[34] for many of the most widely 
prescribed insulins, leading to a multitude of active research programs to develop additional 
biosimilars. In addition, the biosimilar market is expected to grow by over 50 % through 
2015[35] with insulins and diabetic treatments holding a prominent position. All of these 
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factors support the strong need to continue research on a viable LC-MS method for insulin 
quantification, leading to the work presented in Section II. Additionally, as mentioned in 
Section I, insulin administration has a forensic interest [36] and is of interest to the anti-
doping industry[37, 38]. More selective, accurate and more sensitive analytical methods 
than the assay described in Section I of this chapter are urgently needed for such 
applications. 
Historically, insulins have been analyzed using radioimmunoassay (RIA) or enzyme-
linked immunosorbent assay (ELISA). LC-MS analysis of insulins is needed due to the 
many shortcomings of ELISA and RIA assays. For example problems with lack of 
standardization, cross-reactivity, limited linear dynamic range, and sample preparation time, 
are all well documented [18, 39-41]. These factors have driven the development of 
alternative LC-MS/MS assays and LC-MS method standardization [42]. For insulin analysis 
specifically, hybrid assays based on immuno-capture followed by LC-MS have been the 
most effective [11, 18-20, 27, 31, 41] though they lack the simplicity and throughput 
required for routine testing and bioanalysis. 
Arguably the main challenge in developing LC-MS assays for large peptides such as 
insulin is in achieving detection limits equivalent to gold-standard immunoassays. Factors 
affecting sensitivity include (but are not limited to) selectivity during the sample preparation 
step, MS sensitivity (as peptide signal is shared across multiple precursors) and poor 
transfer into the gas phase. Furthermore, for an insulin assay to be readily implemented into 
labouratories, it must provide high throughput (several hundred samples a day), adequate 
dynamic range and utilize a simple sample preparation step. 
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The most sensitive assays to date have been based on affinity purification, followed 
by SPE and nano-flow LC. Generally, nano-flow methods do not offer high-throughput and 
although affinity purification is highly selective it is also less amenable to automation. 
Moreover a recent report on the development of an insulin analog [43] found that an assay 
based on immunoaffinity (IA) capture could be subject to anti-drug antibody (ADA) effects. 
Kelley et al. [44] demonstrated the need for assays absent of an IA component which is 
reliant on ligand-binding.  
Section I of this chapter and the resultant publication[39] showed feasibility for the 
simultaneous measurement of insulins in human plasma using LC-MS/MS. However, 
targeting human insulin and lispro (Humalog®) and the need to achieve detection limits 
required for clinical samples (i.e. ~ 50 pg/mL.) prompted an entirely new approach. The 
improved method described in this section is based on six steps. These included 
precipitation, mixed-mode solid phase extraction, column trapping and back elution, 
followed by a separation using a fused core C18 column with positively charged surface and 
MS-MS fragmentation based detection.  Figure 5.1 shows the molecular structures for the 
six insulins, including human insulin and insulin lispro, which were added to the improved 
analysis described in this section. Section I of this chapter served to highlight and reinforce 
that each analytical step was going to be crucial to achieve the fasting level sensitivity 
described herein. Previous reported methods which achieved this sensitivity relied on 
affinity sample preparation or two separate validations and/or the analysis of human insulin 
only using the reduced B-chain as a surrogate [11, 18-20, 27, 31, 40, 41]. 
In order to avoid the use of affinity purification, alternatives were considered. One 
such option is the use of multidimensional LC. In proteomic analyses, multidimensional LC 
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has long been a standard tool used to effectively identify peptides, improve peptide mapping 
coverage, and to separate the complex peptide mixture resulting from various proteolytic 
digests of a proteome[45]. In the bioanalytical arena multidimensional chromatography has 
also successfully been implemented to improve assay specificity and sensitivity. For 
example, Ismaiel et al. [46] demonstrated the effective separation and removal of 
phospholipids to reduce matrix effects and improve sensitivity in an assay for octreotide. 
Chen et al [40] applied an on-line extraction and parallel column regeneration approach in 
the analysis of reduced human insulin. Dual reversed-phase (RP) column or RP-HILIC 
systems, described by Rogatsky et al. [47] and Liu et al. [48], also reduced matrix effects 
and improved sensitivity. For these reasons, multidimensional LC seemed a reasonable 
approach to both improve sensitivity and reduce interferences for intact insulin analysis. 
In this investigation a multidimensional platform was designed that achieved the selectivity 
and detection limits needed for the simultaneous analysis of human insulin and five 
recombinant analogues.  
 
5.6 Experimental for Improved Insulin Assay 
5.6.1 Chemicals and Reagents  
Lantus® (insulin glargine) and Apidra® (insulin glulisine), both manufactured by 
Sanofi-Aventis, were used as formulated. Levemir® (insulin detemir) and NovoLog™ 
(insulin aspart), both manufactured by Novo Nordisk, were also used as formulated. 
Humalog® (insulin lispro), manufactured by Eli Lilly and Company, was also used as 
formulated. Human insulin and bovine insulin were purchased from Sigma-Aldrich, St. 
Louis, MO. A representation of the analog sequences and how they differ from human 
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insulin is depicted in Figure 5.1. Human plasma was purchased from Biological Specialty 
Corporation, Colmar, PA. For specificity testing (determination of matrix factors), 6 
different lots of normal control human plasma were used. Lots 82111 and 82740 were 
female, lot 57901 was male, and lots 70193, 57298, and X1803C were pools. Rat plasma 
was purchased from Equitech Bio, Kerrville, TX. Water for mobile phase and sample 
preparation was obtained from a Milli-Q lab water system, (Millipore, Billerica, MA). 
Acetonitrile (ACN), methanol, and formic acid (concentrated solution, 99 %) were 
purchased from Fisher Scientific (Fair Lawn, NJ). All other chemicals and reagents were 
purchased from Sigma (St. Louis, MO) unless otherwise stated.  
5.6.2 Preparation of samples, calibration standards and quality control samples 
For all formulations, the insulin analogs are present at 100 IU/mL. For Lantus®, 
Apidra®, NovoLog™, and Humalog®, 100 IU is equal to 3.638, 3.49, 3.5 and 3.5 mg insulin 
glargine, insulin glulisine, insulin aspart, and insulin lispro, respectively, per mL (values as 
stated in product inserts). For Levemir®, 100 IU insulin detemir is equivalent to 14.2 mg. 
This value was obtained from the European Medicines Agency webpage containing product 
information for Levemir®[49]. The lyophilized human insulin was dissolved in 0.01 M HCl 
to generate a concentrated stock at 1 mg/mL. A diluent consisting of 30/10/60 
CH3OH/CH3COOH/H2O v/v/v plus 0.05% rat plasma was prepared. The various insulin 
formulations or stocks were diluted serially in the above diluent and then combined to 
generate a working solution containing all six at a concentration of 1 µg/mL  Bovine insulin 
was used as the internal standard (IS) and was prepared in the above diluent at a 
concentration of 100 ng/mL to be used for spiking. For standard curve and quality control 
(QC) samples, human plasma was initially fortified with the combined insulin working 
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solution to a final concentration of 50 ng/mL of each of the 6 insulins. The 50 ng/mL 
plasma stock was then diluted with control human plasma to generate appropriate standard 
curve and QC samples. Standard curve samples were prepared at the following 
concentrations: 50, 100, 200, 500, 1000, 2000, 5000, and 10,000 pg/mL in human plasma. 
QC samples were prepared at 150, 750, 2500, and 7500 pg/mL in human plasma. Blank 
human plasma samples were also extracted for determination of limit of detection (LOD) 
and lower limit of quantification (LLOQ.)  
5.6.3 Sample pre-treatment and solid-phase extraction conditions  
Protein precipitation (PPT) pre-treatment: 
A 250 μL aliquot of each patient sample, standard curve point, QC or blank was 
transferred to an Eppendorf tube and 25 µL of IS solution was added. Samples were 
vortexed, followed by addition of 250 μL of 1:1 (v:v) ACN: CH3OH containing 1 % acetic 
acid. Samples were mixed to precipitate and centrifuged at 13,000 rcf for 10 minutes. The 
supernatant was removed and added to a 2 mL plate containing 900 µL 5 % NH4OH in 
water. 
Solid phase extraction (SPE): 
The wells of a strong anion exchange (Oasis MAX) µElution plate were first 
conditioned with 200 µL methanol, followed by equilibration with 200 µL water. The entire 
diluted PPT supernatant was loaded onto the extraction plate in two steps of approximately 
700 µL each. Samples were washed with 200 µL 5 % NH4OH in water, followed by 200 µL 
5 % methanol and 1 % acetic acid in water. Bovine and human insulin and its analogs were 




5.6.4 Collection and Handling of Patient Samples  
Venous blood was collected (Ethics number for the study LREC 10/H0802/86 and 
according to established practice [50, 51]) from 22 patients into commercially available 
standard anticoagulant-treated (EDTA) tubes. Blood samples were centrifuged at 1500-2000 
x g for 15 minutes and plasma was transferred to sterile cryovial storage tubes and stored at 
-80 °C. On the day of analysis, samples were thawed at room temperature and immediately 
re-frozen after an appropriate aliquot was removed for analysis. 
5.6.5 Chromatographic Conditions  
Samples were maintained at 10°C in the autosampler. 30 µL of SPE eluate were 
chromatographed using an ACQUITY UPLC I-Class with 2D Technology, configured for 
at-column dilution and trap and back elution, see Figure 5.12. Insulins were first trapped on 
an XBridge C18 IS, 3.5 µm, 2.1 X 20 mm column and then separated on a CORTECS 
UPLC C18+ 1.6 µm, 2.1 x 50 mm analytical column. The gradient elution solvents were 0.1 
% HCOOH in water (mobile phase A) and 0.1 % HCOOH in acetonitrile (mobile phase B.) 
The trapping/loading solvent was 85:15 mobile phase A:B with a flow rate of 0.1 mL/min. 
The dilution solvent was 100 % mobile phase A with a flow rate of 0.3 mL/min.  
With the valve in position 1, the sample was loaded onto the head of the trap column for 2 
minutes with the combined flow of the trapping and dilution solvents, the valve was then 
switched to position 2 and the analytes were back-eluted onto the analytical column 






Figure 5.12  ACQUITY UPLC 2D valve diagram for at-column-dilution (ACD) and trap 
and back elute chromatography 
  
5.6.6  Mass spectrometry and Software 
For each peptide and the IS, collision induced dissociation (CID) products of 
multiply charged precursors were detected in positive ion multiple reaction monitoring 
(MRM) mode using a Waters Xevo™ TQ-S mass spectrometer (Milford, MA). The 
electrospray voltage, source temperature,  desolvation temperature and desolvation gas flow 
rate were 3.0 kV, 150 °C, 500 °C and 1000 L/Hr, respectively. Primary and secondary 
MRM transitions used for quantification and qualification, respectively, for each peptide 
and the IS as well as their respective cone voltages, collision energies, precursor charge 
states, and fragment identification (where known) are summarized in Table 5.1. MassLynx 

























integration, regression analysis and sample quantification was performed using TargetLynx. 
Peak area ratios (PARs) of the insulin analogs and the bovine insulin internal standard were 
determined and calibration curves generated for each of the analogs. Insulin analog 
concentrations in QC samples were determined from their PARs against their respective 
calibration lines. Calibration curves, prepared in human plasma, were constructed by 
applying a 1/concentration weighted linear regression model. All QC sample concentrations 
were then calculated from their PARs against their respective calibration lines. 
 
5.7 Results and Discussion 
5.7.1 Sample pre-treatment and extraction  
Section I of this chapter described a simple reversed-phase SPE sample preparation 
method. This method however, did not reduce endogenous background enough to allow for 
the achievement of adequate detection limits nor the quantification and differentiation of 
human insulin and insulin lispro. Therefore, a more selective sample preparation method 
needed to be devised. The data in Chapter 2 established that protein precipitation (PPT) may 
be used to selectively eliminate high abundance proteins. It was theorized that this might 
improve specificity for insulin analysis. To test this, a protein precipitation step was 
investigated prior to SPE to both clean-up the sample and disrupt protein binding. Both 
acetonitrile (ACN) and methanol (MeOH) with and without acetic acid, formic acid, or 
NH4OH were evaluated for insulin recovery. In addition, both 1:1 and 2:1 ratios of organic 
to plasma were tested. In all cases, recovery was significantly lower when a 2:1 ratio was 
used. It is believed that the higher ratio results in insulin loss due to partial precipitation of 
the insulins as previously described [29] and as observed in the teriparatide analysis 
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described in Chapter 3. The combination of a mixture of ACN and methanol, modified with 
acetic acid, provided the best recoveries (80-100 %) for the insulins from human plasma. 
Figure 5.13 summarizes results from all pre-treatment conditions evaluated, and supports 
the final choice of pre-treatment. In general, recovery is about twice as high when a 1:1 ratio 
of organic to plasma was used in precipitation than when a 2:1 ratio was used. This is 
consistent with observations in Chapter 2, where a similar study was performed for 
teriparatide analysis. There was no specific trend relating to the use of acidic or basic 
modifier as neither consistently produced higher recoveries than the other. SPE eluates with 
and without the PPT pre-treatment were examined for cleanliness, and it was found that PPT 
pre-treatment prior to SPE, reduced background by as much as 80 % during various 
chromatographic segments, demonstrating its importance. 
 
 




































The reversed-phase SPE described in Section I of this chapter was sufficient to 
extract four insulin analogs (glargine, glulisine, detemir, and aspart) from human 
plasma[39]. This approach however was inadequate for comprehensive, sensitive insulin 
analysis as the remaining endogenous background was very high and quantification of 
human insulin and lispro below 1 ng/mL was not possible. RP clean-up achieved detection 
limits in the range of 200-500 pg/mL for the analogs. However, for clinical applications 
these insulins should be accurately quantified down to levels of ~ 50 pg/mL., as 
demonstrated by pharmacokinetic profiles [3, 52-54] and known fasting insulin levels [55].  
Mixed-mode (MM) sorbents have been shown not only to reduce matrix effects, but also to 
provide significantly more selective elutions [56]. Data in Chapter 2 emphasized the 
importance of its use for peptide extractions. Strong anion exchange (SAX) was chosen as 
insulins were negatively charged at high pH (≥9). Low pH (≤3) was also investigated with 
cation exchange resins, however experiments with both weak and strong mixed-mode cation 
exchange sorbents yielded reduced recovery when compared to the SAX sorbent.  Since an 
LLOQ of 50 pg/mL was readily achieved on the SAX-MM sorbent, this phase was chosen.  
 
5.7.2 Mass Spectrometry of Insulin and Analogs 
Peptides are challenging molecules to analyze by LC/MS, however, many of the 
guidelines summarized in Chapter 2 were applied to the development of this new method. 
Flow rate impacted the relative abundance of precursors formed, so fine-tuning of the 
fragmentation at the utilized chromatographic flow rate was performed. First, CID of 
several of the highest intensity precursors from each insulin was optimized as not all 
precursors fragmented to the same extent. Specificity of the MRM transition in the final 
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extracted sample could not be predicted, and was critical to the success of the assay. 
Therefore at least three to four transitions for each of the insulins were monitored and 
intensity optimized. Considering the guideline developed in Chapter 2, of particular interest 
were the higher m/z precursor/fragment pairs, specifically those where the fragment m/z 
was higher than its precursor. This unique combination most often produced signal with the 
greatest specificity and lowest background in extracted samples. The MRM transitions for 
glulisine, detemir, and aspart that were identified in Section I of this chapter were adequate 
to achieve the required sensitivity using the modified extraction procedure and 
multidimensional chromatography described in this section. For glargine, the use of MRM 
m/z 867->984 produced a low level interference detected in several lots of plasma during 
our specificity testing, therefore an alternative m/z 1011->1179 was tested and chosen, 
achieving a quantification limit of 50 pg/mL (8.25 fmol/mL).  This interference was not 
found during the proof of concept work as only a single lot of plasma was used in testing. 
The discovery of the interference in m/z 867-> 984 underlines the importance of specificity 
testing in multiple lots/sources of biological matrix and also serves to further highlight the 
importance of higher m/z precursor/fragment pairs. 
The primary focus rested on differentiation between human insulin and lispro, and 
the identification of the most specific precursor and fragment pairs. Human insulin and 
lispro produce the same precursor pattern (Figure 5.14) and share almost complete overlap 
in their fragmentation profiles due to a simple reversal in the positions of amino acids 28 





Figure 5.14 MS spectra for human insulin; insulin lispro produces the same precursor mass profile 
 
A single low molecular weight fragment differentiated the two, with human insulin 
yielding a diagnostic fragment at m/z 226 and lispro producing a characteristic fragment at 
m/z 217, both arising from cleavage at the last 2 amino acids in the B chain. MSMS spectra 
are shown in Figure 5.15; fragments used for quantification are highlighted with an asterisk. 
Although lispro produces a very low level of the m/z = 226 product at high concentrations, 
it did not interfere with this assay under the analytical conditions.  
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Figure 5.15 MSMS spectra for human insulin and insulin lispro 
 
Higher MS background, which is generally observed when monitoring fragments 
below ~m/z 300 (for peptides), made sample preparation and chromatography crucial. In 
Chapter 2, Figure 2.15 is evidences the value of choosing a higher m/z precursor, even if a 
low m/z fragment must be used. In Figure 2.15, although the absolute intensity of the 969 -> 
217 MRM is higher than that of 1163 -> 217, the signal to noise is greater in the latter case. 
This effect is magnified further in the presence of matrix. When the influence of precursor 
choice was examined in human plasma, as Figure 5.16 demonstrates, higher specificity was 
obtained when the 5+ precursor (m/z 1162, panel A) was chosen versus the 6+ at m/z 968 
(panel B).  
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Human insulin MSMS of 5+ 1163






Figure 5.16 Effect of precursor choice on specificity of insulin lispro in extracted human plasma: m/z 1162-
>217 (A) and m/z 968->217 (B); arrow indicates lispro peak 
 
With the exception of human insulin and lispro, which are only distinguished by 
mass spectrometry, all other insulins were differentiated from each other and identified 
based on both retention time and MRM transition. Identity was further confirmed using 
retention time match to within 2 % and MRM peak area ratio match of the sample against an 
authentic standard run in the same batch. Figure 5.17 compares extracted ion 
chromatograms for insulin glargine and lispro detected in patient 20 with the standard run in 
the same batch. Retention times in the patient sample are identical to the calibration 
standard. This is in accordance with the criteria required by the World Anti-Doping Agency 
to evidence the administration of an insulin in a sports sample[38].   
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Figure 5.17 Comparison of extracted ion chromatograms for insulin lispro, RT 4.27 (left) and glargine, RT 
4.12 (right) from patient sample 20 (top) and an extracted insulin standard (bottom) 
 
5.7.3 Liquid Chromatography 
Unlike small molecules, larger peptides and small proteins like insulin suffer from 
poor mass transfer. Thus, using a column packed with solid-core particles allowed for 
sharper peak shapes at the higher flow rates typically needed for bioanalytical studies [57, 
58]. For insulin and analogs specifically, a column packed with particles containing a low 
level positive surface charge gives superior peak shapes [39] as shown in Chapter 2. 
Furthermore, <2 µm particle column employed uses a flow rate of several hundred µL/min 
with high peak capacity[59]. Gilar et al. [60] demonstrated a marked increase in peak 
capacity for peptides using 1.8 µm particles. The CORTECS C18+ column employed here 
Patient Sample 20
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combined solid-core particle technology, a low level positive surface charge, and sub-2 µm 
particles. Using this column, insulin peaks were typically 4 to 4.5 seconds wide at base. In 
addition, to the narrow peaks  9-40 % higher area counts were observed with the 
superficially porous, positiviely charged columns, for the 6 insulins, than when an 
equivalent fully porous particle column with a positively charged surface was tested. These 
observations are derived from the data in Figure 5.18. This data is consistent with the 
column testing performed in Chapter 2.  
 
 
Figure 5.18 A representative comparison of peak areas for insulin and analogs chromatographed on sub-2 µm 
solid core charged-surface C18 columns (A) versus fully porous charged-surface C18 columns (B). Peak 
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The final separation for human insulin, its analogs, and the internal standard (IS), 
bovine insulin, is shown in Figure 5.19  Human insulin, lispro, glulisine, aspart and the IS 
nearly or completely co-elute, while glargine and detemir are both well separated from each 
other and from all other insulins. Experiments performed on several columns, mobile phases 
and gradients all failed to eliminate these co-elutions. As this was the case, the 50 mm 
column and 3 minute gradient (20-65 % B) were used to improve throughput. Though a 
longer column may have improved resolution between the insulins, good sensitivity and 
adequate specificity were obtained on the 50 mm column. Ideally one might strive to resolve 
human insulin and insulin lispro, but the increase in run time that would accompany a 150 
mm length column, for example, was not deemed an acceptable trade-off.  
 
 






























































A multidimensional system provided the increased selectivity and reduced 
background necessary to use low molecular weight fragments for human insulin and lispro 
as well as to achieve the required lower detection limits for all insulin analogs. Initially, it 
was hypothesized that a heart-cut configuration (two analytical columns and selected 
window fractionation) would provide the best method. However, several column 
chemistries, (C4, C8, 300Å C18) and two pHs (pH 3 and pH 11) were tested for the first 
dimension analytical column. Poor sensitivity was observed at high pH and the insulin 
analogs did not elute closely enough together, under any condition, to perform an efficient 
fractionation from the first column to the second. If detemir were eliminated from the mix, a 
true heart-cut separation may have been possible. Detemir requires significantly more 
organic (than the other analogs or human insulin) to elute from both the proposed and tested 
first dimension and certainly the second dimension chromatographic columns, rendering the 
use of a narrow fractionation window impossible. For these reasons, an alternative 
multidimensional LC strategy was employed. 
The use of at-column dilution (ACD) onto a 2.1 X 20 mm XBridge C18 column 
facilitated the higher injection volume of 40 µL and allowed for lower limits of detection. 
The trapping was followed by back-elution of the insulins under optimized conditions which 
provided an initial reversed-phase (RP) separation. During trapping, the initial organic 
mobile phase composition and valve switch timing were of particular importance. Trapping 
under lower or higher organic composition conditions reduced sensitivity, possibly due to 
incomplete elution or retention, respectively. Detemir sensitivity was particularly affected 
when samples were loaded under reduced organic (<15 %) conditions. To improve recovery 




5.7.4  Human Plasma Standard Curve and Quality Control Data: Sensitivity, Linearity, 
Accuracy and Precision 
All curves were linear using the 1/x regression. A summary of standard curve 
performance for all insulins can be found in Table 5.5.  
 
 
Table 5.5 Standard curve ranges, r2 values, and mean accuracy for curve points for all compounds 
 
For human insulin, the basal concentration in pooled or individual control plasma 
was determined by calculating the x-intercept. The basal level of human insulin (average 
1940 pg/mL) was then added to the spiked concentration for all standard curve and QC 
samples, to enable accurate quantification. The lower limit of quantification (LLOQ) was 
50 pg/mL (8.3-8.6 fmol/mL) for human insulin, glargine, glulisine, and lispro. A 
representative LC/MS chromatogram for insulin glargine at the LLOQ and the low QC (150 

















Insulin lispro 50‐10,000 8.6‐1720 0.998 99.99 90.1 4.28
Insulin glargine 50‐10,000 8.25‐1650 0.996 99.98 85.1 4.13
Human insulin 50‐10,000 8.6‐1720 0.996 100 108.7 4.30
Insulin detemir 200‐10,000 33.8‐1690 0.998 96.4 87.0 5.52
Insulin glulisine 50‐10,000 8.6‐1720 0.995 100 91.5 4.29
Insulin Aspart 100‐10,000 17.16‐1716 0.995 100 114.4 4.27
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insulin lispro and glulisine are shown in Figures 5.21 and 5.22, respectively. These figures 
clearly show the performance improvement using the modified method. A comparison of 
Figures 5.11 and 5.20 verify that greater than a 10-fold improvement in sensitivity was 
achieved, from an LLOQ of 500 pg/mL to a 50 pg/mL LLOQ for insulin glargine.  A similar 
comparison of Figures 5.10 and 5.22 exhibit the same performance improvement for insulin 
glulisine. The analysis of insulin lispro, while not possible using the methods in the proof of 
concept study, was accurately and precisely quantified, achieving an LLOQ of 50 pg/mL, 
when the improved method was applied. Quantification of both human insulin and insulin 
lispro at low levels such as these was made possible primarily through a significant 
reduction in endogenous background. This was accomplished through a combination of 
improved sample preparation (including the use of mixed-mode SPE instead of reversed 
phase only SPE and protein precipitation to remove albumin and other interferences) and 
trapping, focusing, and isolating the analytes on a trap column prior to the analytical 
separation. The LLOQs for aspart and detemir were 100 pg/mL (17.2 fmol/mL) and 200 
pg/mL (33.8 fmol/mL), respectively. All curves were linear with r2 values >0.995 using 1/x 




Figure 5.20  LC-MS/MS extracted ion chromatograms for insulin glargine (Lantus) in human plasma at the 
low QC (A) and LLOQ (B) as compared to blank extracted human plasma (C). 
 
 
Figure 5.21 LC-MS/MS extracted ion chromatograms for insulin lispro (Humalog) in human plasma at the low 
QC (A) and LLOQ (B) as compared to blank extracted human plasma (C) 
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Figure 5.22 LC-MS/MS extracted ion chromatograms for insulin glulisine (Apidra) in human plasma at 100 
pg/mL (A) and LLOQ (B) as compared to blank extracted human plasma (C) 
 
Inter- and intra-day accuracy and precision were calculated for all QC samples. 
Representative summary statistics for insulin glargine, lispro, and human insulin can be 
found in Tables 5.6, 5.7 and 5.8, respectively. All other analogs exhibited similar 
performance. For insulin glargine, inter- and intra- day accuracy ranged from 95-103 % and 
95-112 %, respectively. For insulin lispro, the same ranges were 96-103 % and 97-110 %. 
Human insulin inter- and intra-day accuracies were 92-104 and 90-101 %, respectively. QC 
sample precision was excellent with average inter- and intra- day values ranging from 2.5 to 
8.3 %. These values comfortably meet regulatory criteria for bioanalytical method 
validation for chromatographic assays[61-63]. 
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  Table 5.6 . Inter- and intra-day accuracy and precision for QC samples for insulin glargine. 
 










150 150.1 18.7 12.4 102.7
750 718.4 47.3 6.6 95.8
2500 2369.3 131.2 5.5 94.8








150 167.4 16.6 9.9 111.6
750 757.7 62.4 8.2 101.1
2500 2378.0 184.9 7.8 95.1









150 144.0 17.5 12.2 96.0
750 721.8 32.3 4.5 96.2
2500 2447.1 202.9 8.3 97.9








150 164.6 14.9 9.1 109.8
750 748.2 19.8 2.6 99.8
2500 2417.6 230.4 9.5 96.7




    Table 5.8 Inter- and intra-day accuracy and precision for QC samples for human insulin. 
 
5.7.5 Specificity 
Matrix factors and CVs of matrix factors for all analogs were calculated in 6 
separate sources of normal control human plasma (see the experimental section for details) 
as outlined in the 2007 AAPS white paper [61]. The CVs of the matrix factors were 12.3, 
11.6, 11.8, 9, and 7.7 % for insulin detemir, glargine, aspart, glulisine, and lispro, 
respectively, well below the recommended criteria of <15% CV[64]. 
In addition, a study was performed to assess the impact of relatively high levels of 
human insulin, such as one might expect to find in type II diabetic patients, on the assay 
specificity. This is particularly important for two reasons. First, not all insulins are 
chromatographically resolved from one and another. Second, due to the use of a nominal 









150 1915.1 125.4 6.5 92.0
750 2542.5 141.0 5.5 94.8
2500 4326.0 146.7 3.4 97.6








150 2056.5 16.7 0.8 90.2
750 2506.3 46.6 1.9 99.3
2500 4269.8 206.4 4.8 101.3
7500 10233.2 265.2 2.6 100.3
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analogs themselves, and with human insulin, there exists the possibility of MS overlap in 
some of the transitions. For this test, plasma samples were fortified to a final concentration 
of 5 ng/mL with all of the analogs. A subset of these samples was also spiked with human 
insulin at 200 times greater concentration, to a final concentration of 1 µg/mL human 
insulin. All samples were then pretreated, extracted and quantified. There was no significant 
change in area counts for of any of the analogs when human insulin was present in high 
concentration.  
 
5.7.6  Analysis of Patient Samples 
Twenty-two venous blood samples were collected from patients and were comprised 
of patients with Type I and one Type II diabetes (on a variety of individual and combination 
insulin therapies) as well as normal controls. In a blind study, human insulin and/or its 
analogs were detected in the samples and calculated concentrations are shown and 
summarized in Table 5.9. The analysis revealed that most patients received a combination of 
long and fast acting analog treatments. (No patient was treated with insulin glulisine). In all 
but a single case, insulin detection was in agreement with dosing regimes. In two instances, 
insulin glargine was administered but detected below LLOQ. Below LLOQ detection was 
perhaps due to the low circulating levels of glargine and the sample collection time relative 
to dosing as glargine is dosed once a day. Perhaps more importantly, glargine is rapidly 
enzymatically converted into its major metabolite M1[65], which is likely to be the primary 
reason that glargine itself was not detected in all dosed subjects. Patient #1 received insulin 
aspart, however it was not detected by the assay. As aspart reaches peak serum levels within 
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an hour post dose[66] and rapidly declines from that point, it is also possible that sampling 
time relative to dosing was a the factor for the detection failure.  
Patient 22 represents the sole case where detection did not correlate with recorded 
dosing. Levemir was detected, however dosing records indicated that only Lantus and 
Humalog were dosed.  
Low levels of human insulin, an average of approximately 200 pg/mL, were detected 
in most Type I diabetic patients. In patient #4, a Type II diabetic, 4490 pg/mL human 
insulin was detected. A shortcoming of this method was highlighted by Patients # 9 and 19 
who were dosed with Insulatard® and Humulin®, respectively. These two insulins were 
detected as “human insulin” since this current assay does not distinguish these recombinant 
forms from the endogenous insulin with which they have an identical peptide sequence. A 
possible future modification to this method would be to add C-peptide, the precursor to 
endogenous human insulin. Its presence or lack thereof would enable identification of 






Table 5.9 Calculated concentrations of human insulin and/or its analogs detected in patient samples.  
Note: for those values that fall outside of the reported concentration range, samples were diluted as required 




Conc. (pg/mL) Conc. (pg/mL) Conc. (pg/mL) Conc. (pg/mL) Conc. (pg/mL) Conc. (pg/mL)
Sample ID Humalog (lispro) Lantus (glargine) NovoRapid (aspart) Levemir (detemir) Human insulin Apidra (glulisine)
1 115 n/d 206
2 855 9402 253
3 597 1813 341
¥ 4 4056 4486
5 n/d 118 188
6 147 702 222
7 615 49 231
8 212 1229 247
¤ 9  5567
10 178 3960 391
11 2439 116106 283
12 266 § 31 181
13 138 1546 189
14 451 125 213
15 218
16 289 32280 209
17 n/d 455 191
18 828 § 34 234
¤ 19 1342
20 1494 1526 598
21 1024 §









5.8 Conclusions on the Use of Multidimensional LC and Improved Sample Preparation 
for Insulin Quantification 
Using analytical scale chromatography and a 96-well SPE sample prep, this method 
simultaneously quantifies human insulin and 5 analogs with high throughput, and reaches 
detection limits which are equivalent to those previously achieved using immuno-
precipitation and nano-scale chromatography.  
The method is divided in six steps. Protein precipitation (1:1) with 1 % acetic acid 
acetonitrile:methanol resulted in 80-100 % recovery with minimal insulin precipitation. 
Mixed-mode strong anion SPE provided an additional layer of selectivity and facilitated the 
use of the low m/z MS fragments that were necessary to distinguish human insulin and 
lispro. The use of multidimensional trapping and back dilution with a XBridge C18 trap 
column and further separation on a sub-2 µm solid-core, charged-surface column provided 
significantly improved sensitivity and efficiency for insulin analogs enabling quantification 
limits down of 50 to 200 pg/mL (8.3-33.8 fmol/mL or 1.4-5.6 µIU/mL) for the 6 insulins, 
extracted from 250 µL human plasma.  
All FDA criteria[64] for accuracy and precision of the method were achieved for this 
assay. Average accuracies for standard curve points and QC samples were >92 %, with most 
being close to 99 %. Inter- and intra-day precision for all QC samples was better than 7.5 %. 
CVs of matrix factors across 6 lots of human plasma were <15 %, further supporting the 
selectivity of the method. Furthermore, qualitative identification criteria were met showing 




To obtain the required level of specificity and sensitivity for rapid and routine multi-
insulin analysis in plasma, many independent factors from the various analytical stages were 
studied and carefully optimized. For clarity, an overall summary of the final analytical 
workflow, detailing specific contributions of the various individual technical components to 
this method, is summarized in Figure 5.23. 
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Preliminary Investigations into the Benefits of Integrated 






Chapter 1 established that the two major hurdles that LC/MS faces relative to the 
gold-standard ligand binding assays for the quantification of peptides and proteins in 
biofluids are sensitivity and sample volume requirements. Chapter 2 of this thesis identified 
and developed screening methods and guidelines aimed at addressing these very issues in 
LC/MS analyses. The subsequent chapters applied these principles to quantify several 
therapeutic and endogenous peptides. However, sample volumes of 100-300 µL were still 
required and although detection limits described in Chapters 3-5 were adequate for the 
intended application, a niche remains to be filled whereby available sample volumes are 
limited to ≤ 100 µL and frequently ≤ 50 µL. 
The demand for low sample volume assays is derived from two primary trends. Over 
the past few years, the bioanalytical industry has seen an increasing interest in 
microsampling. At the same time, the use of LC/MS in biomarker discovery and validation 
studies has increased. Both of these trends share a common key requirement, to obtain 
higher sensitivity from smaller sample volumes.  
Microsampling has emerged as an attractive option to traditional methods [1-3] for 
several reasons. Smaller rodent animal models (i.e. mice versus rats) are being used and 
there is a strong desire to reduce overall animal usage both from a financial and 
humanitarian perspective. Naturally, researchers prefer to euthanize as few animals as 
possible.  Also genetically modified rodents (“knock-out” models) used in specific disease 
testing are extremely costly (in the region of $5000).  The ability to re-use these animals 
facilitates the investigation of disease models. In addition, if the sample volume required 
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can be sufficiently minimized , a full PK profile can be obtained from a single animal in 
contrast to the previous practice of obtaining composite profiles whereby each time point 
was represented by an animal[2]. This ultimately improves the quality and reproducibility of 
PK data obtained from rodent models.  
Extensions into pediatrics and/or inhaled dose forms or biomarker validation studies 
where the matrix may be in limited supply such as with exhaled breath condensate[4], also 
require that assays be developed which require the least amount of sample possible. 
One has only to look at the field of proteomics to see that a common way to maximize 
sensitivity for very small sample volumes is through the use of low flow LC such as nano or 
capillary flow. Therefore, a natural extension of the work presented in all preceding chapters 
is to assess the value of low flow LC in further improving sensitivity whilst reducing sample 
volumes in bioanalytical methods/studies for peptides. In theory, if the particle size and 
column length are kept constant, reducing the column diameter should significantly increase 
sensitivity if the same sample volume is injected. This increase in sensitivity is directly 
related to the ratio of the square of the 2 column diameters i.e. d12 /d22 where d1 is the 
diameter of the larger column and d2 is the diameter of the smaller column. In addition to the 
improvement due to scale[5], low flow LC provides also greater sensitivity versus analytical 
scale due to reduced matrix effects[6, 7], and improved ionization efficiency[8].   The 
benefits of capillary scale LC at the 300μm scale for the analysis of a small molecule 
candidate pharmaceutical was demonstrated by Fraser et-al [9], here they demonstrated that 
a full PK profile could be obtained from a single rodent.   
This chapter will investigate the practical aspects of adapting the highly optimized 
analytical scale methods presented in Chapters 3 and 5 to an integrated microfluidic LC/MS 
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device. In addition, the interest in diabetes research also prompted an assessment of the 
value of this technology for the analysis of glucagon. Finally, several small cyclic peptides, 
representing biosimilars and an endogenous hormone were subjected to the same approach. 
  
6.2 Experimental 
6.2.1 Source of  Reagents and Preparation of Stock Solutions 
Teriparatide and human insulin and its analogs were prepared as described in 
sections 3.2.1 through 3.2.3 and 5.6.1 through 5.6.3, respectively. Glucagon, desmopressin, 
octreotide and vasopressin were purchased from Sigma Aldrich (St. Louis, MO). Glucagon 
stock solutions were prepared in 70/30 water/methanol plus 1% acetic acid and 0.05% rat 
plasma (added as carrier protein), by volume. Desmopressin, octreotide, and vasopressin 
stock solutions were prepared in 80/20 water/acetonitrile plus 1% formic acid and 0.05% rat 
plasma added by volume.  
6.2.2 Sample preparation 
Human plasma samples were spiked with peptide(s) to an initial starting 
concentration of 50 ng/mL. Standard curves and QC samples were prepared through serial 
dilutions of the 50 ng/mL plasma standard with additional control, non-diseased sterile 
human plasma. 
6.2.3 Liquid Chromatography 
Analytical scale (2.1 mm ID) chromatographic methods for teriparatide, insulin and 
analogs, and the cyclic peptide mixture (desmopressin, vasopressin, and octreotide) are 
described in Chapters 3, 5 and 2, respectively. At the 2.1 mm ID scale, glucagon was 
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separated on a Waters 1.6 µm CORTECS C18+ 2.1 mm X 50 mm column. The column 
temperature was 60°C. A gradient from 15-50% organic mobile phase over 3 minutes at a 
flow rate of 0.25 mL/min. resolved glucagon from interferences and produced the best peak 
shape and intensity. Mobile phases consisted of 0.1% formic acid in either water (mobile 
phase A) or acetonitrile (mobile phase B). The injection volume was 25-30 µL on the 2.1 
mm ID column. 
All microscale LC separations were performed using a Waters ACQUITY M-Class 
pump and sample manager, equipped with an optional trap valve manager. Mobile phases A 
and B were comprised of  aqueous formic acid 0.1% (v/v) and acetonitrile respectively, for 
all compounds. In each instance, the analytical separation device was preceded by a 300 µm 
X 50mm Symmetry C18 trap column. The trapping configuration is depicted in Figure 6.1. 
Glucagon and the insulins were separated on 150 µm X 100 mm BEH (bridged hybrid) 
130Å 1.7 µm integrated microfluidic devices using the gradient conditions described in 
Tables 6.1A and 6.1B. Teriparatide was separated on a 150 µm X 50 mm BEH 130Å 1.7 
µm integrated microfluidic device using the gradient detailed in Table 6.1C. Desmopressin, 
octreotide, and vasopressin were separated on a 150 µm X 50 mm HSS T3 (silica-based) 
130Å, 1.8 µm integrated microfluidic device using the gradient in Table 6.1D. All 
separations performed on the microfluidic devices were carried out at 75° C, whilst the 
experiments on the Waters 1.6 µm CORTECS C18+ 2.1 mm X 50 mm column were 





Table 6.1A Gradient conditions for microscale analysis of glucagon  
 
Table 6.1B Gradient conditions for microscale analysis of insulins 
 
Table 6.1C Gradient conditions for microscale analysis of teriparatide 
 










0.00 2.00 85 15 Initial
6.00 2.00 55 45 6
6.50 2.00 15 85 6
8.50 2.00 15 85 6










0.00 2.50 75 25 Initial
5.00 2.50 45 55 6
6.00 2.50 5 95 6
8.00 2.50 5 95 6










0.00 2.00 85 15 Initial
5.00 2.00 55 45 6
6.00 2.00 5 95 6
8.00 2.00 5 95 6










0.00 3.00 98 2 Initial
5.00 3.00 50 50 6
5.50 3.00 50 50 6
7.00 3.00 10 90 6
8.00 3.00 10 90 6




Figure  6.1 Schematic of single pump trapping configuration used for microscale separations performed  in this 
study 
 
6.2.4 Mass Spectrometry 
Mass spectrometric conditions for teriparatide and insulin and its analogs can be 
found in Chapters 3 and 5, respectively. Infusions were performed to ensure that the relative 
abundance of the various precursors had not changed, or was accounted for, due to the LC 
flow rate scale. For all other compounds, MS was performed in ESI+ mode using a Waters 
Xevo TQ-S triple quadrupole mass spectrometer. The optimal MRM transitions for 
glucagon, desmopressin, octreotide, and vasopressin were m/z 697-> 940, m/z 535-> 328, 
m/z 510 ->120, and m/z 543-> 328, respectively.   
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6.2.5 Sample Preparation 
Teriparatide, insulin and analogs, and desmopressin, vasopressin, and octreotide 
were extracted according to the optimized SPE protocols described in Chapters 3, 5, and 2, 
respectively. Extracted sample volumes ranged from 25-100 µL of spiked human plasma. 
Human plasma samples spiked with glucagon were treated with a protease inhibitor cocktail 
and aliquots were extracted on a mixed-mode strong anion exchange, low sorbent bed 
volume 96-well plate. The protocol was as follows: wells were conditioned with 200 µL 
methanol and then equilibrated with 200 µL water. 200 µL sample was diluted 1:1 with 5% 
(v:v) ammonium hydroxide in water and then loaded into the wells of the 96-well plate. 
Samples were washed with 200 µL 5% ammonium hydroxide in water, followed by 200 µL 
10% acetonitrile in water. Glucagon was eluted with 2 X 25 µL 65:25:10 
acetonitrile:water:acetic acid and the final eluate was diluted with 50 µL water prior to 
injection. 
 
6.3 Results and Discussion 
6.3.1 Chromatographic Method Development 
If microscale LC is to be implemented in a routine bioanalytical labouratory, one 
must first identify the column ID which is best suited for balancing the sensitivity and 
throughput requirements. To make a decision it was important to fully understand the 
sensitivity gains that were possible scaling chromatography from the microbore 2.1 mm 
format to the nanoflow format.   A test was performed whereby a mixture of small 
molecules (lidocaine, propanolol, dextromethophan, fluconazole, alprazolam and verapamil) 
was injected (N=3) at various chromatographic scales. Figure 6.2 summarizes the sensitivity 
340 
 
enhancement for the series of small molecules in relation to a 2.1mm separation performed 
on an Acquity UPLC instrument.  The same volume and concentration of the sample were 
injected on each column format. The data show that as the column dimension is reduced 
from 2.1 mm to 1 mm ID a modest two-fold gain may be realized.  A 300 µm capillary may 
yield approximately a four-fold gain. (While Rainville et al[2] showed a 20-30X gain using 
a prototype 300 µm ceramic device, this was performed on a highly optimized research-
grade source that is not commercially available). The 150 µm dimension appears to be an 
inflection point where the observed sensitivity gain begins to increase non-linearly with 
reduced flow rate.  For this series of molecules a 4-30-fold gain was observed.  Finally, a 
common nanoflow format of 75 µm ID provided the greatest average gain of ~50-fold. In 
general, none of the observed sensitivity increases corresponded to the expected gains, it is 
believed that this is largely due to extra column band broadening (which is exaggerated as 
the column ID is reduced) and packing efficiency differences. However, from these data, it 
was determined that the best balance between throughput and sensitivity can be achieved 
using 150 µm ID columns. Although the 75 µm ID column scale provides the greatest 
absolute improvements in sensitivity, the flow rates employed (<1 µL/min) result in 
excessively long run times of between 30 minutes to several hours. This does not yield 
acceptable throughput for a bioanalytical lab desiring to process an entire 96-well plate 
during a 24 hour period. While flow rates, and thus run times are faster when 300 µm and 
larger ID columns are used, the sensitivity gains are marginal when compared to those 
obtained from 150 µm ID columns. Flow rates of 2-5 µL/min, common for 150 µm 




   
Figure 6.2 Average increase in sensitivity for a group of small molecules injected (constant volume and 
concentration) at various chromatographic scales from 2.1 mm to 75 µm ID. Figure reproduced with 
permission from Waters Corporation and James Murphy. 
 
The aim of the work presented in this chapter was to determine whether microscale 
LC could be successfully implemented for bioanalytical methods for peptides. Specifically, 
the key question was whether its use could provide any incremental benefit in terms of 
sensitivity and/or reduction in sample volume requirements for methods which were already 
highly optimized and exhibited ultra-high sensitivity. In theory, decreasing the diameter of 
the chromatographic column (all else being equal) should improve sensitivity if an equal 
sample load is injected. Theoretically, the increase is a result of the ratio of the squares of 
the column diameters. For example, scaling from a 2.1 mm ID to a 150 µm ID column 
should yield a 196X increase in signal. There are, however, several factors affecting the 
results and the ability to fully realize this benefit from a practical standpoint. Firstly, 
injection volumes such as those used in Chapters 3 and 5 for teriparatide and insulin 
75µm ID
150µm ID




analysis were 30 and 35 µL, respectively. This represents approximately one-fifth of the 
column volume of a 2.1 mm X 50mm column. This same volume injected onto a 150 µm ID 
column of the same length would correspond to approximately 203 times the column 
volume. The larger the injection volume is, relative to the column volume, the more 
chromatographic performance is affected by solvent composition, over-loading, and band 
spread. Secondly, the ability to achieve the predicted sensitivity increase also assumes that 
columns are packed equally as efficiently. While most 2.1 X 50 mm columns used in this 
study produced plate counts of approximately 9000-11000, 150 µm microfluidic devices of 
the same l/dp were tested in another labouratory and shown to produce plate counts closer to 
3000-5000. In his book on HPLC columns and theory[5], Uwe Neue described how 
reducing the column diameter in order to increase sensitivity has its limitations due to 
injection volume/solvent effects and bandspread related processes. 
The first step in transferring from 2.1mm ID scale to 150 µm was to determine the 
optimum flow rate, gradient time, and gradient profile. It was hypothesized that an 
appropriate geometric scale would provide the best starting point. However, using the 
insulin method as an example, scaling the flow rate and gradient time from 2.1 mm (0.25 
mL/min, 4 minute gradient from 15-40% organic mobile phase) to 150 µm scale resulted in 
unnecessarily long run times (in excess of 30 min) and a flow rate of 1.3 µL/minute. These 
conditions were rapidly discarded due to a failure to meet throughput requirements. There 
was concern though that increasing the flow rate or gradient slope to reduce run time would 
degrade peak performance. This was not, in fact, the case. As a first test, the flow rate was 
increased to either 2 or 3 µL/min and the gradient steepness reduced to 5 minutes in 
duration. Neither of these changes decreased performance, but rather resulted in improved 
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sensitivity and narrower peak widths. It seemed appropriate to use the same gradient profile 
as was used in the analytical separation as a starting point. For example, the analytical 
separation of insulin was achieved by linearly ramping the organic composition from 15-
40% in 4 minutes, therefore the initial micro-scale conditions relied on separation at 2, 2.5 
or 3 µL/min using the same 15-40% B ramp. While this indeed produced excellent peak 
shapes, 2-3 seconds wide at base for all 6 of the insulins tested, optimal sensitivity was 
reached at the 2.5 µL/min flow rate and by methodically adjusting the starting and ending 
mobile phase compositions in conjunction with gradient slope. Final conditions for insulin 
analysis included a linear gradient ramp from 25-55% B in 5 minutes.  
The data in Chapter 2 suggest that either a 300Å pore size or positively charged 
surface columns might provide a further enhancement in sensitivity. Therefore three 150 µm 
X 50 mm columns were compared under constant gradient conditions to rapidly confirm 
column choice. The results are shown in Figure 6.3. 
 
 
Figure 6.3 Comparison of insulin separation on 50mm x 150 µm ID columns packed with various stationary 
phases. The first peak in each chromatogram is insulin glargine, the second peak contains human insulin and 
insulin lispro, aspart, and glulisine. The last peak is insulin detemir. 
Time






























BEH C18 130Å, 1.7µm
BEH C18 300Å, 1.7µm




The outcome was somewhat surprising in that, under microflow conditions, neither 
pore size nor surface charge had a positive influence. In fact, Figure 6.3 indicates that the 
best peak shape for all insulins and the greatest intensity were realized on a traditional 
hybrid C18, 130Å column. While peak shape for most insulins was comparable across the 
stationary phases compared, optimal peak shape for the most retentive insulin, detemir, was 
obtained on the BEH C18, 130Å. This stationary phase also produced sensitivity that was 
50% greater than the BEH C18 300Å, and 20-50% greater than the charged surface C18, 
130Å phase. The difference in behaviour between 2.1 mm scale and the microflow 
conditions used here can be explained quite simply by the difference in gradient slope. That 
is to say that the microflow conditions employed a steeper gradient (approximately 14.15 
column volumes over the linear ramp time) than the 2.1 mm ID  gradient (5.8 column 
volumes over the linear ramp). This steeper gradient would likely be expected to result in 
the narrower peaks that were observed. 
A similar approach was taken to optimize methods for teriparatide and glucagon. 
The final flow rates (2 µL/min) and gradient profiles (15-45% B) were the same for each 
and were derived from their 2.1 mm scale methods. 
Not surprisingly, a faster flow rate of 3 µL/min. could be used for the small peptide 
mixture without compromising performance. As these peptides are all significantly more 
polar than any of the larger peptides previously tested, a stationary phase designed for polar 
retention   (high strength silica) was evaluated against the BEH C18 130Å that provided 
optimal performance for the larger peptides. The results are shown in Figure 6.4. Peak shape 
for vasopressin (the most polar and earliest eluting molecule) is improved significantly 
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using the high strength silica column, therefore this column was chosen for sample analysis. 
Performance for desmopressin is comparable between the columns.  
 
 
Figure 6.4 Comparison of vasopressin (first peak) and desmopressin (second peak) separation on150 µm ID 
columns packed with two stationary phases. 
  
The next step in development was to optimize injection volume. Although theory 
predicts nearly a 200-fold gain in increase in sensitivity if the injection volume is constant, 
this did not prove to be the case in actual practice. For the small molecule performance 
summarized in Figure 6.2, a 4-30-fold gain was observed. The same test was performed for 
glucagon and insulin. The results are shown in Figures 6.5A and 6.5B. The outcome of these 
tests in solvent standards was a 5-7-fold increase in sensitivity from microscale LC, relative 
to analytical scale. This data is consistent with what was observed for small molecules. 
Neither approaches the theoretical predictions. This is believed to be due to a combination 
of factors: worse efficiency values for the microscale columns, a lack of understanding of 
the role MS plays in influencing the observed gains, and other column related phenomena. It 
is not yet understood whether the fact that the ceramic channels into which stationary phase 
Time


















High strength Silica, 130Å, 1.8 µm
BEH C18, 130Å, 1.7 µm
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is packed are square on the 150 µm columns, versus the cylindrical geometry that 
characterizes 2.1 mm columns, plays a role. One may also question whether the nature of 
the column hardware contributes in an unexpected way; for example are there interactions 
between the ceramic material and the peptides which are absent in stainless steel hardware? 
Unlike optical detection where the theoretical increase may be achieved more readily, when 
working with mass spectrometry, there are simply too many confounding factors on both 
sides (2.1 mm ID and microflow scale) to have a simplistic, numerical and geometric 
comparison between the two. It has become a multivariant problem for which we do not 




Figure 6.5A Comparison of a 5 µL injection of a 5 ng/mL standard of glucagon at analytical scale (top) and 
microscale (bottom) 
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Figure 6.5B Comparison of a 5 µL injection of a 5 ng/mL standard of insulin glargine at analytical scale 
(bottom) and microscale (top) 
Although an increase of 5-7-fold from a 5 µL injection is certainly a positive step, 
most optimized and high sensitivity bioanalytical methods have the advantage of larger 
injection volumes to help achieve the required detection limits. Therefore it becomes 
important to understand the practical injection volume limitations of the integrated 
microscale system. To this end, 5, 10, or 15 µL extracted human plasma samples containing 
glucagon were injected onto the microscale LC/MS system. The results are shown in Figure 
6.6. The data verify that peak area increases linearly up to a 15 µL injection. This is actually 
rather remarkable when one considers that this would be the equivalent of injecting up to 3 
mL of extracted plasma on a 2.1 mm ID scale column. The presence of the trap column is 
critical for re-focusing the peptides and removing residual protein. The former is largely 
responsible for achieving narrow peak widths in spite of large volumes of aggressive 
injection solvents, the latter safeguards the 150 µm ceramic tile from over-pressuring due to 
excess protein load. 
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Figure 6.6 Injections of 5, 10 or 15 µL of human plasma extract containing 50 pg/mL glucagon  
 
6.3.2 Sensitivity, Linearity, Accuracy and Precision 
  Using the sample preparation methods previously described, detection limits and 
additional validation tests were performed on human plasma samples.  For each peptide 
tested, sample volume was minimized as much as possible without losing sensitivity relative 
to that achieved by the analytical scale method. A comparison of the final analytical and 
microscale methods for teriparatide and glucagon are shown in Figures 6.7A and 6.7B, 
respectively. In each case, the cumulative benefit of chromatographic scale, reduction in 
sample volume, and reduction in injection volume is significant, yielding an approximately 
30-fold improvement for teriparatide and a 15-fold improvement for glucagon. The final 
method for insulins resulted in a 15-fold overall improvement in sensitivity, also derived 
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from reducing sample volume, reducing injection volume, and changing chromatographic 
scale. While the quantification limits for insulin glargine and insulin glulisine were 50 
pg/mL from 250 µL of plasma (30 µL injection) at the analytical scale (2.1mm), an LLOQ 
of 25 pg/mL was readily obtained from 100 µL of plasma using a 10 µL injection at 





Figure 6.7A Comparison of the analysis of a 20 pg/mL teriparatide extracted plasma sample using either 
analytical (bottom) or microscale (top) chromatography 
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Figure 6.7B Comparison of the analysis of a 25 pg/mL glucagon extracted plasma sample using either 
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Figure 6.8A Representative chromatograms of insulin glargine at 25, 100, and 200 pg/mL compared to blank 
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Figure 6.8B Representative chromatograms of insulin glulisine at 25, 100, and 200 pg/mL compared to blank 
extracted plasma, separated on a 150 µm column 
 
 
  Analysis of desmopressin, vasopressin and octreotide presented the best example of 
maintaining sensitivity whilst significantly reducing sample volume. Chapter 2 described an 
optimized analytical scale method for desmopressin which achieved an LOD of 1 pg/mL 
from 500 µL of plasma. Figure 6.9 (bottom panel) clearly shows that similar detection limits 
can be obtained from only 25 µL of plasma using the 150 µm ID column. A detection limit 
of 1 pg/mL was reached for desmopressin, vasopressin, and octreotide if 100 µL of plasma 
was extracted. This is shown in Figures 6.10A-C. 
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Figure 6.10A Separation of desmopressin at various concentrations, extracted from 100 µL human plasma 
 
 
Figure 6.10B Separation of vasopressin at various concentrations, extracted from 100 µL human plasma 
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Figure 6.10C Separation of octreotide at various concentrations, extracted from 100 µL human plasma 
 
With sensitivity established, the linear dynamic range and accuracy of the method 
must also be demonstrated. Stock fortified human plasma was diluted down with additional 
human plasma to yield final concentrations of the peptides ranging from 1 to 10,000 pg/mL. 
Samples were then extracted according to the method prescribed for each analyte. The linear 
dynamic ranges for teriparatide, glucagon, and most insulins were 1-1000, 12.5-1000, and 
25-10,000 pg/mL, respectively. For the small cyclic peptides, the range was 1-2000 pg/mL. 
Representative standard curves for teriparatide, glucagon, and insulin gargine are shown in 
Figures 6.11A-C. Representative statistics for glucagon, insulin glargine, and the three 
cyclic peptides are summarized in Tables 6.2- 6.4. With rare exception, all calculated 
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Figure 6.11B Representative standard curve for glucagon extracted from 200 µL human plasma, from 12.5-
1000 pg/mL 
Compound name: Teriparatide 687
Correlation coefficient: r = 0.999254, r^2 = 0.998508
Calibration curve: 0.010184 * x + 0.0879951
Response type: Internal Std ( Ref 4 ), Area * ( IS Conc. / IS Area )
Curve type: Linear, Origin: Exclude, Weighting: 1/x, Axis trans: None
pg/mL


















Teriparatide Extracted from 50 µL Human Plasma: 10-1000 pg/mL
Linear fit and broader range than analytical
Compound name: Glucagon 1040
Correlation coefficient: r = 0.998699, r^ 2 = 0.997400
Calibration curve: 42.6771 * x + -120.577
Response type: External Std, Area
Curve type: Linear, Origin: Exclude, Weighting: 1/x, Axis trans: None
pg/mL





















Table 6.2 Representative standard curve performance statistics for glucagon extracted from human plasma 
Compound name: Lantus
Correlation coefficient: r = 0.995564, r^2 = 0.991147
Calibration curve: 0.000398185 * x + -0.00299844
Response type: Internal Std ( Ref 2 ), Area * ( IS Conc. / IS Area )
Curve type: Linear, Origin: Exclude, Weighting: 1/x, Axis trans: None
Conc





















Blank ‐ ‐ ‐ ‐
Blank ‐ ‐ ‐ ‐
12.5 469 13.8 10.5 89.5
12.5 461 13.6 9 91
25 982 25.8 3.3 96.7
25 959 25.3 1.1 98.9
50 2005 49.8 ‐0.4 100.4
50 2080 53.5 6.9 93.1
100 3958 95.6 ‐4.4 104.4
100 3733 90.3 ‐9.7 109.7
250 10142 240.5 ‐3.8 103.8
250 9481 225 ‐10 110
500 20893 492.4 ‐1.5 101.5
500 20184 475.8 ‐4.8 104.8
1000 44244 1039.5 4 96










Table 6.4 Representative standard curve performance statistics desmopressin, vasopressin, and octreotide 





Time Area IS Area Conc. %Dev
Blank Plasma 4.75 41
25 pg/mL plasma Standard 25 4.75 279 31017 30 20.4
50 pg/mL plasma Standard 50 4.75 620 33096 55 9.2
100 pg/mL plasma Standard 100 4.75 1313 32043 111 10.5
200 pg/mL plasma Standard 200 4.75 2199 34167 169 ‐15.4
500 pg/mL plasma Standard 500 4.75 5515 30733 458 ‐8.4
1 ng/mL plasma Standard 1000 4.74 11575 32504 902 ‐9.8
2 ng/mL plasma Standard 2000 4.75 20828 31912 1647 ‐17.7
5 ng/mL plasma Standard 5000 4.76 59151 26498 5614 12.3
10 ng/mL plasma Standard 10000 4.76 112246 28524 9890 ‐1.1
QC 1 QC 150 4.76 2013 33144 160 6.7
QC 2 QC 750 4.76 9477 33670 714 ‐4.7
QC 3 QC 2500 4.76 28692 31598 2288 ‐8.5































1.0 215 0.95 94.8 1.0 107 0.98 98.9 1.0 668 1.06 106.0
2.5 319 2.58 103.5 2.5 193 2.50 99.9 2.5 1474 2.38 95.3
5.0 453 4.70 94.3 5.0 344 5.15 103.1 5.0 3017 4.91 98.1
10.0 898 11.75 117.5 10.0 646 10.50 104.8 10.0 5820 9.50 95.0
25.0 1965 28.63 114.5 25.0 1551 26.38 105.6 25.0 16404 26.82 107.3
50.0 3363 50.70 101.5 50.0 2781 48.05 96.1 50.0 29385 48.08 96.2
100.0 6376 98.35 98.4 100.0 5454 95.08 95.1 100.0 59131 96.77 96.8
250.0 15625 244.60 97.9 250.0 13751 241.10 96.5 250.0 149267 244.34 97.8
500.0 33594 528.68 105.7 500.0 28805 506.05 101.2 500.0 304504 498.48 99.7
1000.0 62242 981.60 98.2 1000.0 55252 971.53 97.2 1000.0 584899 957.52 95.8







The data in this chapter firmly establish that LC/MS using integrated microscale LC 
can finally obtain the sensitivity of ligand binding assays whilst consuming only a minimum 
volume of sample. Sensitivity gains of 15-30-fold were realized when comparing final 
results from 2.1 mm ID LC/MS methods to those attained on a 150 µm ID integrated 
microfluidic device LCMS system.  The data acquired using this platform easily met 
recommended accuracy and precision guidelines[10-12] and analysis speed was adequate 
for high throughput bioanalytical assays. Use of integrated microscale LC shows promise 
for quantification of peptides from sample volumes as low as 25 µL, facilitating single 
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Chapter 7  




7.1 Final Conclusions 
The focus of this research project was to improve the specificity and sensitivity of 
LC/MS such that it could be applied to the quantification of therapeutic and endogenous 
peptides. Traditional ligand binding assays (LBAs) have dominated quantitative methods for 
large molecules such as these, however they suffer serious shortcomings. For example, 
LBAs suffer from lack of standardization, variable reagents, matrix effects, poor linear 
dynamic range, inability to multiplex, cross reactivity and long development times. In spite 
of these apparent weaknesses, LBAs remain the technique of choice over LC/MS, in part 
due to their ability to achieve extremely low detection limits, fast analysis speeds and to 
minimize sample consumption.  These shortcomings being amongst the LC/MS hurdles 
surmounted in this thesis.  
The work presented in Chapter 2 encompassed LC, MS, and sample preparation in 3 
sections. Each section aimed to study and identify the optimal conditions for peptide 
quantification. The initial investigation focused on the role that chromatographic particle 
size, pore size, stationary phase chemistry and particle porosity play in attaining optimal 
peptide separations. Relative to traditional 3.5 µm and larger particles,  sub 2-µm size 
particles significantly extended the flow rate range under which efficient peptide separations 
can be performed, thus enabling the increased throughput required in bioanalytical 
labouratories to be achieved. In addition, the study determined that for fully porous 
stationary phases, both larger pore sizes (i.e. 300Å) and a positive surface charge may 
improve chromatographic peak shape and thus intensity, especially for peptides >2000 Da. 
The data showed that columns packed with newer solid-core particles also provide excellent 
peak shape for peptides both large and small, using flow rates which allow for adequate 
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throughput. The work in Chapter 2 also established the importance of temperature, flow 
rate, gradient slope, and mobile phase modifier selection on assay performance. This 
prompted the consideration to increase temperature, decrease flow rate, reduce gradient 
steepness and possibly add a modifier such as TFE to mobile phase B, all if greater 
sensitivity and/or reduced carry-over were desired. The sample preparation section 
examined multiple techniques in detail, and compared and contrasted all on the basis of 
specificity and recovery. None were deemed suitable as is, using a basic protocol designed 
for small molecules. This necessitated the development of an SPE method specifically for 
peptides, which simultaneously screened two complementary mixed-mode sorbents. The 
value of the ability of mixed mode sorbents to impart orthogonality onto the method 
selectivity as a whole was demonstrated. In addition, the use of a low-bed volume 96-well 
plate format allowed for concentration of the analyte without risk of adsorption related 
losses. Although a wide-pore sorbent prototype was tested, this served only to retain more 
serum albumin at the expense of the recovery of low-level peptides of interest, and therefore 
was not pursued. Experiments described in the mass spectrometry section resulted in 
concrete rules for choosing precursor and product ions. These included the recommendation 
to choose the highest precursor/product pairs possible, avoid immonium ions, monitor 
multiple MRM transitions during method development, and the importance of tuning at the 
chosen chromatographic flow rate was also noted, amongst other recommendations. The 
rules derived in this MS research became the foundation for the current scoring algorithm 
applied in the Waters mass spectrometry automated tuning software.  Chapter 2 concluded 
with a comprehensive set of rules and guidelines which will facilitate the efficient 
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development of highly specific and sensitive methods by any researcher- novice or 
otherwise. 
 Chapter 3 implemented the strategies and recommendations from Chapter 2 to 
develop an assay to quantify the osteoporosis drug teriparatide. This presented a unique case 
where adequate recovery could not be obtained on mixed-mode sorbents as desired. 
Therefore, reversed-phase only SPE was used. On its own, this technique was not specific 
enough to enable detection at the low concentration levels required (based on dosing and 
systemic exposure). Extensive evaluation of various pre-treatment options resulted in the 
inclusion of a carefully controlled protein precipitation step to eliminate high abundance 
proteins such as albumin and immunoglobulins as well as other interferences. The result 
was a validated assay with detection limit of 15 pg/mL  (3.6 pMolar) teriparatide from 200 
µL of human plasma, which permits analysis of PK samples, previously performed by radio 
immunoassay, by LC/MS.  
 Solutions for addressing non-specific binding, aggregation, and protein binding were 
a key part of successful quantification of amyloid β peptides, putative Alzheimer’s disease 
biomarkers, in Chapter 4. An extensive study of surrogate matrices resulted in the 
identification of a surrogate based on artificial CSF containing 5% rat plasma. A parallelism 
study was carried out which confirmed equivalency to human CSF. The use of a guanidine 
HCl denaturation step increased recovery to >90% for a series of amyloid peptide isoforms 
studied in Alzheimer’s research. This higher recovery ensured that all the amyloid peptide 
was accounted for and facilitated the achievement of ultra-low detection limits in human 
cerebrospinal fluid. This, in conjunction with exceptional accuracy and precision, made the 
assay an optimal platform for Alzheimer’s research. In fact, this work ultimately became the 
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foundation for a method being progressed towards a candidate reference method for 
amyloid β 1-42 through a joint effort between the Alzheimer’s Association and the Global 
Biomarker Standardization Committee[1]. 
Chapter 5 presented the development of a method for simultaneous quantification of 
6 intact insulins using multidimensional LC and a dual stage sample preparation scheme 
which included mixed-mode SPE. The final assay is the most sensitive and comprehensive 
LC/MS method to date. In fact it is more sensitive and significantly faster than a nano-flow 
LC method using affinity purification and multiple SPE processes, firmly supporting the 
value of the guidelines established in Chapter 2. The first section of Chapter 5 focused on 
overcoming the challenges that plague large peptides in particular. At almost 6000 Da, 
insulins actually sit on the border between large peptides and small proteins. The focus was 
on developing an LC/MS method which could simultaneously quantify human insulin and 5 
analogs, intact, without reduction to individual chains. MS sensitivity is particularly low for 
large peptides such as insulin, especially for those having two amino acid chains which are 
stabilized by multiple disulfide bridges. This placed a greater burden on the LC and sample 
preparation processes to deliver the sensitivity required. A two-stage sample clean-up 
similar to that of teriparatide, was developed. This approach demonstrated the advantages of 
using both finely tuned protein precipitation and mixed-mode SPE for the quantification of 
these analytes. This was coupled to further on-line clean-up, at column dilution to minimize 
solvent effects and therefore maximize injection volume, and high m/z MRM transitions to 
aid specificity.  Final detection limits of 50 pg/mL (8.6 fmol/mL or 8.6 pMolar) were 
achieved for various insulins extracted from human plasma. This allowed for detection of 
fasting insulin levels and identification and quantification of human insulin and analogs in a 
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blind study of Type I and Type II diabetic volunteers on a variety of multi-dosing regimes. 
The assay described in the chapter easily met regulatory guidelines for validated 
bioanalytical methods.  
Chapter 6 addressed the issue of sample consumption, filling the final remaining gap 
between LC/MS assays and LBAs for routine peptide quantification. This was accomplished 
by employing an integrated microflow LC system to both reduce sample volume 
requirements and provide an incremental increase in sensitivity over what was described in 
earlier chapters. This chapter detailed the process and challenges encountered during scaling 
of analytical scale (2.1 mm ID) methods for teriparatide, insulins, and glucagon to 150 µm 
ID scale. The analysis of several small cyclic peptides was also presented. In all cases, both 
of the primary objectives were attained. Although the “theoretical” increase in sensitivity of 
196-fold was not achieved, the chapter presented the practical side of adjusting to this 
chromatographic scale, including the influence of injection volume, solvent effects, and 
optimization. Moreover, it set appropriate expectations for adapting highly optimized 
analytical scale methods, such as those presented in Chapters 3 and 5 where injection 
volumes of 30-35 µL were common, through to microscale. In comparison with the standard 
LC/MS 2.1 mm chromatographic scale, sensitivity increases of 15-30X were realized.  For 
the smaller cyclic peptides, integrated microscale LC enabled a 20-fold reduction in plasma 
volume required. The work described in this chapter paves the way for peptide analysis 
from dried blood spots, rodent species, and pediatric patients. These studies also 
demonstrated the utility of microscale LC in biomarker discovery research where sample 
available for bioanalysis is limited due to the multitude of tests that must be performed on 
that sample.  
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 In summary, this thesis has shown that, following the guidelines developed herein, 
LC/MS can provide both the sensitivity and specificity to enable direct, ultra high sensitivity 
quantification of therapeutic and endogenous peptides in biological fluids for biomarker 
research, drug development and monitoring, or forensic/doping applications. 
 
7.2 Recommendations for Future Work 
During the course of this research several areas of possible future focus were identified 
which have  the potential to provide even greater sensitivity gains and /or specificity 
improvements over what has been achieved to date. 
 
1. Research aimed at establishing/confirming a correlation between CSF and plasma 
amyloid beta levels would require a more specific method for amyloid quantification 
by LC/MS than that described in Chapter 4. Therefore, it may be useful to combine 
mixed-mode SPE with 2D chromatography for amyloid beta peptides in plasma. 
This would include analysis in the first dimension using a low pH mobile phase 
followed by heart-cutting the amyloid fraction onto a second analytical dimension 
using a high pH mobile phase. 
2. Another option that may prove beneficial for improving sensitivity for amyloid 
peptides would be the use of a microflow LC/MS system. Current low flow systems 
have limited pH stability primarily due to the presence of fused silica in the system 
construction, whose polyimide coating dissolves at elevated pH. Analysis would 
have to be performed at a pH ≤ 10, which is lower than the current analysis, 
however, this is worth investigating. 
369 
 
3. The microflow experiments described in Chapter 6 showed great promise for ultra-
high sensitivity peptide quantification, particularly in cases where sample volume is 
limited. These benefits may be further augmented through the use of 2D microflow. 
This could include two analytical dimensions such as HILIC/ RP, low pH/high pH, 
or other configurations. 
4. Recently, the sensitivity of accurate mass instrumentation has approached that of 
triple quadrupole instruments. Significant background signal reduction is possible by 
employing accurate mass detection through the extraction of very narrow mass range 
windows. This combined with mixed-mode SPE or other pre-fractionation 
techniques may result in adequate/improved detection limits. A further extension of 
this could include ion mobility to improve selectivity. 
5. While traditional C18 (both silica and hybrid particles) and charged surface 
stationary phases were evaluated in Chapter 6 for use in microflow separations, all 
were fully porous particles. Chapter 5 demonstrated the incremental benefit of solid 
core particles for insulin quantification. It would be interesting to investigate any 
benefit that might be derived from their use at microflow scale. 
6. Chapter 6 established that the theoretical increase in sensitivity scaling from a 2.1 
mm ID to a 150 µm ID column should be 196-fold, if all else were equal. The 
average improvement actually obtained ranged from 5-30-fold, this is significantly 
different from the theoretical value. An investigation into why the theoretical 




7. Finally, Chapter 2 described an orthogonal and highly selective sample preparation 
strategy based on mixed-mode SPE. A study which assesses the benefits of HILIC or 
pure ion exchange SPE for the pre-fractionation of therapeutic, endogenous 
biomarker peptides or proteins (including monoclonal antibodies and antibody drug 
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